DDI-DrugBank.d423.s2	At IN 0	least JJS 0	14 CD B-adj.all	days NNS B-noun.phenomenon	should MD 0	elapse VB B-verb.motion	between IN 0	discontinuation NN B-noun.act	of IN 0	a DT 0	MAO_inhibitor NN B-noun.person	and CC 0	initiation NN B-noun.act	of IN 0	treatment NN B-noun.plant	with IN 0	dexfenfluramine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d476.s2	In IN 0	patients NNS B-noun.artifact	receiving VBG B-verb.change	concurrent JJ B-adj.all	therapy NN B-noun.person	with IN 0	clonidine NN B-noun.person	, , 0	if IN 0	therapy NN 0	is VBZ B-verb.stative	to TO 0	be VB 0	discontinued VBN B-verb.stative	, , 0	it PRP 0	is VBZ 0	suggested VBN B-verb.communication	that IN 0	ZEBETA NNP B-noun.group	be VB 0	discontinued VBN B-verb.stative	for IN 0	several JJ B-adj.all	days NNS B-noun.phenomenon	before IN 0	the DT 0	withdrawal NN B-noun.act	of IN 0	clonidine NN B-noun.phenomenon	. . 0	. . 0
DDI-MedLine.d76.s2	Cysteine NNP B-noun.person	was VBD B-verb.stative	covalently RB B-adv.all	linked VBN B-verb.cognition	to TO 0	carbodiimide VB 0	activated VBN B-verb.creation	NaCMC NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d236.s22	Norepinephrine NNP B-noun.person	, , 0	Amphetamines NNS B-noun.person	enhance VBP B-verb.change	the DT 0	adrenergic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	norepinephrine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d384.s8	Ketoconazole NNP B-noun.person	, , 0	Ketoconazole NNP B-noun.person	may MD 0	inhibit VB B-verb.possession	both DT 0	synthetic JJ B-adj.all	and CC 0	catabolic JJ B-adj.all	enzymes NNS B-noun.event	of IN 0	vitamin_D. NNP B-noun.person	. . 0
DDI-DrugBank.d412.s0	In IN 0	one CD 0	survey NN B-noun.location	, , 0	2.3 CD 0	% NN 0	of IN 0	patients NNS B-noun.person	taking VBG B-verb.social	labetalol_HCl NN I-verb.social	in IN 0	combination NN 0	with IN 0	tricyclic_antidepressants NNS B-noun.person	experienced VBD B-verb.communication	tremor NN B-noun.feeling	, , 0	as IN 0	compared VBN 0	to TO 0	0.7 CD 0	% NN 0	reported VBD B-verb.communication	to TO 0	occur VB B-verb.stative	with IN 0	labetalol_HCl NN B-noun.group	alone RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d307.s1	In IN 0	addition NN 0	, , 0	several JJ B-adj.all	AED NNP B-noun.group	s NN 0	that WDT 0	are VBP B-verb.stative	cytochrome JJ B-adj.all	P450 NN B-noun.person	inducers NNS B-noun.person	can MD 0	decrease VB B-verb.change	plasma NN B-noun.act	concentrations NNS B-noun.attribute	of IN 0	oxcarbazepine NN B-noun.person	and CC 0	MHD NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d179.s33	- : 0	Vitamin_K NN B-noun.person	( ( 0	e.g. UH 0	, , 0	AquaMEPHYTON NNP B-noun.person	, , 0	Synkayvite NNP B-noun.location	) ) 0	Use NNP 0	of IN 0	sulfapyridine NN 0	with IN 0	these DT 0	medicines NNS B-noun.artifact	may MD 0	increase VB B-verb.change	the DT 0	chance NN B-noun.act	of IN 0	side JJ B-adj.all	effects NNS B-noun.phenomenon	affecting VBG B-verb.change	the DT 0	blood NN B-noun.location	. . 0
DDI-DrugBank.d568.s12	Because IN 0	lithium NN 0	may MD 0	enhance VB B-verb.change	the DT 0	serotonergic JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	escitalopram NN B-noun.food	, , 0	caution NN B-noun.communication	should MD 0	be VB 0	exercised VBN B-verb.social	when WRB 0	LEXAPRO NNP B-noun.person	and CC 0	lithium NN B-noun.person	are VBP 0	coadministered VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d353.s14	Investigations NNS B-noun.artifact	into IN 0	the DT 0	effect NN B-noun.cognition	of IN 0	acitretin NN B-noun.person	on IN 0	the DT 0	protein NN B-noun.substance	binding NN B-verb.contact	of IN 0	anticoagulants_of_the_coumarin_type NNP B-noun.person	( ( 0	warfarin NN 0	) ) 0	revealed VBD B-verb.perception	no DT 0	interaction NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d179.s12	- : 0	Divalproex NNP B-noun.person	( ( 0	e.g. UH 0	, , 0	Depakote NNP B-noun.location	) ) 0	or CC 0	. . 0
DDI-DrugBank.d522.s10	Serious JJ B-adj.all	cardiac NN B-noun.artifact	dysrhythmias NNS I-noun.artifact	, , 0	some DT 0	resulting VBG B-verb.stative	in IN 0	death NN 0	, , 0	have VBP 0	occurred VBN B-verb.cognition	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	terfenadine NN I-verb.communication	concomitantly RB B-adv.all	with IN 0	other JJ B-adj.all	macrolide_antibiotics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d42.s0	The DT 0	potential NN B-noun.person	for IN 0	clinically RB B-adj.all	significant JJ B-adj.all	drug NN B-noun.person	- : 0	drug NN B-noun.group	interactions NNS 0	posed VBN B-verb.stative	by IN 0	dolasetron NN B-noun.person	and CC 0	hydrodolasetron NN B-noun.person	appears VBZ B-verb.cognition	to TO 0	be VB B-verb.stative	low JJ B-adj.all	for IN 0	drugs NNS B-noun.person	commonly RB B-adv.all	used VBN B-verb.consumption	in IN 0	chemotherapy NN B-noun.animal	or CC 0	surgery NN B-noun.location	, , 0	because IN 0	hydrodolasetron NN B-noun.person	is VBZ 0	eliminated VBN B-verb.cognition	by IN 0	multiple JJ B-adj.all	routes NNS B-noun.time	. . 0	. . 0
DDI-MedLine.d20.s0	Interaction NN B-noun.act	between IN 0	glycine NN B-noun.person	and CC 0	glutamate NN B-noun.person	in IN 0	the DT 0	development NN B-noun.process	of IN 0	spontaneous JJ B-adj.all	motility NN B-noun.motive	in IN 0	chick JJ B-adj.all	embryos NNS B-noun.person	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d411.s9	b SYM 0	- : 0	Adrenergic_Blocking_Agents NNS B-noun.person	, , 0	Actions NNPS B-noun.person	of IN 0	some DT 0	of IN 0	beta JJ B-adj.pert	- : 0	blocking_agents NNS B-noun.group	may MD 0	be VB 0	impaired VBN B-verb.change	when WRB 0	hypothyroid NN B-noun.person	patients NNS B-noun.person	become VBN B-verb.emotion	euthyroid NN I-verb.emotion	. . 0	. . 0
DDI-DrugBank.d17.s18	for IN 0	adult NN B-noun.act	- : 0	onset JJ B-adj.all	diabetics NNS B-noun.person	, , 0	dosage NN B-noun.phenomenon	adjustment NN B-noun.process	of IN 0	hypoglycemic_medications NNS B-noun.group	may MD 0	be VB B-verb.stative	necessary JJ B-adj.all	during IN 0	and CC 0	after IN 0	thiazide_diuretic JJ B-adj.all	therapy NN B-noun.act	, , 0	. . 0
DDI-DrugBank.d148.s5	Thrombolytic_agents NNS B-noun.artifact	, , 0	The DT 0	safety NN B-noun.artifact	and CC 0	effectiveness NN B-noun.cognition	of IN 0	Argatroban NNP B-noun.person	with IN 0	thrombolytic_agents NNS B-noun.artifact	have VBP 0	not RB 0	been VBN 0	established VBN B-verb.creation	. . 0	. . 0
DDI-DrugBank.d73.s5	If IN 0	replacing VBG B-verb.change	clonidine NN B-noun.phenomenon	by IN 0	beta NNS B-noun.person	- : 0	blocker NN B-noun.person	therapy NN B-noun.person	, , 0	the DT 0	introduction NN B-noun.act	of IN 0	beta_blockers NNS B-noun.person	should MD 0	be VB 0	delayed VBN B-verb.social	for IN 0	several JJ B-adj.all	days NNS B-noun.phenomenon	after IN 0	clonidine JJ B-adj.all	administration NN B-noun.person	has VBZ 0	stopped VBN B-verb.stative	. . 0	. . 0
DDI-DrugBank.d82.s24	Therefore RB 0	, , 0	when WRB 0	INDOCIN NNP B-noun.group	and CC 0	INDOCIN NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d178.s7	A DT 0	possible JJ B-adj.all	interaction NN B-noun.act	between IN 0	glyburide NN B-noun.person	and CC 0	ciprofloxacin NN B-noun.person	, , 0	a DT 0	fluoroquinolone_antibiotic JJ B-adj.all	, , 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	, , 0	resulting VBG B-verb.stative	in IN 0	a DT 0	potentiation NN B-noun.person	of IN 0	the DT 0	hypoglycemic JJ B-adj.all	action NN B-noun.state	of IN 0	glyburide NN 0	. . 0	. . 0
DDI-DrugBank.d198.s8	A DT 0	5-mg JJ B-noun.person	Vardenafil NNP I-noun.person	dose NN I-noun.person	should MD 0	not RB 0	be VB 0	exceeded VBN B-verb.change	when WRB 0	used VBN B-verb.consumption	in IN 0	combination NN 0	with IN 0	200 CD 0	mg NN B-noun.quantity	once RB B-adv.all	daily JJ B-adj.pert	ketoconazole NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d172.s16	Fluconazole NNP B-noun.person	, , 0	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	fluconazole NN B-noun.shape	at IN 0	200 CD 0	mg IN 0	QD NNP 0	resulted VBD B-verb.communication	in IN 0	a DT 0	two CD 0	- : 0	fold JJ B-adj.all	increase NN B-noun.act	in IN 0	celecoxib NN B-noun.body	plasma NN B-noun.substance	concentration NN B-noun.event	. . 0	. . 0
DDI-DrugBank.d73.s0	Catecholamine SYM 0	- : 0	depleting VBG B-verb.communication	drugs NNS B-noun.person	( ( 0	eg UH 0	, , 0	reserpine NN B-noun.location	) ) 0	may MD 0	have VB B-verb.possession	an DT 0	additive JJ B-adj.all	effect NN B-noun.cognition	when WRB 0	given VBN B-verb.possession	with IN 0	beta JJ B-noun.body	- : 0	blocking_agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d459.s0	The DT 0	daily JJ B-noun.event	dose NN 0	of IN 0	ENABLEX NNP B-noun.group	should MD 0	not RB B-adv.all	exceed VB B-verb.stative	7.5 CD 0	mg NN B-noun.quantity	when WRB 0	coadministered VBN B-verb.communication	with IN 0	potent JJ B-noun.person	CYP3A4 JJ I-noun.person	inhibitors NNS I-noun.person	( ( 0	e.g. UH 0	, , 0	ketoconazole NN B-noun.person	, , 0	itraconazole NN B-noun.person	, , 0	ritonavir NN B-noun.person	, , 0	nelfinavir NN B-noun.person	, , 0	clarithromycin NN B-noun.person	and CC 0	nefazadone NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d318.s0	When WRB 0	administered VBN B-verb.communication	concurrently RB B-adv.all	, , 0	the DT 0	following VBG 0	drugs NNS B-noun.animal	may MD 0	interact VB B-verb.change	with IN 0	amphotericin_B JJ 0	, , 0	Antineoplastic_agents NNS B-noun.location	, , 0	may MD 0	enhance VB B-verb.change	the DT 0	potential NN B-noun.person	for IN 0	renal JJ B-adj.all	toxicity NN B-noun.attribute	, , 0	bronchospasm NN B-noun.person	and CC 0	hypotension NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d54.s11	Estrogen NN 0	, , 0	Oral NNP B-noun.group	Contraceptives NNPS I-noun.group	, , 0	Estrogens NNS B-noun.person	tend VBP 0	to TO 0	increase VB B-verb.social	serum NN B-noun.person	thyroxine NN B-noun.person	- : 0	binding JJ B-verb.contact	globulin NN B-noun.substance	( ( 0	TBg NNP 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d41.s12	Tolbutamide NNP 0	, , 0	In IN 0	in IN 0	vitro NN B-noun.artifact	studies NNS B-noun.artifact	, , 0	M1 PRP 0	was VBD 0	shown VBN B-verb.perception	to TO 0	cause VB B-verb.communication	increases NNS B-noun.event	ranging VBG B-verb.stative	from IN 0	13 CD B-adj.all	; : 0	50 CD B-adj.all	% NN 0	in IN 0	the DT 0	free JJ B-adj.all	fraction NN B-noun.act	of IN 0	tolbutamide NN 0	at IN 0	concentrations NNS B-noun.food	in IN 0	the DT 0	clinical JJ B-adj.all	range NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d115.s3	Drugs NNS B-noun.artifact	that WDT 0	may MD 0	decrease VB B-verb.change	imatinib JJ B-adj.all	plasma NN B-noun.substance	concentrations NNS I-noun.substance	, , 0	Substances NNS B-noun.person	that WDT 0	are VBP B-verb.stative	inducers NNS B-noun.person	of IN 0	CYP3A4 JJ B-noun.phenomenon	activity NN B-noun.process	may MD 0	increase VB B-verb.change	metabolism NN B-noun.artifact	and CC 0	decrease VB B-verb.change	imatinib JJ B-adj.all	plasma NN B-noun.substance	concentrations NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d374.s1	Auranofin NNP B-noun.person	should MD 0	not RB 0	be VB 0	used VBN B-verb.consumption	together RB 0	with IN 0	penicillamine NN B-noun.person	( ( 0	Depen NNP B-noun.person	, , 0	Cuprimine NNP B-noun.location	) ) 0	, , 0	another DT 0	arthritis NN B-noun.artifact	medication NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d448.s0	MAO_inhibitors NNS B-noun.person	prolong VBP B-verb.stative	and CC 0	intensify VB B-verb.change	the DT 0	effects NNS B-noun.phenomenon	of IN 0	antihistamines NNS B-noun.object	. . 0	. . 0
DDI-MedLine.d0.s1	Quetiapine_fumarate VB B-verb.communication	( ( 0	' '' 0	Seroquel NNP B-noun.person	' POS 0	) ) 0	is VBZ B-verb.stative	a DT 0	newly RB B-adv.all	introduced VBN B-verb.creation	atypical_antipsychotic JJ B-adj.all	with IN 0	demonstrated JJ B-adj.all	efficacy NN B-noun.person	in IN 0	the DT 0	treatment NN B-noun.communication	of IN 0	positive JJ B-adj.all	and CC 0	negative JJ B-adj.all	symptoms NNS B-noun.relation	of IN 0	schizophrenia NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d98.s7	Digitalis NNP B-noun.person	, , 0	Vitamin_D JJ B-adj.all	dosage NN B-noun.artifact	must MD 0	be VB 0	determined VBN B-verb.communication	with IN 0	care NN B-noun.food	in IN 0	patients NNS B-noun.person	undergoing VBG B-verb.communication	treatment NN I-verb.communication	with IN 0	digitalis NNS B-noun.food	, , 0	as IN 0	hypercalcemia NN B-noun.person	in IN 0	such JJ B-adj.all	patients NNS B-noun.person	may MD 0	precipitate VB B-verb.stative	cardiac JJ B-adj.all	arrhythmias NN B-noun.person	. . 0	. . 0
DDI-MedLine.d124.s9	There EX 0	was VBD 0	not RB B-adv.all	a DT 0	significant JJ B-adj.all	difference NN B-noun.cognition	( ( 0	p IN 0	> $ 0	0.05 CD 0	) ) 0	in IN 0	AUC NNP 0	( ( 0	48.59 CD 0	+ : 0	/- $ 0	8.52 CD B-noun.other	vs. FW I-noun.other	49.9 CD I-noun.other	+ : 0	/- $ 0	9.93 CD 0	) ) 0	, , 0	Cmax NNP B-noun.person	( ( 0	7.73 CD 0	+ : 0	/- $ 0	2.6 CD 0	vs. FW 0	6.6 CD 0	+ : 0	/- $ 0	2.0 CD B-noun.quantity	) ) 0	, , 0	and CC 0	tmax NN B-noun.person	( ( 0	1.1 CD 0	+ : 0	/- $ 0	0.6 CD 0	vs. FW 0	1.6 CD 0	+ : 0	/- $ 0	1.1 CD 0	) ) 0	for IN 0	levofloxacin NN B-noun.attribute	versus NN I-noun.attribute	levofloxacin NN B-noun.communication	/ '' 0	oxycodone NN 0	regimens VBZ B-verb.communication	. . 0	. . 0
DDI-DrugBank.d500.s3	Absorption NNP B-noun.person	of IN 0	tetracycline NN B-noun.phenomenon	is VBZ 0	impaired VBN B-verb.change	by IN 0	bismuth_subsalicylate JJ B-noun.other	. . 0	. . 0
DDI-DrugBank.d411.s15	Sodium_Iodide RB 0	( ( 0	123I NN 0	and CC 0	131I NNP B-noun.location	) ) 0	, , 0	Sodium_Pertechnetate_Tc99 JJ B-adj.all	m NN B-noun.attribute	, , 0	Uptake NNP B-noun.location	of IN 0	radiolabeled JJ B-adj.all	ions NNS B-noun.artifact	may MD 0	be VB 0	decreased VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d509.s25	In IN 0	in IN 0	vivo JJ B-adj.all	studies NNS B-noun.artifact	, , 0	10- UH 0	to TO 0	30-mg VB 0	/ DT 0	day NN B-noun.phenomenon	doses NNS B-noun.event	of IN 0	aripiprazole NN B-noun.communication	had VBD B-verb.perception	no DT 0	significant JJ B-adj.all	effect NN B-noun.cognition	on IN 0	metabolism NN B-noun.artifact	by IN 0	CYP2D6 NNP B-noun.person	( ( 0	dextromethorphan NN 0	) ) 0	, , 0	CYP2C9 NNP B-noun.person	( ( 0	warfarin NN 0	) ) 0	, , 0	CYP2C19 NNP B-noun.person	( ( 0	omeprazole NN B-noun.person	, , 0	warfarin NN B-noun.location	) ) 0	, , 0	and CC 0	CYP3A4 NNP B-noun.person	( ( 0	dextromethorphan NN 0	) ) 0	substrates NNS B-noun.location	. . 0	. . 0
DDI-DrugBank.d148.s6	Co SYM 0	- : 0	administration NN B-noun.time	, , 0	Concomitant JJ 0	use NN 0	of IN 0	Argatroban NNP B-noun.person	with IN 0	antiplatelet_agents NNS B-noun.person	, , 0	thrombolytics NNS B-noun.person	, , 0	and CC 0	other JJ 0	anticoagulants NNS B-noun.person	may MD 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	bleeding NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d564.s0	The DT 0	administration NN B-noun.time	of IN 0	local JJ B-adj.all	anesthetic_solutions NNS 0	containing VBG B-verb.stative	epinephrine NN B-noun.substance	or CC 0	norepinephrine NN B-noun.person	to TO 0	patients NNS B-noun.person	receiving VBG B-verb.communication	monoamine_oxidase_inhibitors NNS B-noun.person	or CC 0	tricyclic_antidepressants NNS B-noun.group	may MD 0	produce VB B-verb.cognition	severe JJ 0	, , 0	prolonged VBD B-verb.communication	hypertension NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d441.s1	Therefore RB 0	, , 0	linezolid NN B-noun.person	has VBZ B-verb.possession	the DT 0	potential NN B-noun.person	for IN 0	interaction NN B-noun.act	with IN 0	adrenergic JJ B-adj.all	and CC 0	serotonergic_agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d67.s5	Desloratadine NNP B-noun.person	3-Hydroxydesloratadine NNP I-noun.person	. . 0
DDI-DrugBank.d325.s6	Dopamine SYM 0	- : 0	induced VBN B-verb.creation	renal JJ B-adj.all	and CC 0	mesenteric JJ B-adj.all	vasodilation NN B-noun.attribute	is VBZ B-verb.stative	not RB B-adv.all	antagonized VBN B-verb.cognition	by IN 0	either DT 0	alpha- NNP B-noun.location	or CC 0	beta JJ B-noun.body	- : 0	adrenergic_blocking_agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d12.s6	Fulminant JJ B-adj.all	rhabdomyolysis NN B-noun.cognition	has VBZ 0	been VBN 0	seen VBN B-verb.perception	as IN 0	early RB 0	as IN 0	three CD 0	weeks NNS B-noun.time	after IN 0	initiation NN B-noun.time	of IN 0	combined VBN B-verb.change	therapy NN 0	with IN 0	another DT 0	fibrate NN B-noun.person	and CC 0	lovastatin NN B-noun.person	but CC 0	may MD 0	be VB 0	seen VBN B-verb.perception	after IN 0	several JJ B-adj.all	months NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d382.s13	Aprepitant NNP B-noun.person	, , 0	when WRB 0	given VBN B-verb.possession	as IN 0	a DT 0	regimen NNS B-noun.person	of IN 0	125 CD 0	mg NN B-noun.quantity	on IN 0	Day NNP 0	1 CD 0	and CC 0	80 CD 0	mg RB 0	/ JJ 0	day NN 0	on IN 0	Days NNS B-noun.time	2 CD 0	and CC 0	3 CD B-adj.all	, , 0	increased VBD B-verb.change	the DT 0	AUC NNP B-noun.group	of IN 0	methylprednisolone NN B-noun.attribute	, , 0	a DT 0	CYP3A4 JJ B-adj.all	substrate NN B-noun.person	, , 0	by IN 0	1.34-fold JJ B-noun.other	on IN I-noun.other	Day NNP I-noun.other	1 CD I-noun.other	and CC 0	by IN 0	2.5-fold JJ 0	on IN 0	Day NN 0	3 CD 0	, , 0	when WRB 0	methylprednisolone NN B-noun.person	was VBD 0	coadministered VBN B-verb.contact	intravenously RB I-verb.contact	as IN 0	125 CD 0	mg NN B-noun.quantity	on IN 0	Day NNP 0	1 CD 0	and CC 0	orally RB B-adv.all	as IN 0	40 CD B-adj.all	mg NN B-noun.quantity	on IN 0	Days NNS B-noun.time	2 CD 0	and CC 0	3 CD B-adj.all	. . 0	. . 0
DDI-MedLine.d125.s4	Animals NNS 0	dosed VBN 0	with IN 0	1,3-difluoroacetone CD 0	did VBD 0	not RB B-adv.all	display VB B-verb.perception	the DT 0	2 CD B-adj.all	- : 0	3 CD B-adj.all	hour NN 0	lag NN 0	phase NN B-noun.time	in IN 0	either DT 0	( ( 0	-)-erythro UH 0	- : 0	fluorocitrate JJ B-adj.all	synthesis NN B-noun.cognition	or CC 0	in IN 0	citrate NN B-noun.location	and CC 0	fluoride JJ B-adj.all	accumulation NN 0	characteristic NN 0	of IN 0	animals NNS 0	dosed VBN 0	with IN 0	1,3-difluoro-2-propanol NN 0	. . 0	. . 0
DDI-DrugBank.d217.s12	Videx NNP B-noun.person	( ( 0	Didanosine NNP B-noun.person	) ) 0	chewable NN B-noun.communication	/ : 0	buffered VBN B-verb.creation	tablets NNS B-noun.artifact	or CC 0	the DT 0	pediatric JJ B-adj.pert	powder NN B-noun.state	for IN 0	oral JJ B-adj.all	solution NN B-noun.cognition	should MD 0	not RB 0	be VB 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	, , 0	or CC 0	within IN 0	2 CD B-adj.all	hours NNS B-noun.person	of IN 0	, , 0	the DT 0	administration NN B-noun.time	of IN 0	norfloxacin NN B-noun.food	, , 0	because IN 0	these DT 0	products NNS B-noun.artifact	may MD 0	interfere VB B-verb.stative	with IN 0	absorption NN B-noun.artifact	resulting VBG B-verb.stative	in IN 0	lower JJR B-adj.all	serum NN B-noun.person	and CC 0	urine NN B-noun.body	levels NNS B-noun.attribute	of IN 0	norfloxacin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d219.s2	Antacids NNP B-noun.person	, , 0	The DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	antacids NNS B-noun.animal	has VBZ B-verb.possession	no DT 0	apparent JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	extent NN B-noun.attribute	of IN 0	absorption NN B-noun.process	of IN 0	Lodine NNP B-noun.location	. . 0	. . 0
DDI-DrugBank.d324.s11	In IN 0	addition NN 0	, , 0	there EX 0	was VBD B-verb.stative	no DT 0	pharmacodynamic JJ B-adj.pert	interaction NN B-noun.act	as IN 0	a DT 0	result NN B-noun.act	of IN 0	coadministration NN B-noun.person	of IN 0	zaleplon NN B-noun.person	and CC 0	venlafaxine VB B-verb.change	ER NNP 0	. . 0	. . 0
DDI-DrugBank.d277.s10	Effects NNS B-noun.phenomenon	of IN 0	other JJ 0	Antiepilepsy NNP B-noun.person	Drugs NNP I-noun.person	( ( 0	AEDs NNP B-noun.group	) ) 0	on IN 0	GABITRIL NNP B-noun.group	, , 0	Carbamazepine NNP B-noun.person	, , 0	Population NNP B-noun.other	pharmacokinetic JJ B-adj.all	analyses NNS B-noun.act	indicate VBP B-verb.cognition	that IN 0	tiagabine JJ B-adj.all	clearance NN B-noun.attribute	is VBZ B-verb.stative	60 CD B-adj.all	% NN 0	greater JJR B-adj.all	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	carbamazepine NN I-verb.social	with IN 0	or CC 0	without IN 0	other JJ 0	enzyme- JJ 0	inducing VBG B-verb.communication	AEDs NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d161.s1	For IN 0	information NN B-noun.cognition	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	Gemzar NNP B-noun.person	and CC 0	cisplatin NN B-noun.person	in IN 0	combination NN 0	, , 0	see VBP B-verb.social	Drug NNP B-noun.person	Interactions NNP I-noun.person	under IN 0	CLINICAL NNP B-noun.group	PHARMACOLOGY NNP I-noun.group	section NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d499.s6	however RB 0	, , 0	in IN 0	a DT 0	study NN B-noun.artifact	of IN 0	12 CD B-adj.all	normal JJ B-adj.all	subjects NNS B-noun.person	, , 0	concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	aspirin NN B-noun.person	decreased VBD B-verb.change	ketoprofen JJ B-adj.all	protein NN B-noun.substance	binding NN B-verb.contact	and CC 0	increased VBD B-verb.change	ketoprofen JJ B-adj.all	plasma NN B-noun.person	clearance NN B-noun.person	from IN 0	0.07 CD 0	L NNP B-noun.quantity	/ , 0	kg PRP 0	/ : 0	h PRP 0	without IN 0	aspirin NN B-noun.person	to TO 0	0.11 CD 0	L NNP B-noun.quantity	/ , 0	kg PRP 0	/ : 0	h PRP 0	with IN 0	aspirin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d525.s5	Eprosartan NNP B-adj.pert	doses NNS B-noun.event	of IN 0	up RB 0	to TO 0	300 CD 0	mg IN 0	b.i.d NNP B-noun.person	. . 0	have VB 0	been VBN 0	safely RB B-adv.all	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	sustained VBN B-verb.cognition	- : 0	release NN B-noun.communication	calcium_channel_blockers NNS B-noun.communication	( ( 0	sustained VBN B-verb.body	- : 0	release NN B-verb.body	nifedipine NN 0	) ) 0	with IN 0	no DT 0	clinically RB B-adv.all	significant JJ B-adj.all	adverse JJ B-adj.all	interactions NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d153.s3	Concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	vasopressor_drugs NNS B-noun.artifact	and CC 0	of IN 0	ergot NN B-noun.person	- : 0	type_oxytocic_drugs NNS B-noun.object	may MD 0	cause VB B-verb.cognition	severe JJ 0	, , 0	persistent JJ B-adj.all	hypertension NN B-noun.feeling	or CC 0	cerebrovascular JJ B-adj.all	accidents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d16.s2	Since IN 0	hydroxyurea NN 0	may MD 0	raise VB B-verb.change	the DT 0	serum NN B-noun.body	uric JJ B-adj.all	acid NN B-noun.attribute	level NN I-noun.attribute	, , 0	dosage NN B-noun.phenomenon	adjustment NN B-noun.process	of IN 0	uricosuric_medication NN B-noun.act	may MD 0	be VB B-verb.stative	necessary JJ B-adj.all	. . 0
DDI-DrugBank.d277.s11	Phenytoin NN B-noun.person	, , 0	Population NNP B-noun.other	pharmacokinetic JJ B-adj.all	analyses NNS B-noun.act	indicate VBP B-verb.cognition	that IN 0	tiagabine JJ B-adj.all	clearance NN B-noun.attribute	is VBZ B-verb.stative	60 CD B-adj.all	% NN 0	greater JJR B-adj.all	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	phenytoin NN I-verb.social	with IN 0	or CC 0	without IN 0	other JJ 0	enzyme- JJ 0	inducing VBG B-verb.communication	AEDs NNP B-noun.person	. . 0	. . 0
DDI-MedLine.d17.s4	PGF2alpha RB 0	produced VBN B-verb.creation	significantly RB 0	increased VBN B-verb.change	vasoconstriction NN I-verb.change	after IN 0	a DT 0	single JJ B-adj.all	administration NN B-noun.time	of IN 0	oxytocin NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d275.s3	Two CD 0	percent NN B-noun.person	of IN 0	patients NNS B-noun.person	treated VBD B-verb.communication	concurrently RB B-adv.all	with IN 0	Kineret NNP B-noun.person	and CC 0	etanercept VBD 0	developed VBN B-verb.creation	neutropenia NN B-noun.person	( ( 0	ANC NNP 0	_ $ 0	1 CD B-adj.all	x IN 0	109/L NNP 0	) ) 0	. . 0	. . 0
DDI-MedLine.d67.s7	Midazolam NN B-noun.person	used VBN B-verb.consumption	at IN 0	doses NNS B-noun.act	of IN 0	1.25 CD 0	mg FW B-noun.quantity	/ FW 0	kg FW 0	and CC 0	2.5 CD 0	mg PRP B-noun.quantity	/ : 0	kg PRP 0	decreased VBD B-verb.change	the DT 0	antinociceptive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	morphine NN B-noun.person	, , 0	metamizol NN B-noun.person	( ( 0	only RB B-adv.all	in IN 0	the DT 0	tail NN B-noun.body	- : 0	flick NN 0	test NN 0	) ) 0	and CC 0	indomethacin NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d39.s0	Persons NNS B-noun.person	taking VBG 0	most JJS 0	antibiotics NNS B-noun.person	, , 0	methotrexate NN B-noun.person	and CC 0	pyrimethamine NN 0	invalidate VB B-verb.stative	folic_acid JJ 0	and CC 0	vitamin_B12 JJ B-adj.all	diagnostic JJ B-adj.all	blood NN B-noun.body	assays NNS I-noun.body	. . 0	. . 0
DDI-DrugBank.d340.s10	Terfenadine NN B-noun.person	, , 0	Administration NNP B-noun.person	of IN 0	terfenadine NN 0	with IN 0	VIRACEPT NNP B-noun.group	resulted VBD B-verb.competition	in IN 0	the DT 0	appearance NN B-noun.act	of IN 0	unchanged JJ B-adj.all	terfenadine NN B-noun.person	in IN 0	plasma NN B-noun.substance	, , 0	. . 0
DDI-MedLine.d115.s0	Concomitant JJ B-adj.all	cyclophosphamide NN 0	, , 0	doxorubicin NN B-noun.person	, , 0	vincristine NN B-noun.person	, , 0	and CC 0	prednisone NN B-noun.person	chemotherapy NN B-noun.cognition	plus CC 0	highly_active_antiretroviral JJ B-adj.all	therapy NN B-noun.act	in IN 0	patients NNS B-noun.person	with IN 0	human JJ B-adj.all	immunodeficiency NN B-noun.person	virus NN B-noun.person	- : 0	related VBN B-verb.cognition	, , 0	non RB 0	- : 0	Hodgkin NNP B-noun.person	lymphoma NN I-noun.person	. . 0	. . 0
DDI-DrugBank.d495.s1	Clonidine_hydrochloride NN B-noun.artifact	may MD 0	enhance VB B-verb.change	the DT 0	CNS NNP B-noun.group	- : 0	depressive JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	alcohol NN B-noun.food	, , 0	barbiturates NNS B-noun.artifact	or CC 0	other JJ B-adj.all	sedatives NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d25.s1	OBJECTIVE NNP B-noun.group	, , 0	To TO 0	report VB B-verb.communication	a DT 0	case NN B-noun.state	of IN 0	rhabdomyolysis NN B-noun.state	resulting VBG B-verb.stative	from IN 0	concomitant JJ B-adj.all	use NN 0	of IN 0	clarithromycin NN B-noun.person	and CC 0	simvastatin NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d81.s10	If IN 0	rifampicin JJ B-adj.all	therapy NN B-noun.person	is VBZ 0	required VBN B-verb.stative	, , 0	isradipine JJ B-adj.all	concentrations NNS B-noun.artifact	and CC 0	therapeutic JJ B-adj.pert	effects NNS B-noun.phenomenon	are VBP B-verb.stative	likely JJ B-adj.all	to TO 0	be VB B-verb.stative	markedly RB B-adv.all	reduced VBN B-verb.change	or CC 0	abolished VBN B-verb.possession	as IN 0	a DT 0	consequence NN B-noun.attribute	of IN 0	increased JJ B-adj.all	metabolism NN B-noun.attribute	and CC 0	higher JJR B-adj.all	clearance NN B-noun.attribute	of IN 0	isradipine NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d367.s13	Antihistamines NNS 0	( ( 0	e.g. UH 0	, , 0	chlorpheniramine NN 0	) ) 0	. . 0	. . 0
DDI-MedLine.d61.s8	Amiodarone NNP B-noun.person	caused VBD B-verb.creation	a DT 0	three- JJ 0	to TO 0	fivefold JJ B-adj.all	increase NN B-noun.act	in IN 0	serum NN 0	reverse VB B-verb.communication	triiodothyronine NN B-noun.communication	levels NNS B-noun.attribute	, , 0	but CC 0	changes NNS B-noun.relation	in IN 0	thyroid JJ B-noun.body	function NN I-noun.body	were VBD B-verb.stative	not RB B-adv.all	quantitatively RB B-adv.all	related VBN B-verb.cognition	to TO 0	the DT 0	changes NNS B-noun.artifact	in IN 0	digoxin NN B-noun.person	pharmacokinetics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d450.s12	Although IN 0	beta JJ 0	- : 0	adrenergic_blockers NNS B-noun.person	or CC 0	calcium_channel_blockers NNS B-noun.communication	and CC 0	digoxin NN B-noun.person	may MD 0	be VB B-verb.stative	useful JJ B-adj.all	in IN 0	combination NN 0	to TO 0	control VB B-verb.social	atrial JJ B-adj.all	fibrillation NN B-noun.act	, , 0	their PRP$ 0	additive JJ B-adj.all	effects NNS B-noun.phenomenon	on IN 0	AV NNP 0	node JJ B-adj.all	conduction NN B-noun.group	can MD 0	result VB B-verb.stative	in IN 0	advanced JJ B-adj.all	or CC 0	complete JJ B-adj.all	heart NN B-noun.person	block NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d531.s45	Coadministration NN B-noun.person	in IN 0	HIV NNP 0	- : 0	infected JJ B-adj.all	individuals NNS B-noun.person	with IN 0	a DT 0	history NN B-noun.cognition	of IN 0	injection NN B-noun.artifact	drug NN I-noun.artifact	use NN 0	resulted VBD B-verb.stative	in IN 0	decreased VBN B-verb.change	plasma NN B-noun.substance	levels NNS B-noun.state	of IN 0	methadone NN B-noun.attribute	and CC 0	signs NNS B-noun.communication	of IN 0	opiate JJ B-adj.all	withdrawal NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d68.s5	Beta SYM 0	- : 0	adrenergic_blocking_agents NNS B-noun.person	, , 0	Coadministration NNP B-noun.person	of IN 0	beta JJ B-adj.pert	- : 0	adrenergic_blocking_agents NNS B-noun.person	did VBD 0	not RB B-adv.all	have VB B-verb.change	any DT 0	effect NN B-noun.cognition	on IN 0	either CC 0	the DT 0	safety NN B-noun.artifact	or CC 0	efficacy NN B-noun.phenomenon	of IN 0	ibutilide NN B-noun.food	in IN 0	the DT 0	clinical JJ B-adj.all	trials NNS B-noun.communication	. . 0	. . 0
DDI-DrugBank.d440.s10	Among IN 0	aspirin NN B-noun.attribute	or CC 0	NSAID NNP B-noun.group	users NNS B-noun.attribute	, , 0	the DT 0	incidence NN B-noun.event	of IN 0	upper JJ B-adj.all	gastrointestinal JJ B-adj.pert	adverse JJ B-noun.possession	events NNS I-noun.possession	in IN 0	patients NNS B-noun.person	treated VBD B-verb.social	with IN 0	ibandronate JJ B-adj.all	2.5 CD 0	mg NN B-noun.quantity	daily RB B-adv.all	( ( 0	28.9 CD 0	% NN 0	) ) 0	was VBD B-verb.stative	similar JJ B-adj.all	to TO 0	that DT 0	in IN 0	placebo NN 0	- : 0	treated VBN B-verb.communication	patients NNS B-noun.person	( ( 0	30.7 CD 0	% NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d64.s91	The DT 0	beneficial JJ B-adj.all	effects NNS B-noun.phenomenon	on IN 0	arterial JJ B-adj.all	thrombus NN 0	formation NN B-noun.act	from IN 0	combined VBN B-verb.stative	therapy NN 0	with IN 0	antiplatelet NN B-noun.attribute	and CC 0	anticoagulant_medication NN B-noun.person	must MD 0	be VB 0	weighed VBN B-verb.social	against IN 0	an DT 0	increased VBN B-verb.change	risk NN 0	of IN 0	inducing VBG B-verb.communication	hemorrhage NN I-verb.communication	. . 0	. . 0
DDI-DrugBank.d423.s4	A DT 0	rare JJ B-adj.all	, , 0	but CC 0	serious JJ B-adj.all	, , 0	constellation NN B-noun.act	of IN 0	symptoms NNS B-noun.body	, , 0	termed VBD B-verb.communication	serotonin NN B-noun.person	syndrome NN B-noun.person	, , 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	with IN 0	the DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	selective_serotonin_reuptake_inhibitors NNS B-noun.person	( ( 0	SSRIs NNP 0	) ) 0	and CC 0	agents NNS B-noun.person	for IN 0	migraine NN B-noun.act	therapy NN B-noun.act	, , 0	such JJ 0	as IN 0	Imitrex NNP B-noun.person	( ( 0	sumatriptan_succinate NN B-noun.time	) ) 0	and CC 0	dihydroergotamine NN B-noun.person	. . 0	. . 0
DDI-MedLine.d120.s4	filipin NN B-noun.person	was VBD B-verb.stative	more RBR B-adv.all	potent JJ B-adj.all	in IN 0	lysing VBG B-verb.stative	human JJ B-adj.all	red JJ B-adj.all	blood NN B-noun.body	cells NNS B-noun.body	, , 0	whereas IN 0	amphotericin_B NNP B-noun.person	was VBD B-verb.stative	more RBR B-adv.all	potent JJ B-adj.all	in IN 0	inhibiting VBG 0	yeast NN 0	cell NN 0	growth NN 0	, , 0	. . 0
DDI-DrugBank.d296.s0	Diphenhydramine_hydrochloride NN B-noun.cognition	has VBZ B-verb.stative	additive JJ B-adj.all	effects NNS B-noun.phenomenon	with IN 0	alcohol NN B-noun.person	and CC 0	other JJ B-adj.all	CNS_depressants NNS B-noun.person	( ( 0	hypnotics NNS B-noun.person	, , 0	sedatives NNS B-noun.person	, , 0	tranquilizers NNS B-noun.person	, , 0	etc FW 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d438.s31	This DT 0	small JJ B-noun.artifact	decrease NN I-noun.artifact	in IN 0	excretion NN B-noun.act	of IN 0	gabapentin NN B-noun.act	by IN 0	cimetidine NN B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	expected VBN B-verb.cognition	to TO 0	be VB B-verb.stative	of IN 0	clinical JJ B-adj.all	importance NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d455.s8	More JJR B-noun.quantity	than IN 0	600 CD 0	Parkinsons NNPS B-noun.other	disease NN B-noun.state	patients NNS B-noun.person	in IN 0	clinical JJ B-adj.all	trials NNS B-noun.communication	have VBP 0	used VBN B-verb.consumption	selegiline NN B-noun.person	in IN 0	combination NN 0	with IN 0	entacapone NN B-noun.person	and CC 0	levodopa NN B-noun.attribute	/ : 0	dopa_decarboxylase_inhibitor NN B-noun.quantity	. . 0	. . 0
DDI-DrugBank.d566.s0	Cholestyramine JJ B-adj.all	resin NN B-noun.act	may MD 0	delay VB B-verb.emotion	or CC 0	reduce VB B-verb.change	the DT 0	absorption NN B-noun.artifact	of IN 0	concomitant JJ B-adj.all	oral JJ B-adj.all	medication NN B-noun.state	such JJ 0	as IN 0	phenylbutazone NN 0	, , 0	warfarin NN B-noun.location	, , 0	thiazide_diuretics NNS B-noun.person	( ( 0	acidic JJ 0	) ) 0	or CC 0	propranolol NN B-noun.substance	( ( 0	basic JJ B-adj.all	) ) 0	, , 0	as RB 0	well RB 0	as IN 0	tetracycline JJ B-noun.person	penicillin_G NNP I-noun.person	, , 0	phenobarbital JJ B-adj.all	, , 0	thyroid JJ B-noun.body	and CC 0	thyroxine JJ B-noun.body	preparations NNS I-noun.body	, , 0	estrogens NNS B-noun.artifact	and CC 0	progestins NNS B-noun.person	, , 0	and CC 0	digitalis NN B-noun.person	. . 0	. . 0
DDI-MedLine.d21.s9	Imipramine NNP B-noun.person	and CC 0	clonazepam NN B-noun.person	did VBD 0	not RB B-adv.all	change VB B-verb.change	fasting VBG B-verb.creation	or CC 0	overload JJ B-adj.all	glycemia NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d423.s3	At IN 0	least JJS B-noun.communication	3 CD B-adj.all	weeks NNS B-noun.time	should MD 0	elapse VB B-verb.motion	between IN 0	discontinuation NN B-noun.act	of IN 0	dexfenfluramine NN B-noun.person	and CC 0	initiation NN B-noun.act	of IN 0	treatment NN B-noun.plant	with IN 0	a DT 0	MAO_inhibitor NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d325.s0	Because IN 0	dopamine NN 0	is VBZ 0	metabolized VBN B-verb.change	by IN 0	monoamine NN B-noun.phenomenon	oxidase NN B-noun.process	( ( 0	MAO NNP 0	) ) 0	, , 0	inhibition NN 0	of IN 0	this DT 0	enzyme NN B-noun.animal	prolongs NNS I-noun.animal	and CC 0	potentiates VBZ B-verb.communication	the DT 0	effect NN B-noun.cognition	of IN 0	dopamine NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d446.s0	Chlorotrianisene NNP B-noun.person	may MD 0	interact VB B-verb.change	with IN 0	antidepressants NNS B-noun.person	, , 0	aspirin NN B-noun.person	, , 0	barbiturates NNS B-noun.person	, , 0	bromocriptine NN B-noun.person	, , 0	calcium NN B-noun.artifact	supplements NNS B-noun.artifact	, , 0	corticosteroids NNS B-noun.person	, , 0	corticotropin NN B-noun.person	, , 0	cyclosporine NN B-noun.person	, , 0	dantrolene NN B-noun.person	, , 0	nicotine NN B-noun.person	, , 0	somatropin NN 0	, , 0	tamoxifen NNS B-noun.person	, , 0	and CC 0	warfarin NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d222.s1	The DT 0	following JJ B-adj.all	precautions NNS B-noun.communication	should MD 0	be VB 0	kept VBN B-verb.stative	in IN 0	mind NN 0	in IN 0	the DT 0	treatment NN B-noun.communication	of IN 0	anticholinesterase NN B-noun.animal	poisoning VBG B-verb.motion	although IN 0	they PRP 0	do VBP 0	not RB B-adv.all	bear VB B-verb.competition	directly RB I-verb.competition	on IN 0	the DT 0	use NN 0	of IN 0	atropine NN B-noun.act	and CC 0	pralidoxime NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d404.s11	Corticosteroids NNS B-noun.person	, , 0	A DT 0	relationship NN B-noun.state	of IN 0	functional JJ B-adj.all	antagonism NN B-noun.attribute	exists VBZ B-verb.stative	between IN 0	vitamin_D JJ B-adj.all	analogues NNS B-noun.attribute	, , 0	which WDT 0	promote VBP B-verb.stative	calcium NN B-adj.all	absorption NN B-noun.artifact	, , 0	and CC 0	corticosteroids NNS B-noun.person	, , 0	which WDT 0	inhibit VBP B-verb.stative	calcium NN B-adj.all	absorption NN B-noun.artifact	. . 0	. . 0
DDI-MedLine.d34.s0	Interactions NNS B-noun.person	of IN 0	cobalt NN B-noun.food	and CC 0	iron NN B-noun.person	in IN 0	absorption NN B-noun.artifact	and CC 0	retention NN B-noun.act	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d224.s8	Since IN 0	apraclonidine NN B-noun.act	may MD 0	reduce VB B-verb.change	pulse NN B-noun.food	and CC 0	blood NN B-noun.act	pressure NN B-noun.act	, , 0	caution NN B-noun.cognition	in IN 0	using VBG B-verb.consumption	drugs NNS I-verb.consumption	such JJ 0	as IN 0	beta NNS B-noun.person	- : 0	blockers NNS B-noun.person	( ( 0	ophthalmic JJ B-adj.all	and CC 0	systemic JJ B-noun.body	) ) 0	, , 0	antihypertensives NNS B-noun.person	, , 0	and CC 0	cardiac_glycosides NNS B-noun.group	is VBZ 0	advised VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d165.s9	In IN 0	vitro NN B-noun.animal	data NNS B-noun.cognition	suggest VBP B-verb.communication	that IN 0	itraconazole NN B-noun.person	also RB B-adv.all	markedly RB I-adv.all	inhibits VBZ B-verb.change	the DT 0	biotransformation NN B-noun.cognition	system NN I-noun.cognition	mainly RB B-adv.all	responsible JJ B-adj.all	for IN 0	the DT 0	metabolism NN B-noun.attribute	of IN 0	cisapride NN B-noun.location	, , 0	. . 0
DDI-DrugBank.d397.s10	Erythromycin NNP B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	significantly RB 0	alter VB B-verb.change	the DT 0	metabolism NN B-noun.attribute	of IN 0	nonsedating JJ B-adj.all	antihistamines NNS B-noun.communication	terfenadine NN B-noun.communication	and CC 0	astemizole NN B-noun.attribute	when WRB 0	taken VBN 0	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d220.s9	This DT 0	appears VBZ B-verb.stative	to TO 0	be VB B-verb.stative	the DT 0	only RB B-adv.all	clinically RB B-adj.all	relevant JJ B-adj.pert	interaction NN B-noun.act	of IN 0	this DT 0	kind NN 0	with IN 0	Mefloquine NNP B-noun.person	, , 0	although IN 0	theoretically RB B-adv.all	, , 0	coadministration NN B-noun.person	of IN 0	other JJ 0	drugs NNS B-noun.artifact	known VBN B-verb.cognition	to TO 0	alter VB B-verb.change	cardiac JJ B-adj.all	conduction NN B-noun.cognition	( ( 0	eg UH 0	, , 0	anti NNS B-noun.person	- : 0	arrhythmic JJ B-verb.contact	or CC 0	beta JJ B-noun.body	- : 0	adrenergic_blocking_agents NNS B-noun.person	, , 0	calcium_channel_blockers NNS B-noun.person	, , 0	antihistamines NNS B-noun.attribute	or CC 0	H1-blocking_agents NNS B-noun.artifact	, , 0	tricyclic_antidepressants NNS B-noun.person	and CC 0	phenothiazines NNS B-noun.body	) ) 0	might MD 0	also RB B-adv.all	contribute VBP B-verb.communication	to TO 0	a DT 0	prolongation NN B-noun.person	of IN 0	the DT 0	QTc NNP B-noun.person	interval NN I-noun.person	. . 0	. . 0
DDI-DrugBank.d384.s4	Thiazides NNS B-noun.person	, , 0	Thiazides NNS 0	are VBP 0	known VBN B-verb.cognition	to TO 0	induce VB B-verb.cognition	hypercalcemia NN B-noun.person	by IN 0	the DT 0	reduction NN B-noun.act	of IN 0	calcium NN B-adj.all	excretion NN B-noun.act	in IN 0	urine NN B-noun.location	. . 0	. . 0
DDI-MedLine.d90.s11	It PRP 0	was VBD 0	concluded VBN B-verb.cognition	that IN 0	, , 0	although IN 0	gentamycin NN B-noun.person	did VBD 0	augment VB B-verb.communication	the DT 0	neuromuscular JJ B-adj.all	blockade NN B-noun.attribute	of IN 0	atracurium NN B-noun.artifact	, , 0	the DT 0	effect NN B-noun.cognition	was VBD B-verb.stative	minimal JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d277.s26	This DT 0	indicates VBZ B-verb.communication	that IN 0	tiagabine NN 0	does VBZ 0	not RB B-adv.all	cause VB B-verb.communication	induction NN B-noun.cognition	or CC 0	inhibition NN B-noun.attribute	of IN 0	the DT 0	hepatic JJ B-adj.all	microsomal JJ B-adj.all	enzyme NN B-noun.plant	systems NNS B-noun.body	responsible JJ B-adj.all	for IN 0	the DT 0	metabolism NN B-noun.attribute	of IN 0	antipyrine NN B-noun.attribute	. . 0	. . 0
DDI-MedLine.d3.s6	Rifabutin NNP B-noun.person	did VBD 0	not RB B-adv.all	significantly RB B-adv.all	affect VB B-verb.body	amprenavir NN B-noun.person	's POS 0	pharmacokinetics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d76.s14	Alprazolam NNP B-noun.person	, , 0	When WRB 0	fluvoxamine_maleate JJ B-adj.all	( ( 0	100 CD 0	mg NN B-noun.quantity	qd NN 0	) ) 0	and CC 0	alprazolam NN B-noun.person	( ( 0	1 CD 0	mg IN 0	q.d NNP 0	. . 0	were VBD B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	to TO 0	steady JJ B-adj.all	state NN B-noun.state	, , 0	plasma NN B-noun.substance	concentration NN B-noun.event	and CC 0	other JJ 0	pharmacokinetics NNS B-noun.person	parameters NNS B-noun.person	( ( 0	AUC NNP 0	, , 0	Cmax NNP B-noun.person	, , 0	T1/2 NNP B-noun.person	, , 0	) ) 0	of IN 0	alprazolam NN B-noun.person	were VBD B-verb.stative	approximately RB B-adv.all	twice RB 0	those DT 0	observed VBN B-verb.perception	when WRB 0	alprazolam NN B-noun.person	was VBD 0	administered VBN B-verb.perception	alone RB B-adv.all	, , 0	. . 0
DDI-DrugBank.d72.s3	Since IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	BUSULFEX NNP B-noun.group	were VBD 0	studied VBN B-verb.cognition	in IN 0	patients NNS B-noun.person	treated VBD B-verb.social	with IN 0	phenytoin NN B-noun.person	, , 0	the DT 0	clearance NN B-noun.act	of IN 0	BUSULFEX NNP B-noun.group	at IN 0	the DT 0	recommended VBN B-noun.artifact	dose NN I-noun.artifact	may MD 0	be VB B-verb.stative	lower JJR B-adj.all	and CC 0	exposure NN B-noun.cognition	( ( 0	AUC NNP 0	) ) 0	higher JJR B-adj.all	in IN 0	patients NNS B-noun.person	not RB B-adv.all	treated VBN B-verb.change	with IN 0	phenytoin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d234.s2	Particular JJ B-adj.all	caution NN B-noun.communication	is VBZ B-verb.stative	necessary JJ B-adj.all	when WRB 0	using VBG B-verb.consumption	ROMAZICON NNP B-noun.group	in IN 0	cases NNS B-noun.state	of IN 0	mixed JJ B-adj.all	drug NN B-noun.person	overdosage NN 0	since IN 0	the DT 0	toxic JJ B-adj.all	effects NNS B-noun.phenomenon	( ( 0	such JJ 0	as IN 0	convulsions NNS B-noun.person	and CC 0	cardiac JJ 0	dysrhythmias NNS 0	) ) 0	of IN 0	other JJ 0	drugs NNS B-noun.artifact	taken VBN B-verb.possession	in IN 0	overdose JJ 0	( ( 0	especially RB B-adv.all	cyclic_antidepressants NNS 0	) ) 0	may MD 0	emerge VB B-verb.change	with IN 0	the DT 0	reversal NN B-noun.act	of IN 0	the DT 0	benzodiazepine JJ B-adj.all	effect NN B-noun.phenomenon	by IN 0	flumazenil NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d188.s1	Data NNS B-noun.cognition	from IN 0	a DT 0	randomized JJ B-adj.all	trial NN B-noun.act	of IN 0	HEXALEN NNP B-noun.group	and CC 0	cisplatin NN B-noun.person	plus CC 0	or CC 0	minus CC 0	pyridoxine NN 0	in IN 0	ovarian JJ B-adj.all	cancer NN B-noun.person	indicated VBD B-verb.communication	that IN 0	pyridoxine NN 0	significantly RB B-adv.all	reduced VBN B-verb.change	neurotoxicity NN I-verb.change	, , 0	. . 0
DDI-DrugBank.d107.s6	In IN 0	a DT 0	clinical JJ B-adj.all	pharmacology NN B-noun.phenomenon	study NN B-noun.artifact	, , 0	indomethacin NN B-noun.communication	or CC 0	sulindac NN B-noun.substance	was VBD 0	administered VBN B-verb.perception	to TO 0	hypertensive JJ B-adj.all	patients NNS B-noun.person	receiving VBG B-verb.change	VASOTEC NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d507.s7	The DT 0	gradual JJ B-adj.all	withdrawal NN B-noun.act	of IN 0	guafacine NN B-noun.location	or CC 0	a DT 0	cardioselective_beta JJ B-noun.group	- : 0	blocker NN B-noun.person	could MD 0	be VB 0	substituted VBN B-verb.possession	. . 0	. . 0
DDI-DrugBank.d231.s14	There EX 0	are VBP B-verb.stative	case NN 0	reports NNS B-noun.communication	of IN 0	patients NNS B-noun.person	who WP 0	developed VBD 0	increased VBN B-verb.change	BUN NNP 0	, , 0	serum NN B-noun.person	creatinine NN B-noun.person	and CC 0	serum NN B-noun.body	potassium NN I-noun.body	levels NNS B-noun.attribute	, , 0	and CC 0	weight NN B-noun.artifact	gain NN B-noun.artifact	when WRB 0	furosemide NN 0	was VBD 0	used VBN B-verb.consumption	in IN 0	conjunction NN 0	with IN 0	NSAIDs NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d554.s0	Certain JJ B-adj.all	antibiotic JJ B-adj.all	, , 0	cisplatin NN B-noun.person	, , 0	cyclosporine NN B-noun.person	, , 0	diuretic JJ B-adj.all	, , 0	foscarnet NN B-noun.person	, , 0	and CC 0	vaccines NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d427.s0	Elevated JJ B-adj.all	plasma NN B-noun.substance	levels NNS B-noun.state	of IN 0	theophylline PRP 0	have VBP 0	been VBN 0	reported VBN B-verb.communication	with IN 0	concomitant JJ B-adj.all	quinolone NN B-noun.artifact	use NN I-noun.artifact	. . 0	. . 0
DDI-DrugBank.d480.s9	Clozapine NN B-noun.person	may MD 0	potentiate VB B-verb.communication	the DT 0	hypotensive JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	antihypertensive_drugs NNS B-noun.object	and CC 0	the DT 0	anticholinergic JJ B-adj.pert	effects NNS B-noun.phenomenon	of IN 0	atropine JJ B-adj.all	- : 0	type NN B-noun.person	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d87.s16	Drugs NNS B-noun.artifact	that WDT 0	inhibit VBP B-verb.possession	cytochrome JJ B-noun.person	P450IID6 NNP I-noun.person	, , 0	such JJ 0	as IN 0	quinidine NN B-noun.location	, , 0	might MD 0	increase VB B-verb.change	the DT 0	plasma NN B-noun.plant	concentrations NNS B-noun.attribute	of IN 0	flecainide NN B-noun.food	in IN 0	patients NNS B-noun.artifact	that WDT 0	are VBP B-verb.stative	on IN 0	chronic JJ B-adj.all	flecainide NN B-noun.artifact	therapy NN B-noun.artifact	, , 0	. . 0
DDI-MedLine.d34.s9	Consequently RB B-adv.all	, , 0	the DT 0	effect NN B-noun.cognition	of IN 0	iron NN B-noun.person	on IN 0	the DT 0	retention NN B-noun.act	of IN 0	cobalt NN B-noun.person	was VBD B-verb.stative	lower JJR B-adj.all	than IN 0	on IN 0	absorption NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d468.s0	Beta SYM 0	- : 0	Blockers NNS B-noun.person	, , 0	In IN 0	controlled VBN B-verb.social	clinical JJ B-adj.all	studies NNS B-noun.communication	, , 0	adrenergic_beta JJ B-noun.group	- : 0	receptor_blockers NNS B-noun.person	have VBP 0	been VBN 0	frequently RB B-adv.all	administered VBN B-verb.change	concomitantly RB B-adv.all	with IN 0	nicardipine_HCl NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d226.s1	Digoxin NNP B-noun.person	and CC 0	verapamil NN B-noun.artifact	use NN I-noun.artifact	may MD 0	be VB B-verb.stative	rarely RB B-adv.all	associated VBN B-verb.cognition	with IN 0	ventricular JJ B-adj.all	fibrillation NN B-noun.artifact	when WRB 0	combined VBN B-verb.creation	with IN 0	Adenocard NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d82.s23	In IN 0	some DT 0	patients NNS B-noun.person	, , 0	the DT 0	administration NN B-noun.time	of IN 0	INDOCIN NNP B-noun.group	can MD 0	reduce VB B-verb.change	the DT 0	diuretic JJ B-adj.all	, , 0	natriuretic JJ B-adj.all	, , 0	and CC 0	antihypertensive JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	loop NN B-noun.location	, , 0	potassium NN B-noun.person	- : 0	sparing NN B-verb.communication	, , 0	and CC 0	thiazide_diuretics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d252.s2	Patients NNS B-noun.person	receiving VBG B-verb.communication	beta NN B-noun.person	- : 0	adrenergic_blocking_agents NNS B-noun.person	along IN 0	with IN 0	either DT 0	oral JJ B-adj.all	or CC 0	intravenous JJ B-adj.all	calcium_antagonists NNS B-noun.group	should MD 0	be VB 0	monitored VBN B-verb.perception	for IN 0	possible JJ B-adj.all	atrioventricular JJ B-adj.all	conduction NN B-noun.phenomenon	disturbances NNS B-noun.artifact	, , 0	left VBD B-verb.stative	ventricular JJ B-adj.all	failure NN B-noun.person	and CC 0	hypotension NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d19.s6	It PRP 0	may MD 0	be VB B-verb.stative	necessary JJ B-adj.all	to TO 0	adjust VB B-verb.change	the DT 0	dosage NN B-noun.quantity	of IN 0	oral JJ B-adj.all	anticoagulants NNS B-noun.attribute	upon IN 0	beginning VBG B-verb.change	or CC 0	stopping VBG B-verb.motion	disulfiram NN B-noun.person	. . 0	since IN 0	disulfiram NN B-noun.act	may MD 0	prolong VB B-verb.stative	prothrombin NN B-adj.all	time NN B-noun.time	. . 0	. . 0
DDI-MedLine.d60.s4	The DT 0	genotypes NNS B-noun.time	of IN 0	CYP2C9 NNP B-noun.person	and CC 0	2C19 NNP B-noun.person	, , 0	the DT 0	enzymes NNS B-noun.location	responsible JJ B-adj.all	for IN 0	phenytoin NN B-noun.substance	metabolism NN B-noun.attribute	, , 0	were VBD B-verb.stative	homozygous JJ B-adj.all	for IN 0	the DT 0	wild JJ B-noun.group	- : 0	type NN B-noun.person	alleles NNS B-noun.artifact	( ( 0	CYP2C9 NNP B-noun.person	1/ $ I-noun.person	1 CD B-adj.all	and CC 0	2C19 NNP B-noun.person	1/ ( 0	_ : 0	1 LS 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d533.s6	Effects NNS B-noun.phenomenon	of IN 0	Aliskiren NNP B-noun.other	on IN I-noun.other	Other NNP I-noun.other	Drugs NNP I-noun.other	Aliskiren NNP I-noun.other	does VBZ 0	not RB B-adv.all	inhibit VB B-verb.change	the DT 0	CYP450 JJ B-noun.body	isoenzymes NNS I-noun.body	( ( 0	CYP1A2 NNP B-noun.person	, , 0	2C8 NNP B-noun.person	, , 0	2C9 NNP B-noun.person	, , 0	2C19 NNP B-noun.person	, , 0	2D6 NNP B-noun.person	, , 0	2E1 NNP B-noun.person	, , 0	and CC 0	CYP NNP B-noun.group	3A NNP I-noun.group	) ) 0	or CC 0	induce VB B-verb.cognition	CYP NNP B-noun.person	3A4 NNP I-noun.person	. . 0	. . 0
DDI-DrugBank.d12.s3	Atromid SYM 0	- : 0	S PRP 0	may MD 0	displace VB B-verb.change	acidic JJ B-adj.all	drugs NNS B-noun.state	such JJ 0	as IN 0	phenytoin NN B-noun.person	or CC 0	tolbutamide NN 0	from IN 0	their PRP$ 0	binding JJ B-adj.pert	sites NNS B-noun.location	. . 0	. . 0
DDI-DrugBank.d482.s9	Wait VB B-verb.stative	5 CD B-adj.all	weeks NNS B-noun.time	after IN 0	stopping VBG B-verb.motion	escitalopram NN 0	before IN 0	starting VBG B-verb.change	a DT 0	non NN B-noun.person	- : 0	selective_MAO_inhibitor NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d121.s2	The DT 0	bioavailability NN B-noun.cognition	of IN 0	the DT 0	capsule NN B-noun.location	formulation NN B-noun.act	of IN 0	cefprozil NN B-noun.body	was VBD B-verb.stative	not RB B-adv.all	affected VBN B-verb.change	when WRB 0	administered VBN B-verb.possession	5 CD B-adj.all	minutes NNS B-noun.time	following VBG B-verb.stative	an DT 0	antacid NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d333.s7	Pharmacodynamic NNP B-noun.person	Interactions NNP I-noun.person	, , 0	The DT 0	CNS NNP B-noun.group	- : 0	depressant JJ B-adj.all	action NN B-noun.state	of IN 0	the DT 0	benzodiazepine_class NNP B-noun.person	of IN 0	drugs NNS B-noun.animal	may MD 0	be VB 0	potentiated VBN B-verb.communication	by IN 0	alcohol NN B-noun.person	, , 0	narcotics NNS B-noun.person	, , 0	barbiturates NNS B-noun.person	, , 0	nonbarbiturate_hypnotics NNS B-noun.person	, , 0	antianxiety_agents NNS B-noun.location	, , 0	the DT 0	phenothiazines NNS B-noun.artifact	, , 0	thioxanthene NN B-noun.person	and CC 0	butyrophenone_classes_of_antipsychotic_agents NNS B-noun.person	, , 0	monoamine_oxidase_inhibitors NNS B-noun.person	and CC 0	the DT 0	tricyclic_antidepressants NNS B-noun.plant	, , 0	and CC 0	by IN 0	other JJ 0	anticonvulsant_drugs NNS B-noun.object	. . 0	. . 0
DDI-DrugBank.d42.s5	Clearance NN B-noun.person	of IN 0	hydrodolasetron NN B-noun.person	decreased VBN B-verb.change	by IN 0	about IN 0	27 CD B-adj.all	% NN 0	when WRB 0	dolasetron_mesylate NN B-noun.person	was VBD 0	administered VBN B-verb.possession	intravenously RB B-adv.all	concomitantly RB B-adv.all	with IN 0	atenolol NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d364.s9	Caution NN B-noun.person	should MD 0	be VB 0	used VBN B-verb.consumption	when WRB 0	alosetron RB 0	and CC 0	ketoconazole NN B-noun.person	are VBP 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d440.s11	Similarly RB B-adv.all	, , 0	in IN 0	the DT 0	1-year JJ 0	monthly JJ B-adj.all	comparison NN B-noun.artifact	study NN B-noun.artifact	, , 0	aspirin NN B-noun.person	and CC 0	nonsteroidal_anti JJ B-noun.person	- : 0	inflammatory_drugs NNS B-noun.person	were VBD 0	taken VBN B-verb.social	by IN 0	39 CD 0	% NN 0	of IN 0	the DT 0	1602 CD 0	patients NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d521.s7	- : 0	a DT 0	steroid_medicine JJ 0	such JJ 0	as IN 0	prednisone NN B-noun.person	( ( 0	Deltasone NNP B-noun.person	, , 0	Orasone NNP 0	, , 0	others NNS 0	) ) 0	, , 0	methylprednisolone NN B-noun.person	( ( 0	Medrol NNP B-noun.person	, , 0	others NNS 0	) ) 0	, , 0	prednisolone NN B-noun.person	( ( 0	Prelone NNP B-noun.person	, , 0	Pediapred NNP B-noun.person	, , 0	others NNS 0	) ) 0	, , 0	and CC 0	others NNS 0	, , 0	. . 0
DDI-DrugBank.d78.s10	However RB 0	, , 0	because IN 0	some DT 0	quinolones NNS B-noun.communication	have VBP 0	been VBN 0	reported VBN B-verb.communication	to TO 0	enhance VB B-verb.change	the DT 0	effects NNS B-noun.phenomenon	of IN 0	warfarin NN B-noun.act	or CC 0	its PRP$ 0	derivatives NNS B-noun.time	, , 0	prothrombin NN B-adj.all	time NN B-noun.time	or CC 0	other JJ 0	suitable JJ B-adj.all	anticoagulation NN 0	test NN 0	should MD 0	be VB 0	monitored VBN B-verb.change	closely RB B-adj.all	if IN 0	a DT 0	quinolone_antimicrobial JJ B-noun.other	is VBZ 0	administered VBN B-verb.possession	with IN 0	warfarin NN B-noun.act	or CC 0	its PRP$ 0	derivatives NNS B-noun.time	. . 0	. . 0
DDI-DrugBank.d331.s0	- : 0	Drugs NNS B-noun.person	with IN 0	ototoxic JJ B-adj.all	potential NN B-noun.person	, , 0	Especially RB B-adv.all	in IN 0	the DT 0	presence NN B-noun.person	of IN 0	impaired VBN B-verb.change	renal JJ B-adj.all	function NN B-noun.act	, , 0	the DT 0	use NN 0	of IN 0	parenterally RB B-adv.all	administered VBN B-verb.emotion	bumetanide NN I-verb.emotion	in IN 0	patients NNS B-noun.person	to TO 0	whom WP 0	aminoglycoside_antibiotics NNS B-noun.person	are VBP B-verb.stative	also RB B-adv.all	being VBG 0	given VBN B-verb.possession	should MD 0	be VB 0	avoided VBN B-verb.social	, , 0	except IN 0	in IN 0	life NN B-noun.time	- : 0	threatening JJ B-verb.communication	conditions NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d216.s9	Other JJ 0	strong JJ B-adj.all	inhibitors NNS B-noun.person	of IN 0	CYP3A4 NNP B-noun.person	( ( 0	e.g. UH 0	, , 0	itraconazole NN B-noun.person	, , 0	clarithromycin NN B-noun.person	, , 0	nefazodone NN 0	, , 0	troleandomycin NN B-noun.person	, , 0	ritonavir NN B-noun.person	, , 0	nelfinavir NN B-noun.person	) ) 0	would MD 0	be VB 0	expected VBN B-verb.cognition	to TO 0	behave VB B-verb.social	similarly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d570.s0	Drug/ NNP B-noun.group	Laboratory NNP I-noun.group	Test NNP I-noun.group	Interactions NNP I-noun.group	Certain NNP I-noun.group	endocrine NN B-noun.cognition	and CC 0	liver NN B-noun.food	function NN B-noun.act	tests NNS B-noun.cognition	may MD 0	be VB 0	affected VBN B-verb.change	by IN 0	estrogen NN B-noun.person	- : 0	containing VBG B-verb.communication	oral JJ B-noun.body	contraceptives NNS I-noun.body	. . 0	. . 0
DDI-DrugBank.d382.s21	Although IN 0	a DT 0	3-day JJ B-adj.all	regimen NNS B-noun.person	of IN 0	Aprepitant JJ 0	given VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	oral JJ B-adj.all	contraceptives NNS B-noun.person	has VBZ 0	not RB 0	been VBN 0	studied VBN B-verb.cognition	, , 0	alternative NN B-noun.person	or CC 0	back RB B-noun.communication	- : 0	up IN 0	methods NNS B-noun.attribute	of IN 0	contraception NN B-noun.group	should MD 0	be VB 0	used VBN B-verb.consumption	. . 0	. . 0
DDI-DrugBank.d420.s8	Concomitantly RB B-adv.all	administered VBN B-verb.possession	iron NN B-noun.person	- : 0	fortified VBN B-verb.cognition	infant JJ B-adj.all	formula NN B-noun.communication	( ( 0	2.2 CD 0	mg IN 0	elemental JJ B-adj.all	iron/6 NNP B-noun.person	oz LS 0	) ) 0	has VBZ B-verb.possession	no DT 0	significant JJ B-adj.all	effect NN B-noun.cognition	on IN 0	cefdinir NN B-noun.person	pharmacokinetics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d87.s6	The DT 0	effects NNS B-noun.phenomenon	of IN 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	TAMBOCOR NNP B-noun.group	and CC 0	propranolol NN B-noun.person	on IN 0	the DT 0	PR NNP 0	interval NN 0	were VBD B-verb.stative	less JJR B-noun.quantity	than IN 0	additive JJ 0	. . 0	. . 0
DDI-DrugBank.d202.s15	Concomitant JJ B-adj.all	use NN 0	of IN 0	tricyclic_antidepressants NNS B-noun.plant	with IN 0	other JJ 0	drugs NNS B-noun.person	metabolized VBN B-verb.social	by IN 0	cytochrome JJ B-adj.all	P450IID6 NN B-noun.person	may MD 0	require VB B-verb.stative	lower JJR B-adj.all	doses NNS B-noun.person	than IN 0	usually RB B-adv.all	prescribed VBN B-verb.communication	for IN 0	either CC 0	the DT 0	tricyclic_antidepressant JJ B-adj.all	or CC 0	the DT 0	other JJ B-adj.all	drug NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d207.s2	International NNP B-noun.other	Normalized NNP I-noun.other	Ratio NNP I-noun.other	( ( 0	INR NNP 0	) ) 0	elevations NNS B-noun.artifact	and/or CC 0	bleeding VBG B-verb.body	events NNS B-noun.plant	have VBP 0	been VBN 0	reported VBN B-verb.communication	in IN 0	some DT 0	patients NNS B-noun.person	taking VBG 0	warfarin NN B-noun.communication	while IN 0	on IN 0	IRESSA NNP B-noun.person	therapy NN I-noun.person	. . 0	. . 0
DDI-DrugBank.d324.s15	Drugs NNS B-noun.artifact	That IN 0	Induce NNP B-noun.person	CYP3A4 NNP I-noun.person	Rifampin NNP I-noun.person	, , 0	CYP3A4 NNP B-noun.person	is VBZ B-verb.stative	ordinarily RB B-adv.all	a DT 0	minor JJ B-adj.all	metabolizing NN B-noun.person	enzyme NN B-noun.person	of IN 0	zaleplon NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d413.s16	Ampicillin NNP B-noun.person	/ NNP I-noun.person	Amoxicillin NNP I-noun.person	, , 0	An DT 0	increase NN B-noun.event	in IN 0	the DT 0	frequency NN B-noun.person	of IN 0	skin NN B-noun.person	rash NN B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	among IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	ampicillin NN B-noun.person	or CC 0	amoxicillin VB B-verb.social	concurrently RB I-verb.social	with IN 0	allopurinol NN B-noun.feeling	compared VBN B-verb.change	to TO 0	patients NNS B-noun.person	who WP 0	are VBP B-verb.stative	not RB I-verb.stative	receiving VBG B-verb.communication	both DT 0	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d82.s35	INDOCIN NNP B-noun.group	can MD 0	reduce VB B-verb.change	the DT 0	antihypertensive JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	captopril NN B-noun.artifact	and CC 0	losartan NN B-noun.process	. . 0	. . 0
DDI-DrugBank.d561.s11	Lotensin NNP B-noun.person	has VBZ 0	been VBN 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	beta JJ B-noun.body	- : 0	adrenergic JJ B-adj.pert	- : 0	blocking_agents NNS B-noun.person	, , 0	calcium NN B-noun.person	- : 0	channel NN B-noun.act	- : 0	blocking_agents NNS B-noun.person	, , 0	diuretics NNS B-noun.person	, , 0	digoxin NN B-noun.person	, , 0	and CC 0	hydralazine NN B-noun.person	, , 0	without IN 0	evidence NN B-noun.time	of IN 0	clinically RB B-adv.all	important JJ B-adj.all	adverse JJ B-adj.all	interactions NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d46.s3	- : 0	Antidiabetic_drugs NNS B-noun.time	, , 0	( ( 0	Oral JJ 0	agents NNS B-noun.person	and CC 0	insulin NN B-noun.body	) ) 0	Dosage NN 0	adjustment NN 0	of IN 0	the DT 0	antidiabetic_drug NN B-noun.location	may MD 0	be VB 0	required VBN B-verb.stative	. . 0
DDI-MedLine.d3.s14	Amprenavir NNP B-noun.person	significantly RB I-noun.person	decreases VBZ B-verb.communication	clearance NN B-noun.attribute	of IN 0	rifabutin NN B-noun.food	and CC 0	25-O JJ 0	- : 0	desacetylrifabutin NN B-noun.communication	, , 0	and CC 0	the DT 0	combination NN B-noun.communication	is VBZ B-verb.stative	poorly RB B-adv.all	tolerated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d15.s6	Since IN 0	fondaparinux NN B-noun.communication	does VBZ 0	not RB B-adv.all	markedly RB B-adv.all	inhibit JJ B-adj.all	CYP450s NNS B-noun.person	( ( I-noun.person	CYP1A2 NNP I-noun.person	, , 0	CYP2A6 NNP B-noun.person	, , 0	CYP2C9 NNP B-noun.person	, , 0	CYP2C19 NNP B-noun.person	, , 0	CYP2D6 NNP B-noun.person	, , 0	CYP2E1 NNP B-noun.person	, , 0	or CC 0	CYP3A4 NNP B-noun.location	) ) 0	in IN 0	vitro NN B-noun.animal	, , 0	fondaparinux_sodium NN 0	is VBZ B-verb.stative	not RB B-adv.all	expected VBN B-verb.cognition	to TO 0	significantly RB 0	interact VB B-verb.contact	with IN 0	other JJ 0	drugs NNS B-noun.person	in IN 0	vivo NN B-noun.animal	by IN 0	inhibition NN B-noun.time	of IN 0	metabolism NN B-noun.attribute	mediated VBN B-verb.change	by IN 0	these DT 0	isozymes NNS B-noun.act	. . 0	. . 0
DDI-DrugBank.d313.s2	The DT 0	following NN 0	are VBP B-verb.stative	examples NNS B-noun.cognition	of IN 0	substances NNS B-noun.artifact	that WDT 0	may MD 0	reduce VB B-verb.change	the DT 0	blood NN B-noun.act	- : 0	glucose NN B-noun.person	- : 0	lowering VBG B-verb.motion	effect NN 0	, , 0	corticosteroids NNS B-noun.person	, , 0	niacin NN B-noun.person	, , 0	danazol NN B-noun.person	, , 0	diuretics NNS B-noun.person	, , 0	sympathomimetic_agents NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	epinephrine NN B-noun.person	, , 0	salbutamol NN B-noun.act	, , 0	terbutaline NN 0	) ) 0	, , 0	isoniazid NN B-noun.person	, , 0	phenothiazine_derivatives NNS B-noun.person	, , 0	somatropin NN 0	, , 0	thyroid_hormones NNS B-noun.body	, , 0	estrogens VBZ B-verb.cognition	, , 0	progestogens NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	in IN 0	oral JJ B-adj.all	contraceptives NNS B-noun.event	) ) 0	. . 0	. . 0
DDI-DrugBank.d277.s0	In IN 0	evaluating VBG B-verb.communication	the DT 0	potential NN B-noun.person	for IN 0	interactions NNS B-noun.possession	among IN 0	co SYM 0	- : 0	administered VBN B-verb.body	antiepilepsy JJ B-adj.all	drugs NNS B-noun.artifact	( ( 0	AEDs NNP B-noun.group	) ) 0	, , 0	whether IN 0	or CC 0	not RB B-adv.all	an DT 0	AED NNP B-noun.group	induces NNS B-noun.artifact	or CC 0	does VBZ 0	not RB B-adv.all	induce VB B-verb.change	metabolic JJ B-adj.all	enzymes NNS B-noun.event	is VBZ B-verb.stative	an DT 0	important JJ B-adj.all	consideration NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d269.s19	Therefore RB 0	, , 0	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	insulin NN I-verb.social	or CC 0	oral JJ B-adj.all	hypoglycemics NNS B-noun.person	, , 0	regular JJ B-adj.all	monitoring NN B-noun.process	of IN 0	blood NN B-noun.location	glucose NN B-noun.person	is VBZ 0	recommended VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d175.s22	Loop_Diuretics NNS B-noun.artifact	, , 0	Furosemide RB 0	administered VBN B-verb.body	concurrently RB B-adv.all	with IN 0	captopril NN B-noun.communication	does VBZ 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	captopril NN B-noun.act	in IN 0	renally RB B-adv.all	impaired VBN B-verb.change	hypertensive JJ B-adj.all	patients NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d303.s0	Metformin NNP B-noun.person	, , 0	In IN 0	healthy JJ B-adj.all	subjects NNS B-noun.person	given VBN B-verb.possession	single JJ B-adj.all	500 CD 0	mg NN B-noun.quantity	doses NNS B-noun.quantity	of IN 0	cephalexin NN B-noun.food	and CC 0	metformin NN B-noun.person	, , 0	plasma NN 0	metformin NN 0	mean JJ B-adj.all	cmax NN B-noun.person	and CC 0	AUC NNP 0	increased VBN B-verb.change	by IN 0	an DT 0	average NN B-noun.act	of IN 0	34 CD 0	% NN 0	and CC 0	24 CD B-adj.all	% NN 0	, , 0	respectively RB B-adv.all	, , 0	and CC 0	metformin NN B-noun.attribute	mean JJ B-adj.all	renal JJ B-adj.all	clearance NN B-noun.act	decreased VBN B-verb.change	by IN 0	14 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-DrugBank.d236.s3	Adrenergic_blockers NNS B-noun.person	, , 0	Adrenergic_blockers NNS B-noun.person	are VBP 0	inhibited VBN B-verb.change	by IN 0	amphetamines NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d5.s25	Alcohol NNP B-noun.person	, , 0	In IN 0	post NN B-noun.act	- : 0	marketing NN B-verb.communication	experience NN B-noun.cognition	, , 0	there EX 0	have VBP 0	been VBN B-verb.stative	rare JJ B-adj.all	reports NNS B-noun.artifact	of IN 0	adverse JJ B-adj.all	neuropsychiatric JJ B-adj.pert	events NNS B-noun.state	or CC 0	reduced VBN B-verb.change	alcohol NN 0	tolerance NN B-noun.act	in IN 0	patients NNS B-noun.person	who WP 0	were VBD 0	drinking VBG B-verb.consumption	alcohol NN B-noun.food	during IN 0	treatment NN B-noun.plant	with IN 0	WELLBUTRIN NNP 0	. . 0	. . 0
DDI-MedLine.d47.s4	Buforin_II NN 0	may MD 0	be VB B-verb.stative	active JJ B-adj.all	in IN 0	inhibiting VBG B-verb.social	Cryptosporidium NNP B-noun.person	parvum NN I-noun.person	growth NN 0	in IN 0	vitro NN 0	upon IN 0	combination NN B-noun.person	with IN 0	either DT 0	azithromycin NN B-noun.state	or CC 0	minocycline NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d377.s0	Phospholine_Iodide JJ B-adj.all	potentiates NNS B-noun.event	other JJ 0	cholinesterase_inhibitors NNS 0	such JJ 0	as IN 0	succinylcholine NN B-noun.person	or CC 0	organophosphate VB B-verb.social	and CC 0	carbamate_insecticides NNS B-noun.group	. . 0	. . 0
DDI-DrugBank.d60.s14	While IN 0	the DT 0	effects NNS B-noun.phenomenon	of IN 0	chronic JJ B-adj.pert	phenytoin NN B-noun.substance	or CC 0	carbamazepine NN B-noun.substance	therapy NN B-noun.artifact	on IN 0	the DT 0	action NN B-noun.process	of IN 0	NIMBEX NNP B-noun.group	are VBP B-verb.stative	unknown JJ B-adj.all	, , 0	slightly RB B-adv.all	shorter JJR B-adj.all	durations NNS B-noun.attribute	of IN 0	neuromuscular JJ B-adj.all	block NN B-noun.location	may MD 0	be VB 0	anticipated VBN B-verb.cognition	and CC 0	infusion NN B-adj.all	rate NN B-noun.time	requirements NNS B-noun.object	may MD 0	be VB B-verb.stative	higher JJR B-adj.all	. . 0	. . 0
DDI-DrugBank.d342.s0	This DT 0	drug NN B-noun.group	may MD 0	interact VB B-verb.change	with IN 0	alcohol NN B-noun.feeling	or CC 0	other JJ B-adj.all	CNS_depressants NNS B-noun.person	( ( 0	may MD 0	potentiate VB B-verb.communication	the DT 0	CNS NNP B-noun.group	depressant JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	either CC 0	these DT 0	medications NNS B-noun.artifact	or CC 0	antihistamines NNS B-noun.attribute	) ) 0	, , 0	anticholinergics NNS B-noun.person	or CC 0	other JJ B-adj.all	medications NNS B-noun.person	with IN 0	anticholinergic JJ B-adj.all	activity NN B-noun.state	( ( 0	anticholinergic JJ B-adj.pert	effects NNS B-noun.phenomenon	may MD 0	be VB 0	potentiated VBN B-verb.cognition	when WRB 0	these DT 0	medications NNS B-noun.artifact	are VBP 0	used VBN B-verb.consumption	concurrently RB B-adv.all	with IN 0	antihistamines NNS B-noun.attribute	) ) 0	, , 0	and CC 0	monoamine_oxidase_(MAO)_inhibitors NNS B-noun.person	( ( 0	concurrent JJ B-adj.all	use NN 0	with IN 0	antihistamines NNS B-noun.object	may MD 0	prolong VB B-verb.perception	and CC 0	intensify VB B-verb.change	the DT 0	anticholinergic JJ B-adj.all	and CC 0	CNS NNP B-noun.group	depressant JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	antihistamines NNS B-noun.attribute	) ) 0	. . 0	. . 0
DDI-DrugBank.d107.s16	Lithium NNP B-noun.person	, , 0	Lithium NNP B-noun.person	toxicity NN I-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	lithium NN I-verb.communication	concomitantly RB B-adv.all	with IN 0	drugs NNS B-noun.artifact	which WDT 0	cause VBP B-verb.communication	elimination NN B-noun.act	of IN 0	sodium NN B-noun.person	, , 0	including VBG B-verb.stative	ACE_inhibitors NNS I-verb.stative	. . 0	. . 0
DDI-DrugBank.d284.s9	In IN 0	two CD 0	combined JJ B-adj.all	12-week JJ 0	placebo NN 0	controlled VBN B-verb.social	trials NNS B-noun.act	that WDT 0	included VBD B-verb.stative	BROVANA NNP B-noun.group	doses NNS B-noun.event	of IN 0	15 CD B-adj.all	mcg NN B-noun.person	twice RB B-adv.all	daily RB I-adv.all	, , 0	25 CD B-adj.all	mcg NN B-noun.person	twice RB B-adv.all	daily RB I-adv.all	, , 0	and CC 0	50 CD B-adj.all	mcg NN B-noun.quantity	once RB B-adv.all	daily RB I-adv.all	, , 0	54 CD 0	of IN 0	873 CD 0	BROVANA NNP B-noun.group	-treated VBD 0	subjects NNS B-noun.person	received VBD B-verb.possession	concomitant JJ B-adj.all	theophylline NN 0	at IN 0	study NN B-noun.artifact	entry NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d85.s12	Naproxen NNP B-noun.person	, , 0	naproxen_sodium NN B-noun.person	and CC 0	other JJ B-adj.all	NSAIDs NNPS B-noun.person	have VBP 0	been VBN 0	reported VBN B-verb.communication	to TO 0	reduce VB B-verb.change	the DT 0	tubular JJ B-adj.all	secretion NN B-noun.act	of IN 0	methotrexate NN B-noun.food	in IN 0	an DT 0	animal NN B-adj.all	model NN B-noun.person	, , 0	possibly RB 0	increasing VBG B-verb.change	the DT 0	toxicity NN B-noun.attribute	of IN 0	methotrexate NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d143.s9	Reported VBN B-verb.communication	examples NNS B-noun.person	include VBP B-verb.change	the DT 0	following NN 0	, , 0	Protease_Inhibitors NNS B-noun.person	, , 0	Protease_inhibitors NNS B-noun.person	are VBP 0	known VBN B-verb.cognition	to TO 0	inhibit VB B-verb.change	CYP3A4 NNP B-noun.person	to TO 0	varying VBG B-verb.change	degrees NNS B-noun.communication	. . 0	. . 0
DDI-DrugBank.d234.s0	Interaction NN 0	with IN 0	central_nervous_system_depressants NNS B-noun.artifact	other JJ 0	than IN 0	benzodiazepines NNS B-noun.person	has VBZ 0	not RB 0	been VBN 0	specifically RB B-adv.all	studied VBN B-verb.cognition	, , 0	. . 0
DDI-DrugBank.d165.s26	Severe JJ B-adj.all	hypoglycemia NN B-noun.state	has VBZ 0	been VBN 0	reported VBN B-verb.communication	in IN 0	patients NNS B-noun.person	concomitantly RB B-adv.all	receiving VBG B-verb.communication	azole_antifungal_agents NNS B-noun.person	and CC 0	oral JJ B-adj.all	hypoglycemic_agents NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d21.s2	Treatment NN B-noun.person	with IN 0	antidepressant_drugs NNS B-noun.plant	can MD 0	directly RB B-adv.all	interfere VB B-verb.stative	with IN 0	blood NN B-noun.body	glucose NN I-noun.body	levels NNS B-noun.state	or CC 0	may MD 0	interact VB B-verb.change	with IN 0	hypoglycemic_agents NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d49.s7	All DT 0	20 CD B-adj.all	strains NNS B-noun.quantity	of IN 0	enterococcus NN B-noun.food	, , 0	three CD 0	strains NNS B-noun.communication	of IN 0	Clostridium NNP B-noun.other	, , 0	three CD 0	strains NNS B-noun.communication	of IN 0	Escherichia NNP B-noun.location	coli NNS B-noun.person	, , 0	and CC 0	one CD 0	strain NN B-noun.attribute	of IN 0	Proteus NNP B-noun.person	rettgeri NN I-noun.person	were VBD B-verb.stative	resistant JJ B-adj.all	to TO 0	both DT 0	clindamycin NN B-noun.person	( ( 0	minimal JJ B-adj.all	inhibitory JJ B-adj.all	concentration NN B-noun.person	greater JJR B-adj.all	than IN 0	3.1 CD 0	mug NN B-noun.quantity	/ : 0	ml LS 0	) ) 0	and CC 0	gentamicin NN B-noun.person	( ( 0	minimal JJ B-adj.all	inhibitory JJ B-adj.all	concentration NN B-noun.person	greater JJR B-adj.all	than IN 0	6.2 CD 0	mug NN B-noun.quantity	/ : 0	ml LS 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d3.s8	Furosemide RB 0	, , 0	TORADOL NNP B-noun.group	IV NNP 0	/ NNP 0	IM NNP 0	reduced VBD B-verb.change	the DT 0	diuretic JJ B-adj.all	response NN B-noun.communication	to TO 0	furosemide VB B-verb.possession	in IN 0	normovolemic JJ B-adj.all	healthy JJ B-adj.all	subjects NNS B-noun.person	by IN 0	approximately RB B-noun.time	20 CD B-adj.all	% NN 0	( ( 0	mean JJ B-adj.all	sodium NN B-noun.artifact	and CC 0	urinary JJ B-adj.all	output NN B-noun.person	decreased VBD B-verb.change	17 CD B-adj.all	% NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d154.s1	Although IN 0	the DT 0	mechanism NN B-noun.attribute	of IN 0	interaction NN B-noun.act	between IN 0	fenoprofen NN B-noun.person	and CC 0	aspirin NN B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	totally RB B-adj.all	known VBN I-adj.all	, , 0	enzyme JJ B-adj.all	induction NN B-noun.person	and CC 0	displacement NN B-noun.act	of IN 0	fenoprofen NN B-noun.person	from IN 0	plasma NN 0	albumin RB 0	binding JJ B-verb.contact	sites NNS B-noun.location	are VBP B-verb.stative	possibilities NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d234.s8	There EX 0	is VBZ B-verb.stative	no DT 0	pharmacokinetic JJ B-adj.all	interaction NN B-noun.act	between IN 0	ethanol NN B-noun.person	and CC 0	flumazenil NN B-noun.plant	. . 0	. . 0
DDI-DrugBank.d249.s17	Phenobarbital JJ B-adj.pert	toxicity NN B-noun.attribute	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	have VB 0	occurred VBN B-verb.cognition	in IN 0	a DT 0	patient NN B-noun.person	on IN 0	chronic JJ B-adj.all	phenobarbital JJ B-noun.relation	treatment NN I-noun.relation	following VBG B-verb.stative	the DT 0	initiation NN B-noun.act	of IN 0	diclofenac NN B-noun.person	therapy NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d83.s1	Concomitant JJ B-adj.all	use NN 0	of IN 0	barbiturates NNS B-noun.location	usually RB B-adv.all	depresses VBZ B-verb.possession	griseofulvin NN B-noun.phenomenon	activity NN B-noun.process	and CC 0	may MD 0	necessitate VB 0	raising VBG B-verb.change	the DT 0	dosage NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d277.s7	Valproate NNP B-noun.person	, , 0	Tiagabine NNP B-noun.person	causes VBZ B-verb.creation	a DT 0	slight JJ B-adj.all	decrease NN B-noun.time	( ( 0	about IN 0	10 CD B-adj.all	% NN 0	) ) 0	in IN 0	steady JJ B-adj.all	- : 0	state NN B-adj.all	valproate NN B-noun.possession	concentrations NNS B-noun.possession	. . 0	. . 0
DDI-DrugBank.d381.s2	Because IN 0	of IN 0	reports NNS B-noun.communication	of IN 0	prolongation NN B-noun.act	of IN 0	the DT 0	prothrombin NN B-adj.all	time NN B-noun.time	beyond IN 0	the DT 0	therapeutic JJ B-adj.pert	range NN B-noun.state	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	concurrent JJ B-adj.all	levamisole NN B-noun.attribute	and CC 0	warfarin_sodium NN B-noun.location	, , 0	it PRP 0	is VBZ 0	suggested VBN B-verb.communication	that IN 0	the DT 0	prothrombin NN B-noun.person	time NN 0	be VB 0	monitored VBN B-verb.perception	carefully RB B-adv.all	, , 0	and CC 0	the DT 0	dose NN B-noun.quantity	of IN 0	warfarin_sodium NN B-noun.location	or CC 0	other JJ 0	coumarin NN B-noun.person	- : 0	like IN 0	drugs NNS B-noun.artifact	should MD 0	be VB 0	adjusted VBN B-verb.change	accordingly RB B-adv.all	, , 0	in IN 0	patients NNS B-noun.person	taking VBG 0	both DT 0	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d82.s15	NSAIDs NNS B-noun.person	should MD 0	be VB 0	used VBN B-verb.consumption	with IN 0	caution NN B-noun.cognition	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	cyclosporine NN I-verb.social	, , 0	and CC 0	renal JJ B-adj.all	function NN B-noun.act	should MD 0	be VB 0	carefully RB B-adv.all	monitored VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d389.s1	MAO_inhibitors NNS B-noun.person	prolong VBP B-verb.stative	and CC 0	intensify VB B-verb.change	the DT 0	anticholinergic JJ B-adj.pert	effects NNS B-noun.phenomenon	of IN 0	antihistamines NNS B-noun.object	. . 0	. . 0
DDI-DrugBank.d413.s10	The DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	uricosuric_agents NNS B-noun.location	and CC 0	allopurinol NN B-noun.person	has VBZ 0	been VBN 0	associated VBN B-verb.cognition	with IN 0	a DT 0	decrease NN B-noun.event	in IN 0	the DT 0	excretion NN B-noun.act	of IN 0	oxypurines NNS B-noun.animal	( ( 0	hypoxanthine NN 0	and CC 0	xanthine NN B-noun.location	) ) 0	and CC 0	an DT 0	increase NN B-noun.act	in IN 0	urinary JJ B-adj.all	uric JJ B-adj.all	acid NN 0	excretion NN 0	compared VBN B-verb.cognition	with IN 0	that DT 0	observed VBN B-verb.perception	with IN 0	allopurinol NN 0	alone RB 0	. . 0	. . 0
DDI-DrugBank.d198.s39	Vardenafil NNP B-noun.person	( ( 0	20 CD B-adj.all	mg NN B-noun.quantity	) ) 0	did VBD 0	not RB B-adv.all	potentiate VB B-verb.communication	the DT 0	hypotensive JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	alcohol NN B-noun.artifact	during IN 0	the DT 0	4-hour JJ 0	observation NN B-noun.group	period NN B-noun.person	in IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	when WRB 0	administered VBN B-verb.possession	with IN 0	alcohol NN B-noun.person	( ( 0	0.5 CD 0	g FW 0	/ FW 0	kg FW 0	body NN 0	weight NN B-noun.attribute	) ) 0	. . 0	. . 0
DDI-DrugBank.d485.s10	Anticoagulants NNS B-noun.person	, , 0	Combination NNP B-noun.group	hormonal_contraceptives NNPS I-noun.group	may MD 0	increase VB B-verb.change	or CC 0	decrease VB B-verb.cognition	the DT 0	effects NNS B-noun.phenomenon	of IN 0	coumarin_derivatives NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d312.s3	The DT 0	concentrations NNS B-noun.attribute	of IN 0	SN38 NN B-noun.food	, , 0	the DT 0	active JJ B-adj.all	metabolite NN B-noun.attribute	of IN 0	irinotecan JJ B-adj.all	, , 0	were VBD B-verb.stative	on IN 0	average JJ B-adj.all	33 CD 0	% NN 0	higher JJR B-adj.all	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	bolus JJ B-adj.pert	- : 0	IFL NNP B-noun.group	in IN 0	combination NN 0	with IN 0	AVASTIN NNP B-noun.group	when WRB 0	compared VBN B-verb.cognition	with IN 0	bolus JJ 0	- : 0	IFL NNP 0	alone RB 0	. . 0	. . 0
DDI-DrugBank.d368.s14	Acetazolamide NNP B-noun.person	may MD 0	elevate VB B-verb.social	cyclosporine JJ B-adj.all	levels NNS B-noun.attribute	. . 0	. . 0
DDI-MedLine.d119.s2	It PRP 0	is VBZ B-verb.stative	structurally RB B-adv.all	distinct JJ B-adj.all	from IN 0	the DT 0	other JJ 0	currently RB B-adv.all	available JJ B-adj.all	HMGCoA_reductase_inhibitors NNS B-noun.person	( ( 0	lovastatin NN B-noun.person	, , 0	simvastatin NN B-noun.person	, , 0	and CC 0	pravastatin NN B-noun.location	) ) 0	, , 0	leading VBG B-verb.motion	to TO 0	unique JJ B-adj.all	biopharmaceutical JJ B-adj.all	properties NNS B-noun.attribute	relative VBP B-verb.stative	to TO 0	the DT 0	other JJ 0	agents NNS B-noun.person	of IN 0	this DT 0	class NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d179.s37	- : 0	Antidiabetics NNS B-noun.person	, , 0	oral JJ B-adj.all	( ( 0	diabetes VBZ B-verb.communication	medicine NN B-noun.attribute	you PRP 0	take VBP B-verb.motion	by IN 0	mouth NN 0	) ) 0	Use NNP 0	of IN 0	oral JJ B-adj.all	antidiabetics NNS B-noun.person	with IN 0	sulfapyridine NN 0	may MD 0	increase VB B-verb.change	the DT 0	chance NN B-noun.act	of IN 0	side JJ B-adj.all	effects NNS B-noun.phenomenon	affecting VBG B-verb.change	the DT 0	blood NN B-noun.location	and/or CC 0	the DT 0	side NN B-noun.location	effects NNS B-noun.phenomenon	or CC 0	oral JJ B-noun.body	antidiabetics NNS I-noun.body	. . 0
DDI-DrugBank.d324.s29	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	Sonata NNP B-noun.person	( ( 0	10 CD B-adj.all	mg NN B-noun.quantity	) ) 0	and CC 0	cimetidine NN B-noun.person	( ( 0	800 CD 0	mg NN B-noun.quantity	) ) 0	produced VBD B-verb.creation	an DT 0	85 CD 0	% NN 0	increase NN B-noun.event	in IN 0	the DT 0	mean JJ B-adj.all	Cmax NNP B-noun.person	and CC 0	AUC NNP B-noun.group	of IN 0	zaleplon NN B-noun.person	. . 0	. . 0
DDI-MedLine.d87.s4	Morphine NNP B-noun.person	prolonged VBD B-verb.communication	gastrointestinal JJ B-adj.pert	transit NN B-noun.communication	time NN B-noun.time	from IN 0	69 CD 0	to TO 0	103 CD 0	minutes NNS B-noun.time	( ( 0	P UH 0	= : 0	.005 LS 0	) ) 0	, , 0	this DT 0	was VBD 0	prevented VBN B-verb.creation	by IN 0	ADL_8 NNS B-noun.person	- : 0	2698 CD 0	( ( 0	P UH 0	= : 0	.004 LS 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d438.s11	Valproic_Acid NN B-noun.attribute	, , 0	The DT 0	mean JJ B-adj.all	steady JJ B-noun.artifact	- : 0	state NN B-adj.all	trough NN B-noun.person	serum NN B-noun.person	valproic_acid JJ I-noun.person	concentrations NNS I-noun.person	prior RB 0	to TO 0	and CC 0	during IN 0	concomitant JJ B-adj.all	gabapentin NN B-adj.all	administration NN B-noun.time	( ( 0	400 CD 0	mg IN 0	TID NNP 0	, , 0	. . 0
DDI-DrugBank.d438.s29	Cimetidine NNP B-noun.person	, , 0	In IN 0	the DT 0	presence NN B-noun.person	of IN 0	cimetidine NN B-noun.person	at IN 0	300 CD 0	mg IN 0	QID NNP 0	( ( 0	N=12 NN 0	) ) 0	the DT 0	mean JJ B-adj.all	apparent JJ B-adj.all	oral JJ B-adj.all	clearance NN B-noun.attribute	of IN 0	gabapentin NN B-noun.animal	fell VBD B-verb.motion	by IN 0	14 CD B-adj.all	% NN 0	and CC 0	creatinine NN B-noun.person	clearance NN B-noun.person	fell VBD B-verb.change	by IN 0	10 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-MedLine.d124.s3	The DT 0	authors NNS B-noun.person	investigated VBD B-verb.communication	the DT 0	possibility NN B-noun.state	of IN 0	a DT 0	similar JJ B-adj.all	interaction NN B-noun.act	between IN 0	oxycodone NN B-noun.person	and CC 0	levofloxacin NN B-noun.state	. . 0	. . 0
DDI-MedLine.d79.s3	Median JJ B-adj.all	gastric NN B-noun.attribute	pH '' 0	was VBD B-verb.stative	significantly RB B-adv.all	higher JJR B-adj.all	when WRB 0	indinavir NN B-noun.person	was VBD 0	taken VBN B-verb.possession	after IN 0	didanosine JJ B-adj.all	administration NN B-noun.person	, , 0	. . 0
DDI-DrugBank.d380.s3	Based VBN B-verb.cognition	on IN 0	anecdotal JJ B-adj.all	reports NNS B-noun.artifact	, , 0	there EX 0	may MD 0	be VB B-verb.stative	an DT 0	interaction NN B-noun.act	between IN 0	buprenorphine NN B-noun.location	and CC 0	benzodiazepines NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d485.s40	Theophylline PRP 0	, , 0	Ethinyl_estradiol NN 0	may MD 0	inhibit VB B-verb.change	the DT 0	metabolism NN B-noun.attribute	of IN 0	theophylline NN 0	, , 0	leading VBG B-verb.motion	to TO 0	increased VBN B-verb.change	plasma NN B-noun.substance	concentrations NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d210.s13	Furosemide RB 0	, , 0	Clinical JJ B-noun.body	studies NNS I-noun.body	, , 0	as RB 0	well RB 0	as IN 0	post NN B-noun.person	- : 0	marketing NN B-noun.act	observations NNS B-noun.act	, , 0	have VBP 0	shown VBN B-verb.cognition	that IN 0	NSAIDs NNPS B-noun.person	can MD 0	reduce VB B-verb.change	the DT 0	natriuretic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	furosemide NN B-noun.artifact	and CC 0	thiazides NNS B-noun.person	in IN 0	some DT 0	patients NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d124.s3	Because IN 0	ritonavir NN B-noun.person	is VBZ 0	coadministered VBN B-verb.communication	, , 0	prescribers NNS B-noun.person	should MD 0	also RB B-adv.all	refer VBP B-verb.cognition	to TO 0	the DT 0	prescribing VBG B-adj.all	information NN B-noun.cognition	for IN 0	ritonavir NN B-noun.person	regarding VBG B-verb.stative	drug NN 0	interactions NNS 0	associated VBN B-verb.cognition	with IN 0	this DT 0	agent NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d165.s18	When WRB 0	Itraconazole NNP B-noun.person	was VBD 0	coadministered VBN B-verb.contact	with IN 0	phenytoin NN B-noun.person	, , 0	rifampin NN B-noun.person	, , 0	or CC 0	H2antagonists NNS B-noun.person	, , 0	reduced VBN B-verb.change	plasma NN B-noun.substance	concentrations NNS B-noun.attribute	of IN 0	itraconazole NN B-noun.food	were VBD 0	reported VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d395.s3	In IN 0	a DT 0	multiple JJ B-noun.person	- : 0	dose NN B-noun.quantity	study NN B-noun.artifact	, , 0	enoxacin NN B-noun.person	caused VBD B-verb.communication	a DT 0	dose NN B-noun.person	- : 0	related JJ B-adj.all	increase NN B-noun.act	in IN 0	the DT 0	mean JJ B-adj.all	elimination NN B-noun.person	half NN B-noun.person	- : 0	life NN B-noun.time	of IN 0	caffeine NN B-noun.location	, , 0	thereby RB 0	decreasing VBG B-verb.creation	the DT 0	clearance NN B-noun.act	of IN 0	caffeine NN B-noun.phenomenon	by IN 0	up RB 0	to TO 0	80 CD B-adj.all	% NN 0	and CC 0	leading VBG B-verb.motion	to TO 0	a DT 0	five CD 0	- : 0	fold JJ B-adj.all	increase NN B-noun.act	in IN 0	the DT 0	AUC NNP B-noun.group	and CC 0	the DT 0	half NN B-noun.person	- : 0	life NN B-noun.time	of IN 0	caffeine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d52.s0	Concomitant JJ B-adj.all	treatment NN B-noun.communication	with IN 0	thrombolytics NNS B-noun.person	( ( 0	eg UH 0	, , 0	rt SYM 0	- : 0	PA NNP B-noun.person	or CC 0	streptokinase VB B-verb.body	) ) 0	may MD 0	, , 0	; : 0	increase VB B-verb.communication	the DT 0	risk NN 0	of IN 0	bleeding VBG B-verb.body	complications NNS B-noun.person	; : 0	considerably RB B-adv.all	enhance VB B-verb.social	the DT 0	effect NN B-noun.cognition	of IN 0	REFLUDAN NNP B-noun.group	on IN 0	aPTT JJ B-noun.artifact	prolongation NN I-noun.artifact	. . 0
DDI-DrugBank.d187.s8	Ketoconazole NNP B-noun.person	, , 0	Potential JJ B-adj.all	interaction NN B-noun.act	of IN 0	Ketoconazole NNP B-noun.person	and CC 0	Isoniazid NNP B-noun.person	may MD 0	exist VB B-verb.stative	. . 0	. . 0
DDI-DrugBank.d0.s2	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	naltrexone NN 0	with IN 0	Acamprosate NNP B-noun.person	produced VBD B-verb.creation	a DT 0	25 CD B-adj.all	% NN 0	increase NN B-noun.event	in IN 0	AUC NNP 0	and CC 0	a DT 0	33 CD 0	% NN 0	increase NN B-noun.event	in IN 0	the DT 0	Cmax NNP B-noun.person	of IN 0	acamprosate NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d393.s5	There EX 0	was VBD B-verb.stative	a DT 0	small JJ B-noun.artifact	decrease NN I-noun.artifact	in IN 0	the DT 0	clearance NN B-noun.act	of IN 0	cetirizine NN 0	caused VBN B-verb.communication	by IN 0	a DT 0	400-mg JJ 0	dose NN B-noun.quantity	of IN 0	theophylline NN 0	, , 0	. . 0
DDI-DrugBank.d291.s11	- : 0	Perhexiline_hydrogen_maleate JJ B-noun.time	or CC 0	MAO NNP B-noun.group	- : 0	inhibitors NNS B-noun.person	( ( 0	with IN 0	hepatotoxic JJ B-adj.all	potential NN B-noun.cognition	) ) 0	must MD 0	not RB 0	be VB 0	administered VBN B-verb.possession	together RB 0	with IN 0	Bezalip NNP B-noun.person	or CC 0	Bezalip_retard RB 0	. . 0	. . 0
DDI-DrugBank.d258.s0	Loratadine NNP B-noun.person	( ( 0	10 CD B-adj.all	mg RB B-adv.all	once RB B-adv.all	daily JJ I-adv.all	) ) 0	has VBZ 0	been VBN 0	coadministered VBN B-verb.contact	with IN 0	therapeutic JJ B-adj.all	doses NNS B-noun.event	of IN 0	erythromycin NN B-noun.food	, , 0	cimetidine NN B-noun.person	, , 0	and CC 0	ketoconazole NN B-noun.person	in IN 0	controlled VBN B-verb.social	clinical JJ B-adj.all	pharmacology NN B-noun.object	studies NNS I-noun.object	in IN 0	adult NN B-noun.act	volunteers NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d413.s20	Chlorpropamide NN 0	, , 0	Chlorpropamides NNS B-noun.group	plasma VBP B-verb.creation	half NN B-noun.person	- : 0	life NN B-noun.time	may MD 0	be VB 0	prolonged VBN B-verb.creation	by IN 0	allopurinol NN B-noun.person	, , 0	since IN 0	allopurinol NN B-noun.act	and CC 0	chlorpropamide NN B-noun.act	may MD 0	compete VB B-verb.cognition	for IN 0	excretion NN B-noun.act	in IN 0	the DT 0	renal JJ B-noun.body	tubule NN I-noun.body	. . 0	. . 0
DDI-MedLine.d30.s7	In IN 0	both DT 0	species NNS B-noun.artifact	, , 0	( ( 0	-)-NANM UH 0	, , 0	but CC 0	not RB B-adv.all	( ( 0	+ UH 0	) ) 0	-NANM NN B-noun.location	, , 0	antagonized VBD B-verb.communication	the DT 0	rate NN B-noun.time	- : 0	decreasing VBG B-verb.communication	effects NNS B-noun.phenomenon	of IN 0	morphine NN B-noun.person	on IN 0	FI NNP 0	and CC 0	FR NNP 0	responding VBG B-verb.communication	. . 0	. . 0
DDI-MedLine.d46.s13	Coadministration NN B-noun.person	of IN 0	fluoxetine NN B-noun.phenomenon	significantly RB B-adv.all	decreased VBD B-verb.change	cisapride JJ B-adj.all	plasma NN B-noun.substance	concentrations NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d431.s3	When WRB 0	lansoprazole NN B-noun.person	was VBD 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	theophylline PRP 0	( ( 0	CYP1A2 NNP B-noun.person	, , 0	CYP3A NNP B-noun.location	) ) 0	, , 0	a DT 0	minor JJ B-adj.all	increase NN B-noun.act	( ( 0	10 CD B-adj.all	% NN 0	) ) 0	in IN 0	the DT 0	clearance NN B-noun.act	of IN 0	theophylline PRP 0	was VBD 0	seen VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d558.s32	Other JJ 0	Drugs NNP B-noun.person	, , 0	In IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	, , 0	amlodipine NN B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	glyburide NN 0	, , 0	ranitidine NN B-noun.person	, , 0	omeprazole NN B-noun.person	, , 0	hormone NN B-noun.person	replacement NN B-noun.person	therapy NN B-noun.person	( ( 0	a DT 0	combination NN B-noun.event	of IN 0	conjugated JJ B-adj.all	estrogens NNS B-noun.artifact	and CC 0	medroxyprogesterone NN 0	) ) 0	, , 0	antacid NN B-noun.person	( ( 0	aluminum NN B-noun.person	and CC 0	magnesium_hydroxides NNS B-noun.group	) ) 0	and CC 0	theophylline PRP 0	did VBD 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	TIKOSYN NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d143.s36	Combination NN B-noun.person	of IN 0	amiodarone NN 0	with IN 0	other JJ 0	antiarrhythmic JJ B-adj.all	therapy NN B-noun.group	should MD 0	be VB 0	reserved VBN B-verb.cognition	for IN 0	patients NNS B-noun.person	with IN 0	life NN B-noun.person	- : 0	threatening VBG B-verb.communication	ventricular JJ B-adj.all	arrhythmias NN B-noun.person	who WP 0	are VBP 0	incompletely RB B-adv.all	responsive JJ B-adj.all	to TO 0	a DT 0	single JJ B-adj.all	agent NN B-noun.person	or CC 0	incompletely RB B-adj.all	responsive JJ 0	to TO 0	amiodarone VB B-verb.social	. . 0	. . 0
DDI-DrugBank.d176.s13	In IN 0	a DT 0	study NN B-noun.artifact	with IN 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	aspirin NN B-noun.food	and CC 0	fosinopril_sodium NNP B-noun.person	, , 0	the DT 0	bioavailability NN B-noun.cognition	of IN 0	unbound JJ B-adj.all	fosinoprilat NN B-noun.person	was VBD B-verb.stative	not RB B-adv.all	altered VBN B-verb.change	. . 0	. . 0
DDI-MedLine.d135.s8	Since IN 0	chronic NN 0	dosing NN 0	is VBZ 0	required VBN B-verb.stative	for IN 0	therapeutic JJ B-adj.all	efficacy NN B-noun.phenomenon	of IN 0	antipsychotics NNS B-noun.person	, , 0	future JJ B-adj.all	studies NNS B-noun.group	should MD 0	focus VB B-verb.stative	on IN 0	investigation NN B-noun.act	of IN 0	chronic JJ B-adj.all	dosing NN B-noun.phenomenon	effects NNS B-noun.phenomenon	of IN 0	these DT 0	drugs NNS B-noun.artifact	in IN 0	combination NN 0	with IN 0	PCP NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d405.s1	Other JJ 0	depressasnts NNS B-noun.state	such JJ 0	as IN 0	alcohol NN B-noun.person	, , 0	barbiturates NNS B-noun.person	, , 0	and CC 0	MAOIs NNP B-noun.person	may MD 0	enhance VB B-verb.change	CNS NNP B-noun.group	depression NN B-noun.time	when WRB 0	administered VBN B-verb.possession	with IN 0	ethchlorvynol NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d231.s0	Furosemide NN 0	may MD 0	increase VB B-verb.change	the DT 0	ototoxic JJ B-adj.all	potential NN B-noun.state	of IN 0	aminoglycoside_antibiotics NNS B-noun.person	, , 0	especially RB B-adv.all	in IN 0	the DT 0	presence NN B-noun.person	of IN 0	impaired VBN B-verb.change	renal JJ B-adj.all	function NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d179.s34	- : 0	Anticoagulants NNS B-noun.person	( ( I-noun.person	blood_thinners NNS I-noun.person	) ) 0	or CC 0	. . 0
DDI-MedLine.d73.s2	It PRP 0	was VBD 0	observed VBN B-verb.perception	that IN 0	MPTP NNP B-noun.group	induced VBD B-verb.creation	long RB 0	lasting JJ B-adj.all	depletions NNS B-noun.person	of IN 0	striatal JJ B-adj.all	dopamine NN B-noun.act	concentrations NNS I-noun.act	and CC 0	this DT 0	neurotoxic JJ B-adj.all	effect NN B-noun.cognition	could MD 0	be VB 0	prevented VBN B-verb.creation	by IN 0	pargyline NN B-noun.person	pretreatment NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d143.s53	Seizure NN B-noun.person	, , 0	associated VBN B-verb.cognition	with IN 0	increased VBN B-verb.change	lidocaine NN B-noun.body	concentrations NNS I-noun.body	, , 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	with IN 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	intravenous JJ B-adj.all	amiodarone NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d466.s2	Fexofenadine NNP B-noun.person	had VBD 0	no DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	either DT 0	erythromycin NN B-noun.state	or CC 0	ketoconazole NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d516.s20	Lomefloxacin NNP B-noun.person	is VBZ B-verb.stative	unlikely JJ B-adj.all	to TO 0	have VB B-verb.social	a DT 0	significant JJ B-adj.all	effect NN B-noun.cognition	on IN 0	phenytoin NN B-noun.substance	metabolism NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d197.s3	No DT 0	pharmacokinetic JJ B-adj.all	interactions NNS B-noun.relation	between IN 0	dexmedetomidine NN B-noun.person	and CC 0	isoflurane NN B-noun.person	, , 0	propofol NN B-noun.person	, , 0	alfentanil RB 0	, , 0	and CC 0	midazolam NN B-noun.person	have VBP 0	been VBN 0	demonstrated VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d441.s4	Initial JJ B-adj.all	doses NNS B-noun.event	of IN 0	adrenergic_agents NNS B-noun.person	, , 0	such JJ 0	as IN 0	dopamine NN B-noun.act	or CC 0	epinephrine NN B-noun.location	, , 0	should MD 0	be VB 0	reduced VBN B-verb.change	and CC 0	titrated VBN B-verb.communication	to TO 0	achieve VB B-verb.social	the DT 0	desired VBN B-verb.emotion	response NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d479.s2	Marked VBN B-verb.cognition	symptomatic JJ B-adj.all	orthostatic JJ B-adj.all	hypotension NN B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	when WRB 0	calcium_channel_blockers NNS B-noun.person	and CC 0	organic_nitrates NNS B-noun.group	were VBD 0	used VBN B-verb.consumption	in IN 0	combination NN 0	. . 0	. . 0
DDI-DrugBank.d497.s3	Therefore RB 0	, , 0	the DT 0	potential NN B-noun.person	for IN 0	such JJ B-adj.all	drug NN B-noun.group	interaction NN B-noun.act	should MD 0	be VB 0	considered VBN B-verb.cognition	in IN 0	patients NNS B-noun.artifact	receiving VBG B-verb.change	AZOPT NNP B-noun.group	( ( 0	brinzolamide VB 0	ophthalmic JJ 0	suspension NN 0	) ) 0	1 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-DrugBank.d143.s31	Amiodarone NN 0	taken VBN 0	concomitantly RB B-adv.all	with IN 0	procainamide NN B-noun.person	for IN 0	less JJR 0	than IN 0	seven CD 0	days NNS B-noun.phenomenon	increases VBZ B-verb.change	plasma NN B-verb.creation	concentrations NNS B-noun.attribute	of IN 0	procainamide NN B-noun.person	and CC 0	n SYM 0	- : 0	acetyl NN 0	procainamide NN 0	by IN 0	55 CD 0	% NN 0	and CC 0	33 CD 0	% NN 0	, , 0	respectively RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d107.s11	Enalapril NNP B-noun.group	IV NNP I-noun.group	has VBZ 0	been VBN 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	digitalis NN B-noun.food	without IN 0	evidence NN B-noun.time	of IN 0	clinically RB B-adv.all	significant JJ B-adj.all	adverse JJ B-noun.event	reactions NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d153.s4	Phenothiazines NNS B-noun.person	and CC 0	butyrophenones NNS B-noun.animal	may MD 0	reduce VB B-verb.change	or CC 0	reverse VB B-verb.communication	the DT 0	pressor NN B-noun.person	effect NN B-noun.cognition	of IN 0	epinephrine NN B-noun.location	. . 0	. . 0
DDI-MedLine.d137.s9	Haemodynamic JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	glucose NN B-noun.attribute	and CC 0	insulin NN B-noun.person	were VBD B-verb.stative	additive JJ B-adj.all	when WRB 0	somatostatin NN 0	was VBD B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	but CC 0	not RB B-adv.all	under IN 0	basal NN B-noun.state	conditions NNS I-noun.state	. . 0	. . 0
DDI-DrugBank.d103.s20	FORADIL NNP B-noun.group	should MD 0	not RB 0	be VB 0	used VBN B-verb.consumption	as IN 0	a DT 0	substitute NN B-noun.person	for IN 0	oral JJ B-adj.all	or CC 0	inhaled VBN B-verb.emotion	corticosteroids NNS I-verb.emotion	. . 0	. . 0
DDI-DrugBank.d179.s31	- : 0	Quinine NN B-noun.location	( ( 0	e.g. UH 0	, , 0	Quinamm NNP B-noun.location	) ) 0	or CC 0	. . 0
DDI-DrugBank.d438.s35	The DT 0	Cmax NNP B-noun.person	of IN 0	norethindrone NN B-noun.person	was VBD B-verb.stative	13 CD B-adj.all	% NN 0	higher JJR B-adj.all	when WRB 0	it PRP 0	was VBD 0	coadministered VBN B-verb.contact	with IN 0	gabapentin NN B-noun.food	, , 0	. . 0
DDI-MedLine.d118.s0	Sirolimus NNP B-noun.person	, , 0	mammalian JJ B-adj.all	target NN B-noun.location	of IN 0	rapamycin NN B-noun.substance	inhibitor NN 0	to TO 0	prevent VB B-verb.emotion	kidney NN I-verb.emotion	rejection NN B-noun.state	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d434.s33	Phenobarbital JJ B-adj.all	, , 0	It PRP 0	appears VBZ B-verb.stative	that IN 0	phenobarbital NN B-noun.animal	may MD 0	reduce VB B-verb.change	plasma NN B-noun.plant	felbamate NN B-noun.body	concentrations NNS I-noun.body	. . 0	. . 0
DDI-MedLine.d1.s6	No DT 0	interactions NNS B-noun.motive	have VBP 0	been VBN 0	observed VBN B-verb.perception	with IN 0	beta JJ B-noun.body	- : 0	receptor_blockers NNS B-noun.person	, , 0	calcium_antagonists NNS B-noun.person	, , 0	thiazide NN 0	and CC 0	loop_diuretics NNS B-noun.person	and CC 0	ACE_inhibitors NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d143.s37	During IN 0	transfer NN 0	to TO 0	oral JJ B-adj.all	amiodarone NN 0	, , 0	the DT 0	dose NN B-noun.state	levels NNS B-noun.state	of IN 0	previously RB B-adv.all	administered VBN B-verb.possession	agents NNS B-noun.person	should MD 0	be VB 0	reduced VBN B-verb.change	by IN 0	30 CD 0	to TO 0	50 CD B-adj.all	% NN 0	several JJ B-adj.all	days NNS B-noun.phenomenon	after IN 0	the DT 0	addition NN B-noun.act	of IN 0	oral JJ B-adj.all	amiodarone NN 0	. . 0	. . 0
DDI-DrugBank.d536.s9	The DT 0	amount NN B-noun.possession	of IN 0	metformin NN B-noun.substance	absorbed VBN B-verb.contact	while IN 0	taking VBG B-verb.cognition	Acarbose NNP B-noun.person	was VBD B-verb.stative	bioequivalent NN B-noun.person	to TO 0	the DT 0	amount NN B-noun.possession	absorbed VBN B-verb.contact	when WRB 0	taking VBG 0	placebo NN B-noun.substance	, , 0	as IN 0	indicated VBN B-verb.communication	by IN 0	the DT 0	plasma NN B-noun.person	AUC NNP I-noun.person	values NNS B-noun.attribute	. . 0	. . 0
DDI-MedLine.d16.s1	The DT 0	interaction NN B-noun.act	of IN 0	intramuscularly RB B-adv.all	injected VBN B-verb.change	ketamine NN B-noun.artifact	and CC 0	its PRP$ 0	N NNP 0	- : 0	demethylated VBD B-verb.cognition	metabolite NN B-noun.attribute	( ( 0	metabolite VB 0	I PRP 0	) ) 0	with IN 0	halothane NN B-noun.person	was VBD 0	evaluated VBN B-verb.change	in IN 0	rats NNS B-noun.animal	. . 0	. . 0
DDI-DrugBank.d5.s19	MAO_Inhibitors NNS B-noun.person	, , 0	Studies NNPS B-noun.person	in IN 0	animals NNS B-noun.animal	demonstrate VBP B-verb.communication	that IN 0	the DT 0	acute JJ B-adj.all	toxicity NN B-noun.attribute	of IN 0	bupropion NN B-noun.act	is VBZ 0	enhanced VBN B-verb.change	by IN 0	the DT 0	MAO_inhibitor NN B-noun.other	phenelzine NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d328.s48	Plasma NNP B-noun.person	exposure NN I-noun.person	of IN 0	diazepam NN B-noun.person	( ( 0	10 CD 0	mg IN 0	BID NNP 0	) ) 0	was VBD 0	increased VBN B-verb.change	by IN 0	28 CD B-adj.all	% NN 0	following VBG 0	administration NN B-noun.person	of IN 0	valdecoxib NN B-noun.attribute	( ( 0	40 CD 0	mg IN 0	BID NNP 0	) ) 0	for IN 0	12 CD B-adj.all	days NNS B-noun.person	, , 0	while IN 0	plasma NN B-noun.person	exposure NN B-noun.person	of IN 0	valdecoxib NN B-noun.attribute	( ( 0	40 CD 0	mg IN 0	BID NNP 0	) ) 0	was VBD B-verb.stative	not RB B-adv.all	substantially RB B-adv.all	increased VBN B-verb.change	following VBG 0	administration NN B-noun.person	of IN 0	diazepam NN B-noun.person	( ( 0	10 CD 0	mg IN 0	BID NNP 0	) ) 0	for IN 0	12 CD B-adj.all	days NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d509.s11	When WRB 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	ketoconazole NN B-noun.shape	with IN 0	aripiprazole NN B-noun.communication	occurs VBZ B-verb.stative	, , 0	aripiprazole NN B-noun.cognition	dose NN I-noun.cognition	should MD 0	be VB 0	reduced VBN B-verb.change	to TO 0	one CD 0	- : 0	half NN B-noun.quantity	of IN 0	its PRP$ 0	normal JJ B-adj.all	dose NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d53.s2	Although IN 0	a DT 0	dose NN B-noun.communication	adjustment NN B-noun.communication	of IN 0	azithromycin NN B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	when WRB 0	administered VBN B-verb.possession	in IN 0	combination NN 0	with IN 0	nelfinavir NN B-noun.person	, , 0	close JJ B-adj.all	monitoring NN B-verb.perception	for IN 0	known JJ B-adj.all	side NN B-noun.location	effects NNS B-noun.phenomenon	of IN 0	azithromycin NN B-noun.food	, , 0	such JJ 0	as IN 0	liver NN B-noun.act	enzyme NN I-noun.act	abnormalities NNS B-noun.person	and CC 0	hearing NN B-verb.perception	impairment NN B-noun.attribute	, , 0	is VBZ 0	warranted VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d158.s23	Propoxyphene NNP B-noun.person	, , 0	In IN 0	cases NNS B-noun.state	of IN 0	propoxyphene NN B-noun.person	overdosage NN B-noun.person	, , 0	amphetamine JJ 0	CNS NNP 0	stimulation NN 0	is VBZ 0	potentiated VBN B-verb.possession	and CC 0	fatal JJ B-adj.all	convulsions NNS B-noun.person	can MD 0	occur VB B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d260.s2	Zidovudine NN B-noun.person	should MD 0	either RB 0	be VB 0	temporarily RB B-adv.all	discontinued VBN B-verb.contact	or CC 0	decreased VBN B-verb.change	by IN 0	50 CD B-adj.all	% NN 0	when WRB 0	coadministered VBN B-verb.communication	with IN 0	probenecid NN B-noun.person	on IN 0	the DT 0	day NN 0	of IN 0	VISTIDE NNP B-noun.other	infusion NN B-noun.process	. . 0	. . 0
DDI-DrugBank.d121.s0	Nephrotoxicity NN B-noun.motive	has VBZ 0	been VBN 0	reported VBN B-verb.communication	following VBG B-verb.stative	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	aminoglycoside_antibiotics NNS B-noun.person	and CC 0	cephalosporin_antibiotics NNS B-noun.body	. . 0	. . 0
DDI-DrugBank.d5.s6	Following VBG 0	oral JJ B-adj.all	administration NN B-noun.time	of IN 0	two CD 0	150-mg JJ 0	sustained VBD B-verb.communication	- : 0	release NN B-noun.act	tablets NNS B-noun.artifact	with IN 0	and CC 0	without IN 0	800 CD 0	mg NN B-noun.quantity	of IN 0	cimetidine NN B-noun.location	, , 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	bupropion NN B-noun.act	and CC 0	hydroxybupropion NN B-noun.act	were VBD B-verb.stative	unaffected JJ B-adj.all	. . 0	. . 0
DDI-MedLine.d110.s15	Both DT 0	18-MC NNP B-noun.person	and CC 0	ibogaine NN B-noun.person	are VBP 0	sequestered VBN B-verb.contact	in IN 0	fat JJ 0	and CC 0	, , 0	like IN 0	ibogaine NN B-noun.person	, , 0	18-MC NNP B-noun.person	probably RB I-noun.person	has VBZ B-verb.stative	an DT 0	active JJ B-adj.all	metabolite NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d100.s1	Drug NN 0	/ '' 0	Laboratory NNP B-noun.group	Test NNP I-noun.group	Interactions NNP I-noun.group	Cephalosporins NNP I-noun.group	, , 0	including VBG B-verb.stative	cefotaxime_sodium NN 0	, , 0	are VBP 0	known VBN B-verb.cognition	to TO 0	occasionally RB B-adv.all	induce VB B-verb.cognition	a DT 0	positive JJ B-adj.all	direct JJ 0	Coombs NNP 0	test NN 0	. . 0	. . 0
DDI-DrugBank.d12.s5	The DT 0	hypoglycemic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	tolbutamide NN 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	increase VB B-verb.change	when WRB 0	Atromid NNP B-noun.person	- : 0	S PRP 0	is VBZ 0	given VBN B-verb.possession	concurrently RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d328.s22	Lithium_carbonate JJ B-noun.substance	( ( 0	450 CD 0	mg IN 0	BID NNP 0	for IN 0	7 CD B-adj.all	days NNS B-noun.act	) ) 0	had VBD 0	no DT 0	effect NN B-noun.cognition	on IN 0	valdecoxib NN B-noun.artifact	pharmacokinetics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d550.s4	Probenecid NNP B-noun.person	, , 0	As IN 0	with IN 0	other JJ 0	b SYM 0	- : 0	lactam_antibiotics NNS B-noun.person	, , 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	probenecid NN B-noun.person	with IN 0	cefditoren_pivoxil NNP B-noun.person	resulted VBD B-verb.social	in IN 0	an DT 0	increase NN B-noun.act	in IN 0	the DT 0	plasma NN B-noun.plant	exposure NN B-noun.cognition	of IN 0	cefditoren NNS B-noun.person	, , 0	with IN 0	a DT 0	49 CD 0	% NN 0	increase NN B-noun.event	in IN 0	mean JJ B-adj.all	Cmax NNP B-noun.person	, , 0	a DT 0	122 CD 0	% NN 0	increase NN B-noun.event	in IN 0	mean JJ B-adj.all	AUC NNP B-noun.group	, , 0	and CC 0	a DT 0	53 CD 0	% NN 0	increase NN B-noun.event	in IN 0	half NN B-noun.quantity	- : 0	life NN B-noun.time	. . 0	. . 0
DDI-DrugBank.d565.s27	If IN 0	these DT 0	agents NNS B-noun.person	are VBP B-verb.stative	to TO 0	be VB 0	administered VBN B-verb.possession	concurrently RB B-adv.all	, , 0	cyclosporine JJ B-adj.all	concentrations NNS B-noun.attribute	should MD 0	be VB 0	monitored VBN B-verb.perception	, , 0	especially RB B-adv.all	when WRB 0	diltiazem NN B-noun.person	therapy NN B-noun.person	is VBZ 0	initiated VBN B-verb.creation	, , 0	adjusted VBN B-verb.change	, , 0	or CC 0	discontinued VBN B-verb.stative	. . 0	. . 0
DDI-MedLine.d130.s8	This DT 0	study NN B-noun.communication	demonstrates VBZ B-verb.communication	that IN 0	concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	thiosulfate JJ B-adj.all	permits NNS B-noun.person	at IN 0	least JJS 0	a DT 0	twofold JJ B-adj.all	increase NN B-noun.act	in IN 0	dose NN B-noun.animal	and CC 0	total JJ B-adj.all	exposure NN B-noun.act	to TO 0	cisplatin VB B-verb.contact	. . 0	. . 0
DDI-DrugBank.d558.s35	Concomitant JJ B-noun.person	medications NNS I-noun.person	were VBD 0	grouped VBN B-verb.cognition	as IN 0	ACE_inhibitors NNS B-noun.person	, , 0	oral JJ B-adj.all	anticoagulants NNS B-noun.person	, , 0	calcium_channel_blockers NNS B-noun.person	, , 0	beta_blockers NNS B-noun.person	, , 0	cardiac_glycosides NNS B-noun.group	, , 0	inducers NNS B-noun.person	of IN 0	CYP3A4 NNP B-noun.person	, , 0	substrates NNS B-noun.person	and CC 0	inhibitors NNS B-noun.person	of IN 0	CYP3A4 NNP B-noun.person	, , 0	substrates NNS B-noun.person	and CC 0	inhibitors NNS B-noun.person	of IN 0	P NNP 0	- : 0	glycoprotein NN B-noun.person	, , 0	nitrates NNS B-noun.person	, , 0	sulphonylureas NNS B-noun.location	, , 0	loop_diuretics NNS B-noun.location	, , 0	potassium_sparing_diuretics NNS B-noun.person	, , 0	thiazide_diuretics NNS B-noun.person	, , 0	substrates NNS B-noun.person	and CC 0	inhibitors NNS B-noun.person	of IN 0	tubular JJ B-adj.all	organic JJ B-adj.all	cation NN B-noun.artifact	transport NN I-noun.artifact	, , 0	and CC 0	QTc NNP B-noun.person	- : 0	prolonging VBG B-verb.communication	drugs NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d202.s12	Such JJ B-adj.all	individuals NNS B-noun.person	are VBP 0	referred VBN B-verb.cognition	to TO 0	as RB 0	_ JJ 0	poor JJ B-adj.all	metabolizers NNS B-noun.person	_ ( 0	of IN 0	drugs NNS B-noun.object	such JJ 0	as IN 0	debrisoquin NN B-noun.person	, , 0	dextromethorphan NN B-noun.person	, , 0	and CC 0	the DT 0	tricyclic_antidepressants NNS B-noun.plant	. . 0	. . 0
DDI-DrugBank.d165.s8	Data NNS B-noun.cognition	suggest VBP B-verb.communication	that IN 0	coadministration NN B-noun.person	of IN 0	oral JJ B-adj.all	ketoconazole NN B-noun.attribute	and CC 0	cisapride NN B-noun.person	can MD 0	result VB B-verb.stative	in IN 0	prolongation NN 0	of IN 0	the DT 0	QT NNP 0	interval NN 0	on IN 0	the DT 0	ECG NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d466.s20	ALLEGRA NNP B-noun.group	should MD 0	not RB 0	be VB 0	taken VBN B-verb.cognition	closely RB B-verb.contact	in IN 0	time NN B-noun.time	with IN 0	aluminum NN B-noun.person	and CC 0	magnesium NN B-noun.artifact	containing VBG B-verb.stative	antacids NNS B-noun.substance	. . 0	. . 0
DDI-DrugBank.d340.s26	therefore RB B-adv.all	, , 0	nelfinavir NN B-noun.person	should MD 0	be VB 0	administered VBN B-verb.possession	( ( 0	with IN 0	food NN B-noun.food	) ) 0	one CD 0	hour NN 0	after IN 0	or CC 0	more JJR B-noun.quantity	than IN 0	two CD 0	hours NNS 0	before IN 0	didanosine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d497.s2	However RB 0	, , 0	in IN 0	patients NNS B-noun.person	treated VBD B-verb.social	with IN 0	oral JJ B-adj.all	carbonic_anhydrase_inhibitors NNS B-noun.person	, , 0	rare JJ B-adj.all	instances NNS B-noun.time	of IN 0	drug NN B-noun.person	interactions NNS I-noun.person	have VBP 0	occurred VBN B-verb.cognition	with IN 0	high JJ B-noun.group	- : 0	dose NN 0	salicylate NN 0	therapy NN 0	. . 0	. . 0
DDI-DrugBank.d328.s38	Valdecoxib NNP B-noun.person	steady JJ B-adj.all	state NN B-noun.state	plasma NN I-noun.state	concentrations NNS B-noun.cognition	( ( 0	40 CD 0	mg IN 0	BID NNP 0	) ) 0	were VBD B-verb.stative	not RB B-adv.all	affected VBN B-verb.change	significantly RB B-adv.all	with IN 0	multiple JJ B-adj.all	doses NNS B-noun.event	of IN 0	omeprazole NN B-noun.attribute	( ( 0	40 CD B-adj.all	mg NN B-noun.quantity	QD NNP 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d97.s52	Preliminary JJ B-adj.all	clinical JJ B-adj.all	data NNS B-noun.cognition	suggest VBP B-verb.communication	that IN 0	the DT 0	incidence NN B-noun.event	of IN 0	nephrolithiasis NN B-noun.person	is VBZ B-verb.stative	higher JJR B-adj.all	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	indinavir NN B-noun.person	in IN 0	combination NN 0	with IN 0	ritonavir NN B-noun.person	than IN 0	those DT 0	receiving VBG B-verb.communication	CRIXIVAN NNP B-noun.communication	800 CD 0	mg IN 0	q8h NNP 0	. . 0	. . 0
DDI-DrugBank.d565.s30	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	diltiazem NN B-noun.food	with IN 0	carbamazepine NN 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	result VB B-verb.stative	in IN 0	elevated JJ B-adj.all	serum NN B-noun.body	levels NNS B-noun.attribute	of IN 0	carbamazepine NN 0	( ( 0	40 CD B-adj.all	% NN 0	to TO 0	72 CD 0	% NN 0	increase NN B-noun.event	) ) 0	, , 0	resulting VBG B-verb.stative	in IN 0	toxicity NN B-noun.attribute	in IN 0	some DT 0	cases NNS B-noun.state	. . 0	. . 0
DDI-DrugBank.d405.s0	Dicumarol NNP B-noun.person	and CC 0	warfarin NN B-noun.act	may MD 0	decrease VB B-verb.change	hypoprothrombinemic JJ B-adj.all	effect NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d262.s0	The DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	alcohol NN B-noun.animal	or CC 0	other JJ B-adj.all	central_nervous_system_depressants NNS B-noun.location	may MD 0	have VB B-verb.possession	an DT 0	additive JJ B-adj.all	effect NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d566.s4	When WRB 0	cholestyramine NN B-noun.phenomenon	resin NN B-noun.phenomenon	is VBZ 0	given VBN B-verb.possession	for IN 0	long JJ B-adj.all	periods NNS B-noun.person	of IN 0	time NN B-noun.time	, , 0	concomitant JJ B-adj.all	supplementation NN B-noun.person	with IN 0	water NN B-noun.attribute	- : 0	miscible JJ B-adj.all	( ( 0	or CC 0	parenteral JJ B-adj.all	) ) 0	forms NNS 0	of IN 0	fat SYM 0	- : 0	soluble_vitamins NNS B-noun.group	should MD 0	be VB 0	considered VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d328.s5	Because IN 0	of IN 0	its PRP$ 0	lack NN B-noun.state	of IN 0	anti NNS B-noun.person	- : 0	platelet NN B-verb.creation	effect NN B-noun.phenomenon	valdecoxib NN B-noun.attribute	is VBZ B-verb.stative	not RB I-verb.stative	a DT 0	substitute NN B-noun.person	for IN 0	aspirin NN B-noun.person	for IN 0	cardiovascular JJ B-adj.all	prophylaxis NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d450.s6	Antacids NNP B-noun.person	, , 0	kaolin FW 0	- : 0	pectin NN B-noun.person	, , 0	sulfasalazine NN B-noun.person	, , 0	neomycin NN B-noun.person	, , 0	cholestyramine NN B-noun.person	, , 0	certain JJ B-adj.all	anticancer NN B-noun.person	drugs NNS B-noun.artifact	, , 0	and CC 0	metoclopramide NN B-noun.act	may MD 0	interfere VB B-verb.stative	with IN 0	intestinal JJ B-adj.all	digoxin NN B-noun.person	absorption NN B-noun.person	, , 0	resulting VBG B-verb.stative	in IN 0	unexpectedly RB B-adv.all	low JJ B-adj.all	serum NN B-noun.body	concentrations NNS I-noun.body	. . 0	. . 0
DDI-DrugBank.d97.s50	indinavir NN B-adj.all	concentration NN B-noun.event	__ ) 0	ritonavir NN B-noun.person	concentration NN B-noun.event	. . 0
DDI-DrugBank.d106.s11	No DT 0	significant JJ B-adj.all	interactions NNS B-noun.person	were VBD 0	found VBN B-verb.possession	between IN 0	nisoldipine NN B-noun.person	and CC 0	warfarin NN B-noun.act	or CC 0	digoxin NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d143.s14	Histamine_H2_antagonists NNS B-noun.person	, , 0	Cimetidine NNP B-noun.person	inhibits VBZ B-verb.creation	CYP3A4 NNP I-verb.creation	and CC 0	can MD 0	increase VB B-verb.change	serum NN 0	amiodarone NN 0	levels NNS B-noun.attribute	. . 0	. . 0
DDI-MedLine.d49.s8	Combinations NNS B-noun.person	of IN 0	clindamycin NN B-noun.person	and CC 0	gentamicin NN B-noun.state	were VBD B-verb.stative	indifferent JJ B-adj.all	for IN 0	16 CD B-adj.all	and CC 0	synergistic NN B-noun.person	for IN 0	11 CD 0	of IN 0	the DT 0	resistant JJ B-adj.all	strains NNS B-noun.communication	. . 0	. . 0
DDI-DrugBank.d558.s14	In IN 0	patients NNS B-noun.artifact	receiving VBG B-verb.change	HCTZ NNP B-noun.group	alone RB 0	, , 0	dofetilide IN 0	AUC NNP 0	increased VBN B-verb.change	by IN 0	27 CD B-adj.all	% NN 0	and CC 0	Cmax NNP B-noun.person	by IN 0	21 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-DrugBank.d499.s16	Bleeding VBG B-verb.body	from IN 0	a DT 0	number NN B-noun.quantity	of IN 0	sites NNS B-noun.location	may MD 0	be VB B-verb.stative	a DT 0	complication NN B-noun.person	of IN 0	warfarin NN B-noun.act	treatment NN I-noun.act	and CC 0	GI NNP 0	bleeding VBG B-verb.body	a DT 0	complication NN B-noun.person	of IN 0	ketoprofen JJ B-adj.all	treatment NN B-noun.communication	. . 0	. . 0
DDI-MedLine.d34.s4	Cobalt NNP B-noun.person	excretion NN B-noun.act	was VBD 0	enhanced VBN B-verb.change	by IN 0	supplementary JJ B-adj.all	cobalt NN B-noun.person	, , 0	. . 0
DDI-DrugBank.d277.s1	Phenytoin NN B-noun.person	, , 0	phenobarbital JJ B-adj.all	and CC 0	carbamazepine NN B-noun.communication	are VBP B-verb.stative	ge PRP 0	nerally RB B-adv.all	classified VBN B-verb.cognition	as IN 0	enzyme NN B-noun.person	inducers NNS I-noun.person	, , 0	. . 0
DDI-DrugBank.d459.s1	Caution NN B-noun.person	should MD 0	be VB 0	taken VBN B-verb.cognition	when WRB 0	ENABLEX NNP B-noun.group	is VBZ 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	medications NNS B-noun.artifact	that WDT 0	are VBP B-verb.stative	predominantly RB B-adv.all	metabolized VBN B-verb.cognition	by IN 0	CYP2D6 NNP B-noun.person	and CC 0	which WDT 0	have VBP B-verb.stative	a DT 0	narrow JJ B-adj.all	therapeutic JJ B-adj.all	window NN B-noun.artifact	, , 0	such JJ 0	as IN 0	flecainide NN 0	, , 0	thioridazine NN 0	and CC 0	tricyclic_antidepressants NNS B-noun.person	( ( 0	see VB 0	CLINICAL NNP B-noun.group	PHARMACOLOGY NNP I-noun.group	) ) 0	. . 0	. . 0
DDI-DrugBank.d22.s1	In IN 0	the DT 0	case NN B-noun.state	that IN 0	you PRP 0	are VBP 0	taking VBG 0	digoxin NN B-noun.person	while IN 0	taking VBG B-verb.social	aminosalicylic_acid JJ I-verb.social	, , 0	higher JJR B-adj.all	doses NNS B-noun.person	of IN 0	digoxin NN B-noun.person	may MD 0	be VB 0	needed VBN B-verb.consumption	. . 0	. . 0
DDI-DrugBank.d498.s0	Certain JJ B-adj.all	antibiotics NNS B-noun.attribute	, , 0	especially RB B-adv.all	neomycin JJ B-adj.all	, , 0	streptomycin NN B-noun.person	and CC 0	kanamycin NN B-noun.person	, , 0	have VBP 0	a DT 0	mild JJ B-noun.person	but CC 0	definite JJ B-adj.all	nondepolarizing NN 0	blocking VBG B-verb.change	action NN B-noun.act	which WDT 0	may MD 0	accentuate VB B-verb.change	neuromuscular JJ B-adj.all	block NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d531.s92	Clinically RB B-adv.all	significant JJ B-adj.all	interactions NNS B-noun.person	would MD 0	not RB B-adv.all	be VB 0	expected VBN B-verb.cognition	since IN 0	the DT 0	NRTIs NNP B-noun.location	are VBP 0	metabolized VBN B-verb.cognition	via IN 0	a DT 0	different JJ B-adj.all	route NN B-noun.location	than IN 0	efavirenz NN B-noun.person	and CC 0	would MD 0	be VB B-verb.stative	unlikely JJ B-adj.all	to TO 0	compete VB B-verb.communication	for IN 0	the DT 0	same JJ B-adj.all	metabolic JJ B-adj.all	enzymes NNS B-noun.event	and CC 0	elimination NN B-noun.act	pathways NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d378.s0	Renal JJ B-adj.all	function NN B-noun.attribute	should MD 0	be VB 0	monitored VBN B-verb.perception	carefully RB B-adv.all	if IN 0	high JJ B-adj.all	doses NNS B-noun.attribute	of IN 0	aminoglycosides NNS B-noun.animal	are VBP B-verb.stative	to TO 0	be VB 0	administered VBN B-verb.possession	with IN 0	MAXIPIME NNP B-noun.group	because IN 0	of IN 0	the DT 0	increased VBN B-adj.all	potential NN B-noun.state	of IN 0	nephrotoxicity NN B-noun.attribute	and CC 0	ototoxicity NN 0	of IN 0	aminoglycoside_antibiotics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d97.s59	Caution NN B-noun.person	is VBZ 0	warranted VBN B-verb.communication	and CC 0	therapeutic JJ B-adj.all	concentration NN B-noun.event	monitoring NN B-verb.perception	is VBZ 0	recommended VBN B-verb.communication	for IN 0	antiarrhythmics NNS B-noun.time	when WRB 0	coadministered VBN B-verb.communication	with IN 0	CRIXIVAN NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d346.s3	Lethargy NNP B-noun.person	and CC 0	somnolence NN B-noun.act	have VBP 0	been VBN 0	reported VBN B-verb.communication	following VBG 0	doses NNS B-noun.act	of IN 0	REVIA NNP B-noun.group	and CC 0	thioridazine NN 0	. . 0	. . 0
DDI-DrugBank.d324.s8	Thioridazine NNP B-noun.person	, , 0	Coadministration NNP B-noun.person	of IN 0	single JJ B-adj.all	doses NNS B-noun.event	of IN 0	Sonata NNP B-noun.communication	20 CD B-adj.all	mg NN B-noun.quantity	and CC 0	thioridazine JJ 0	50 CD 0	mg IN 0	produced VBN B-verb.creation	additive JJ 0	effects NNS B-noun.phenomenon	on IN 0	decreased VBN B-verb.change	alertness RB B-adv.all	and CC 0	impaired VBN B-verb.communication	psychomotor NN B-noun.person	performance NN B-noun.person	for IN 0	2 CD 0	to TO 0	4 CD B-adj.all	hours NNS B-noun.artifact	after IN 0	administration NN B-noun.time	. . 0	. . 0
DDI-DrugBank.d75.s2	Although IN 0	additional JJ B-adj.all	drug NN B-noun.artifact	interaction NN B-noun.act	studies NNS B-noun.artifact	have VBP 0	not RB 0	been VBN 0	conducted VBN B-verb.communication	, , 0	the DT 0	most RBS 0	common JJ B-noun.person	medications NNS B-noun.person	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	anagrelide NN 0	in IN 0	clinical JJ B-adj.all	trials NNS B-noun.person	were VBD B-verb.stative	aspirin NN B-noun.person	, , 0	acetaminophen NN B-noun.person	, , 0	furosemide RB 0	, , 0	iron NN B-noun.person	, , 0	ranitidine NN B-noun.person	, , 0	hydroxyurea NN B-noun.person	, , 0	and CC 0	allopurinol NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d380.s2	ketoconazole NN B-noun.artifact	) ) 0	, , 0	macrolide_antibiotics NNS B-noun.person	( ( 0	e.g. JJ B-adv.all	erythromycin NN I-adv.all	) ) 0	, , 0	and CC 0	HIV_protease_inhibitors NNS B-noun.person	( ( 0	e.g. JJ B-adj.all	ritonavir NN B-noun.person	, , 0	indinavir NN B-noun.person	and CC 0	saquinavir NN B-noun.location	) ) 0	should MD 0	have VB 0	their PRP$ 0	dose NN 0	of IN 0	SUBUTEX NNP B-noun.group	or CC 0	SUBOXONE NNP B-noun.substance	adjusted VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d17.s28	( ( 0	Thiazides NNS 0	may MD 0	decrease VB B-verb.change	arterial JJ B-adj.all	responsiveness NN B-noun.cognition	to TO 0	norepinephrine VB B-verb.communication	. . 0	. . 0
DDI-DrugBank.d198.s6	It PRP 0	is VBZ 0	recommended VBN B-verb.communication	not RB B-adv.all	to TO 0	exceed VB B-verb.stative	a DT 0	single JJ B-noun.communication	5 CD B-adj.all	mg NN B-noun.quantity	dose NN B-noun.quantity	of IN 0	Vardenafil NNP B-noun.person	in IN 0	a DT 0	24-hour JJ 0	period NN B-noun.time	when WRB 0	used VBN B-verb.consumption	in IN 0	combination NN 0	with IN 0	erythromycin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d429.s2	Cimetidine NNP B-noun.person	, , 0	Cimetidine NNP B-noun.person	can MD 0	inhibit VB B-verb.change	the DT 0	metabolism NN B-noun.attribute	of IN 0	chloroquine NN B-noun.act	, , 0	increasing VBG B-verb.change	its PRP$ 0	plasma NN B-noun.attribute	level NN I-noun.attribute	. . 0	. . 0
DDI-MedLine.d42.s4	METHODS NNS B-noun.attribute	, , 0	Clinical JJ B-noun.body	studies NNS I-noun.body	, , 0	case NN 0	reports NNS B-noun.communication	, , 0	and CC 0	commentaries NNS B-noun.person	and CC 0	editorials NNS B-noun.person	concerning VBG B-verb.stative	sildenafil NN B-noun.attribute	published VBN B-verb.creation	in IN 0	the DT 0	international JJ B-adj.all	literature NN B-noun.act	between IN 0	January NNP B-noun.person	1999 CD 0	and CC 0	August NNP 0	2000 CD 0	were VBD 0	identified VBN B-verb.cognition	through IN 0	searches NNS B-noun.time	of IN 0	MEDLINE NNP B-noun.location	, , 0	PREMEDLINE NNP B-noun.person	, , 0	and CC 0	International NNP B-noun.other	Pharmaceutical NNP I-noun.other	Abstracts NNPS I-noun.other	, , 0	using VBG B-verb.consumption	the DT 0	terms NNS B-noun.communication	sildenafil NN B-noun.attribute	, , 0	Viagra NNP B-noun.person	, , 0	and CC 0	erectile JJ B-adj.all	dysfunction NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d422.s13	Caution NN B-noun.person	should MD 0	be VB 0	exercised VBN B-verb.social	when WRB 0	considering VBG B-verb.communication	the DT 0	use NN 0	of IN 0	BREVIBLOC NNP B-noun.group	and CC 0	verapamil NN B-noun.person	in IN 0	patients NNS B-noun.person	with IN 0	depressed JJ B-adj.all	myocardial JJ B-adj.all	function NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d212.s17	Digoxin NNP B-noun.person	Keppra NNP I-noun.person	_ . 0	( ( 0	1000 CD 0	mg NN B-noun.quantity	twice RB 0	daily JJ 0	) ) 0	did VBD 0	not RB B-adv.all	influence VB B-verb.emotion	the DT 0	pharmacokinetics NNS B-noun.person	and CC 0	pharmacodynamics NNS B-noun.person	( ( 0	ECG NNP 0	) ) 0	of IN 0	digoxin NN B-noun.food	given VBN B-verb.possession	as IN 0	a DT 0	0.25 CD 0	mg DT B-noun.quantity	dose NN B-noun.event	every DT 0	day NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d565.s25	A DT 0	pharmacokinetic JJ B-adj.all	interaction NN B-noun.act	between IN 0	diltiazem NN B-noun.person	and CC 0	cyclosporine NN B-noun.person	has VBZ 0	been VBN 0	observed VBN B-verb.perception	during IN 0	studies NNS B-noun.act	involving VBG B-verb.stative	renal JJ B-adj.all	and CC 0	cardiac JJ B-adj.all	transplant NN B-noun.person	patients NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d293.s0	May MD 0	interact VB B-verb.change	with IN 0	thyroid JJ B-noun.body	medication NN I-noun.body	( ( 0	e.g. UH 0	, , 0	levothyroxine NN B-noun.attribute	) ) 0	, , 0	iodine NN B-noun.person	- : 0	containing VBG B-verb.communication	products NNS B-noun.person	, , 0	antacids NNS B-noun.person	, , 0	H2-antagonists NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	famotidine NN 0	, , 0	ranitidine NN B-noun.location	) ) 0	, , 0	and CC 0	proton_pump_inhibitors NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	lansoprazole NN B-noun.location	, , 0	omeprazole NN B-noun.location	) ) 0	. . 0	. . 0
DDI-DrugBank.d508.s2	Use NNP B-noun.person	of IN 0	Antithrombotics NNP B-noun.person	Aspirin NNP I-noun.person	and CC 0	heparin NN B-noun.person	have VBP 0	been VBN 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	and CC 0	following VBG 0	infusions NNS B-noun.communication	of IN 0	Activase NNP B-noun.person	in IN 0	the DT 0	management NN B-noun.group	of IN 0	acute JJ B-adj.all	myocardial JJ B-adj.all	infarction NN B-noun.cognition	or CC 0	pulmonary JJ B-adj.all	embolism NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d144.s1	If IN 0	treatment NN B-noun.person	with IN 0	inhibitors NNS B-noun.person	of IN 0	CYP3A4 JJ B-noun.phenomenon	activity NN B-noun.process	( ( 0	such JJ 0	as IN 0	ketoconazole NN B-noun.person	, , 0	intraconazole NN B-noun.person	, , 0	ritonavir NN B-noun.person	, , 0	indinavir NN B-noun.person	, , 0	saquinavir NN B-noun.person	, , 0	erythromycin NN B-noun.person	, , 0	etc FW 0	. . 0	) ) 0	is VBZ 0	indicated VBN B-verb.communication	, , 0	reduction NN B-noun.process	of IN 0	the DT 0	budesonide NN 0	dose NN 0	should MD 0	be VB 0	considered VBN B-verb.cognition	. . 0	. . 0
DDI-MedLine.d76.s7	Decreasing VBG B-verb.change	the DT 0	concentration NN B-noun.event	of IN 0	CMC NNP B-noun.group	- : 0	Cys NNP B-noun.person	, , 0	exhibiting VBG B-verb.stative	7.3 CD 0	% NN 0	( ( 0	m UH 0	/ : 0	m LS 0	) ) 0	of IN 0	immobilised JJ B-adj.all	cysteine NN B-noun.person	( ( 0	CMC NNP B-noun.group	- : 0	Cys7.3 NN 0	) ) 0	from IN 0	1 CD B-adj.all	% NN 0	( ( 0	m UH 0	/ : 0	v LS 0	) ) 0	to TO 0	0.5 CD 0	% NN 0	( ( 0	m UH 0	/ : 0	v LS 0	) ) 0	decreased VBD B-verb.change	the DT 0	R NNP 0	- : 0	value NN B-noun.attribute	of IN 0	NaFlu NNP B-noun.person	from IN 0	1.8 CD 0	to TO 0	1.2 CD 0	. . 0	. . 0
DDI-DrugBank.d158.s14	Haloperidol NNP B-noun.person	, , 0	Haloperidol NNP B-noun.person	blocks NNS I-noun.person	dopamine VBP 0	receptors NNS B-noun.person	, , 0	thus RB 0	inhibiting VBG B-verb.change	the DT 0	central JJ B-noun.body	stimulant JJ I-noun.body	effects NNS B-noun.phenomenon	of IN 0	amphetamines NNS B-noun.animal	. . 0	. . 0
DDI-DrugBank.d338.s9	Drug NNP B-noun.person	Interaction NNP I-noun.person	with IN 0	Fluoxetine NNP B-noun.person	, , 0	A DT 0	multiple JJ B-noun.person	- : 0	dose NN B-noun.quantity	study NN B-noun.artifact	was VBD 0	conducted VBN B-verb.communication	to TO 0	assess VB B-verb.cognition	the DT 0	effect NN B-noun.cognition	of IN 0	fluoxetine JJ B-adj.all	20 CD 0	mg DT 0	BID NNP B-noun.group	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	estazolam NN B-noun.communication	2 CD 0	mg IN 0	QHS NNP B-noun.group	after IN 0	seven CD B-adj.all	days NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d97.s41	Increasing VBG B-verb.change	the DT 0	indinavir NN 0	dose NN 0	to TO 0	1000 CD 0	mg IN 0	every DT 0	8 CD B-adj.all	hours NNS B-noun.time	does VBZ 0	not RB B-adv.all	compensate VB B-verb.communication	for IN 0	the DT 0	increased VBN B-verb.change	indinavir NN 0	metabolism NN 0	due JJ 0	to TO 0	efavirenz VB B-verb.social	. . 0	. . 0
DDI-DrugBank.d393.s0	Pharmacokinetic JJ B-adj.all	interaction NN B-noun.act	studies NNS B-noun.artifact	with IN 0	cetirizine NN B-noun.person	in IN 0	adults NNS B-noun.animal	were VBD 0	conducted VBN B-verb.creation	with IN 0	pseudoephedrine NN B-noun.person	, , 0	antipyrine NN B-noun.location	, , 0	ketoconazole NN B-noun.person	, , 0	erythromycin NN B-noun.person	and CC 0	azithromycin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d44.s1	RAPTIVA NNP B-noun.group	should MD 0	not RB 0	be VB 0	used VBN B-verb.consumption	with IN 0	other JJ B-adj.all	immunosuppressive_drugs NNS B-noun.plant	. . 0	. . 0
DDI-DrugBank.d212.s7	Pharmacokinetics NNS B-noun.person	of IN 0	levetiracetam NN B-noun.state	were VBD B-verb.stative	also RB B-adv.all	not RB B-adv.all	affected VBN B-verb.change	by IN 0	phenytoin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d233.s0	Use NN 0	with IN 0	Allopurinol NNP B-noun.person	, , 0	The DT 0	principal JJ B-adj.all	pathway NN B-noun.location	for IN 0	detoxification NN B-noun.act	of IN 0	azathioprine NN B-noun.phenomenon	is VBZ 0	inhibited VBN B-verb.change	by IN 0	allopurinol NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d162.s1	Alcohol NNP B-noun.person	, , 0	barbiturates NNS B-noun.person	, , 0	or CC 0	narcotics NNS B-noun.person	, , 0	potentiation NN B-noun.person	of IN 0	orthostatic JJ B-adj.all	hypotension NN B-noun.act	may MD 0	occur VB B-verb.stative	. . 0	. . 0
DDI-DrugBank.d341.s3	Two CD 0	percent NN B-noun.person	of IN 0	patients NNS B-noun.person	treated VBD B-verb.communication	concurrently RB B-adv.all	with IN 0	ENBREL NNP B-noun.group	_ : 0	and CC 0	anakinra NN B-noun.body	developed VBN B-verb.body	neutropenia NN B-noun.person	( ( 0	ANC NNP 0	__ $ 0	1 CD B-adj.all	x IN 0	109/L NNP 0	) ) 0	. . 0	. . 0
DDI-MedLine.d45.s9	aureus NN B-noun.artifact	, , 0	to TO 0	survive VB B-verb.stative	in IN 0	pentazocine NN 0	and CC 0	tripelennamine NN B-noun.act	may MD 0	explain VB B-verb.communication	in IN 0	part NN 0	a DT 0	shift NN B-noun.act	from IN 0	S. NNP B-noun.location	. . 0
DDI-DrugBank.d522.s3	The DT 0	pharmacokinetics NNS B-noun.time	of IN 0	terfenadine NN B-noun.artifact	and CC 0	its PRP$ 0	acid NN B-noun.act	metabolite NN I-noun.act	and CC 0	the DT 0	electrocardiographic JJ B-adj.all	QT NNP 0	c CC 0	interval JJ B-adj.all	were VBD 0	measured VBN B-verb.cognition	during IN 0	both DT 0	periods NNS B-noun.person	, , 0	with IN 0	terfenadine NN 0	alone RB 0	, , 0	and CC 0	with IN 0	terfenadine NN B-noun.person	plus CC 0	dirithromycin NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d324.s18	An DT 0	alternative JJ B-adj.all	non NN B-noun.person	- : 0	CYP3A4 JJ B-adj.all	substrate JJ I-adj.all	hypnotic_agent NN B-noun.group	may MD 0	be VB 0	considered VBN B-verb.cognition	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	CYP3A4 JJ B-noun.person	inducers NNS I-noun.person	such JJ 0	as IN 0	rifampin NN B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	carbamazepine NN 0	, , 0	and CC 0	phenobarbital NN B-noun.artifact	. . 0	. . 0
DDI-MedLine.d0.s0	The DT 0	effects NNS B-noun.phenomenon	of IN 0	concomitant JJ B-adj.all	phenytoin NN B-noun.person	administration NN B-noun.person	on IN 0	the DT 0	steady JJ B-noun.artifact	- : 0	state NN B-adj.all	pharmacokinetics NNS B-noun.person	of IN 0	quetiapine NN B-noun.communication	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d87.s13	Limited VBN B-verb.contact	data NNS B-noun.cognition	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	known VBN B-verb.cognition	enzyme NN B-noun.person	inducers NNS B-noun.person	( ( 0	phenytoin NN B-noun.person	, , 0	phenobarbital JJ B-adj.all	, , 0	carbamazepine NN 0	) ) 0	indicate VBP B-verb.communication	only RB B-adv.all	a DT 0	30 CD B-adj.all	% NN 0	increase NN B-noun.event	in IN 0	the DT 0	rate NN B-noun.time	of IN 0	flecainide JJ B-adj.all	elimination NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d340.s14	Indinavir NNP B-noun.person	, , 0	Coadministration NNP B-noun.person	of IN 0	indinavir NN B-noun.person	with IN 0	VIRACEPT NNP B-noun.group	resulted VBD B-verb.competition	in IN 0	an DT 0	83 CD B-adj.all	% NN 0	increase NN B-noun.event	in IN 0	nelfinavir JJ B-adj.all	plasma NN B-noun.person	AUC NNP I-noun.person	and CC 0	a DT 0	51 CD 0	% NN 0	increase NN B-noun.event	in IN 0	indinavir NN 0	plasma NN 0	A.C. NNP 0	. . 0
DDI-DrugBank.d210.s26	Therefore RB 0	, , 0	a DT 0	starting VBG 0	daily JJ 0	dose NN 0	of IN 0	25 CD B-adj.all	mg NN B-noun.quantity	of IN 0	VIOXX NNP B-noun.group	should MD 0	be VB 0	considered VBN B-verb.cognition	for IN 0	the DT 0	treatment NN B-noun.communication	of IN 0	osteoarthritis NN 0	when WRB 0	VIOXX NNP B-noun.group	is VBZ B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	potent JJ B-adj.all	inducers NNS B-noun.person	of IN 0	hepatic JJ B-adj.all	metabolism NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d99.s26	Transient NNP B-noun.person	delirium NN B-noun.group	has VBZ 0	been VBN 0	reported VBN B-verb.communication	in IN 0	patients NNS B-noun.person	who WP 0	were VBD 0	treated VBN B-verb.change	with IN 0	one CD 0	gram NN 0	of IN 0	ethchlorvynol NN B-noun.food	and CC 0	75 CD 0	; : 0	150 CD 0	mg NN B-noun.quantity	of IN 0	amitriptyline_HCl NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d237.s6	Antidepressants NNS B-noun.person	, , 0	In IN 0	vitro NN B-noun.animal	data NNS I-noun.animal	indicate VBP B-verb.communication	that IN 0	nefazodone NN 0	inhibits VBZ B-verb.stative	the DT 0	metabolism NN B-noun.attribute	of IN 0	cisapride NN B-noun.location	, , 0	which WDT 0	can MD 0	result VB B-verb.stative	in IN 0	an DT 0	increase NN B-noun.act	in IN 0	plasma NN B-noun.substance	cisapride NN 0	levels NNS B-noun.state	and CC 0	prolongation NN B-noun.act	of IN 0	the DT 0	QT NNP 0	interval NN 0	on IN 0	the DT 0	ECG NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d566.s2	Cholestyramine JJ B-adj.all	resin NN B-noun.act	may MD 0	interfere VB B-verb.stative	with IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	drugs NNS B-noun.artifact	that WDT 0	undergo VBP B-verb.stative	enterohepatic JJ B-adj.all	circulation NN B-noun.act	, , 0	The DT 0	discontinuance NN B-noun.attribute	of IN 0	cholestyramine JJ B-adj.all	resin NN B-noun.person	could MD 0	pose VB B-verb.perception	a DT 0	hazard NN B-noun.person	to TO 0	health NN B-noun.person	if IN 0	a DT 0	potentially RB B-adj.all	toxic JJ B-adj.all	drug NN B-noun.state	such JJ 0	as IN 0	digitalis NN 0	has VBZ 0	been VBN 0	filtrated VBN B-verb.communication	to TO 0	a DT 0	maintenance NN B-noun.phenomenon	level NN B-noun.attribute	while IN 0	the DT 0	patient NN B-noun.person	was VBD 0	taking VBG B-verb.change	cholestyramine JJ B-adj.all	resin NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d499.s1	The DT 0	possibility NN B-noun.state	of IN 0	increased VBN B-verb.change	interaction NN B-noun.act	should MD 0	be VB 0	kept VBN B-verb.stative	in IN 0	mind NN 0	when WRB 0	Orudis NNP B-noun.person	doses VBZ B-verb.communication	greater JJR B-adj.all	than IN 0	50 CD B-adj.all	mg NN B-noun.quantity	as IN 0	a DT 0	single JJ B-adj.all	dose NN B-noun.communication	or CC 0	200 CD 0	mg NN B-noun.quantity	of IN 0	ketoprofen NN B-noun.animal	per IN 0	day NN B-noun.animal	are VBP 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	highly RB B-adv.all	bound VBN B-verb.contact	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-MedLine.d135.s0	Combinations NNS B-noun.person	of IN 0	clozapine NN B-noun.act	and CC 0	phencyclidine NN B-noun.person	, , 0	effects NNS B-noun.phenomenon	on IN 0	drug NN B-noun.artifact	discrimination NN I-noun.artifact	and CC 0	behavioral JJ B-adj.all	inhibition NN B-noun.attribute	in IN 0	rats NNS B-noun.animal	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d114.s2	Concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	drugs NNS B-noun.artifact	possessing VBG B-verb.stative	nephrotoxic JJ B-adj.all	( ( 0	e.g. UH 0	, , 0	aminoglycosides NNS B-noun.person	, , 0	indomethacin NN 0	) ) 0	, , 0	myelotoxic JJ B-adj.all	( ( 0	e.g. UH 0	, , 0	cytotoxic JJ B-adj.all	chemotherapy NN B-noun.body	) ) 0	, , 0	cardiotoxic JJ B-adj.all	( ( 0	e.g. UH 0	, , 0	doxorubicin NN 0	) ) 0	or CC 0	hepatotoxic JJ B-adj.all	( ( 0	e.g. UH 0	, , 0	methotrexate NN B-noun.person	, , 0	asparaginase NN 0	) ) 0	effects NNS B-noun.phenomenon	with IN 0	PROLEUKIN NNP B-noun.group	may MD 0	increase VB B-verb.change	toxicity NN B-noun.attribute	in IN 0	these DT 0	organ NN B-noun.artifact	systems NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d165.s0	Both DT 0	itraconazole NN B-noun.group	and CC 0	its PRP$ 0	major JJ B-adj.all	metabolite NN B-noun.attribute	, , 0	hydroxyitraconazole NN B-noun.person	, , 0	are VBP B-verb.stative	inhibitors NNS B-noun.person	of IN 0	the DT 0	cytochrome NN 0	P450 RB 0	3A4 JJ 0	enzyme NN B-noun.cognition	system NN I-noun.cognition	. . 0	. . 0
DDI-DrugBank.d276.s0	Antacids NNS B-noun.person	containing VBG B-verb.social	magnesium_trisilicate JJ I-verb.social	, , 0	when WRB 0	administered VBN B-verb.communication	concomitantly RB B-adv.all	with IN 0	nitrofurantoin NN B-noun.person	, , 0	reduce VB B-verb.contact	both DT 0	the DT 0	rate NN B-noun.time	and CC 0	extent NN B-noun.act	of IN 0	absorption NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d202.s8	Administration NN B-noun.person	of IN 0	reserpine NN B-noun.act	during IN 0	therapy NN 0	with IN 0	a DT 0	tricyclic_antidepressant NN B-noun.person	has VBZ 0	been VBN 0	shown VBN B-verb.perception	to TO 0	produce VB B-verb.creation	a DT 0	_ , 0	stimulating VBG B-verb.body	_ JJ B-adj.all	effect NN B-noun.cognition	in IN 0	some DT 0	depressed JJ B-adj.all	patients NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d78.s19	Nonsteroidal_Anti SYM 0	- : 0	inflammatory_Drugs NNS B-noun.cognition	( ( 0	NSAIDs NNP B-noun.person	) ) 0	, , 0	The DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	a DT 0	nonsteroidal_anti_inflammatory_drug NN 0	with IN 0	a DT 0	quinolone NN 0	may MD 0	increase VB B-verb.change	the DT 0	risks NNS B-noun.object	of IN 0	CNS NNP B-noun.group	stimulation NN B-noun.artifact	and CC 0	convulsions NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d219.s4	Aspirin NNP B-noun.person	, , 0	When WRB 0	Lodine NNP B-noun.person	is VBZ 0	administered VBN B-verb.possession	with IN 0	aspirin NN B-noun.person	, , 0	its PRP$ 0	protein NN B-noun.substance	binding NN B-verb.contact	is VBZ 0	reduced VBN B-verb.change	, , 0	although IN 0	the DT 0	clearance NN B-noun.act	of IN 0	free JJ B-noun.person	etodolac NN I-noun.person	is VBZ B-verb.stative	not RB B-adv.all	altered VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d54.s17	Digitalis NNP B-noun.person	, , 0	Thyroid_preparations NNS B-noun.artifact	may MD 0	potentiate VB B-verb.communication	the DT 0	toxic JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	digitalis NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d234.s11	An DT 0	adequate JJ B-adj.all	period NN B-noun.person	of IN 0	observation NN B-noun.act	must MD 0	be VB 0	provided VBN B-verb.communication	for IN 0	any DT 0	patient NN B-noun.person	in IN 0	whom WP 0	either RB 0	long RB 0	- : 0	acting_benzodiazepines NNS B-noun.substance	( ( 0	such JJ 0	as IN 0	diazepam NN B-noun.person	) ) 0	or CC 0	large JJ B-adj.all	doses NNS B-noun.event	of IN 0	short JJ B-noun.body	- : 0	acting_benzodiazepines NNS B-noun.substance	( ( 0	such JJ 0	as IN 0	_ $ 0	10 CD B-adj.all	mg NN B-noun.quantity	of IN 0	midazolam NN B-noun.body	) ) 0	have VBP 0	been VBN 0	used VBN B-verb.consumption	. . 0	. . 0
DDI-DrugBank.d148.s7	Drug NN B-noun.person	- : 0	drug NN B-noun.person	interactions NNS I-noun.person	have VBP 0	not RB 0	been VBN 0	observed VBN B-verb.perception	between IN 0	Argatroban NNP B-noun.person	and CC 0	digoxin NN B-noun.person	or CC 0	erythromycin NN B-noun.substance	. . 0	. . 0
DDI-MedLine.d8.s5	ulcerans NNS B-noun.person	was VBD B-verb.stative	between IN 0	0.012 CD 0	and CC 0	0.025 CD 0	mg FW B-noun.quantity	/ FW 0	l FW 0	, , 0	while IN 0	corresponding VBG B-verb.stative	values NNS B-noun.attribute	for IN 0	rifampicin NN B-noun.person	and CC 0	rifabutin NN B-noun.person	were VBD B-verb.stative	in IN 0	the DT 0	range NN B-noun.location	of IN 0	0.1 CD 0	- : 0	0.8 CD 0	mg PRP 0	/ ( 0	l NN B-noun.quantity	and CC 0	0.1 CD 0	- : 0	0.4 CD 0	mg PRP B-noun.quantity	/ : 0	l PRP 0	respectively RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d508.s4	The DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	heparin NN B-noun.state	or CC 0	aspirin NN B-noun.substance	during IN 0	the DT 0	first JJ B-verb.competition	24 CD B-adj.all	hours NNS B-noun.artifact	following VBG B-verb.stative	symptom JJ B-adj.all	onset NN B-noun.event	were VBD 0	prohibited VBN B-verb.communication	in IN 0	The DT 0	NINDS NNPS B-noun.group	t SYM 0	- : 0	PA NNP B-noun.person	Stroke NNP I-noun.person	Trial NNP I-noun.person	. . 0	. . 0
DDI-DrugBank.d99.s20	Paralytic JJ B-adj.all	ileus NN B-noun.group	may MD 0	occur VB B-verb.stative	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	tricyclic_antidepressants NNS B-noun.person	in IN 0	combination NN 0	with IN 0	anticholinergic JJ B-adj.pert	- : 0	type NN B-noun.person	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d135.s0	Effects NNS B-noun.phenomenon	of IN 0	Lapatinib NNP B-noun.person	on IN 0	Drug NNP B-noun.person	Metabolizing NNP I-noun.person	Enzymes NNP I-noun.person	and CC 0	Drug NNP B-noun.other	Transport NNP I-noun.other	Systems NNPS I-noun.other	Lapatinib NNP I-noun.other	inhibits VBZ B-verb.creation	CYP3A4 NNP I-verb.creation	and CC 0	CYP2C8 NNP B-noun.person	in IN B-adj.all	vitro NN I-adj.all	at IN 0	clinically RB B-adv.all	relevant JJ B-adj.all	concentrations NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d382.s18	Tolbutamide NNP 0	, , 0	Aprepitant NNP B-noun.person	, , 0	when WRB 0	given VBN B-verb.possession	as IN 0	125 CD 0	mg NN B-noun.quantity	on IN 0	Day NNP 0	1 CD 0	and CC 0	80 CD 0	mg RB 0	/ JJ 0	day NN 0	on IN 0	Days NNS B-noun.time	2 CD 0	and CC 0	3 CD B-adj.all	, , 0	decreased VBD B-verb.change	the DT 0	AUC NNP B-noun.group	of IN 0	tolbutamide NN 0	( ( 0	a DT 0	CYP2C9 JJ B-adj.all	substrate NN I-adj.all	) ) 0	by IN 0	23 CD B-adj.all	% NN 0	on IN 0	Day NNP 0	4 CD 0	, , 0	28 CD B-adj.all	% NN 0	on IN 0	Day NNP 0	8 CD 0	, , 0	and CC 0	15 CD B-adj.all	% NN 0	on IN 0	Day NNP 0	15 CD 0	, , 0	when WRB 0	a DT 0	single JJ B-adj.all	dose NN B-noun.event	of IN 0	tolbutamide NN 0	500 CD 0	mg NN B-noun.quantity	was VBD B-verb.stative	admini NNS B-noun.person	, , 0	stered VBD B-verb.motion	orally RB B-adv.all	prior RB 0	to TO 0	the DT 0	administration NN B-noun.time	of IN 0	the DT 0	3-day JJ B-adj.all	regimen NNS B-noun.person	of IN 0	Aprepitant NNP B-noun.other	and CC I-noun.other	on IN I-noun.other	Days NNPS I-noun.other	4,8 CD I-noun.other	, , 0	and CC 0	15 CD B-adj.all	. . 0	. . 0
DDI-DrugBank.d331.s7	- : 0	Indomethacin NNP B-noun.person	, , 0	Indomethacin NNP B-noun.person	blunts VBZ B-verb.communication	the DT 0	increases NNS B-noun.event	in IN 0	urine NN 0	volume NN B-noun.artifact	and CC 0	sodium NN 0	excretion NN 0	seen VBN B-verb.perception	during IN 0	bumetanide NN 0	treatment NN B-noun.plant	and CC 0	inhibits VBZ B-verb.stative	the DT 0	bumetanide NN B-noun.person	- : 0	induced VBN B-verb.creation	increase NN B-noun.process	in IN 0	plasma NN 0	renin NN B-noun.body	activity NN B-noun.process	. . 0	. . 0
DDI-DrugBank.d163.s4	Micro SYM 0	- : 0	dosed VBD B-verb.communication	Progesterone NNP B-noun.person	Preparations NNP I-noun.person	, , 0	Micro NNP B-noun.person	- : 0	dosed VBD B-verb.communication	progesterone NN B-noun.person	preparations NNS B-noun.person	( ( 0	minipills NNS B-noun.artifact	that WDT 0	do VBP 0	not RB 0	contain VB B-verb.stative	an DT 0	estrogen NN B-noun.artifact	) ) 0	may MD 0	be VB B-verb.stative	an DT 0	inadequate JJ B-adj.all	method NN B-noun.attribute	of IN 0	contraception NN B-noun.act	during IN 0	Accutane NNP B-noun.person	therapy NN I-noun.person	. . 0	. . 0
DDI-DrugBank.d549.s3	During IN 0	clinical JJ B-adj.all	trials NNS B-noun.communication	, , 0	iloprost NN B-noun.person	was VBD 0	used VBN B-verb.consumption	concurrently RB B-adv.all	with IN 0	anticoagulants NNS B-noun.person	, , 0	diuretics NNS B-noun.person	, , 0	cardiac_glycosides NNS B-noun.group	, , 0	calcium_channel_blockers NNS B-noun.person	, , 0	analgesics NNS B-noun.person	, , 0	antipyretics NNS B-noun.person	, , 0	nonsteroidal_antiinflammatories NNS B-noun.person	, , 0	corticosteroids NNS B-noun.person	, , 0	and CC 0	other JJ 0	medications NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d336.s1	The DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	alcohol NN B-noun.animal	or CC 0	other JJ B-adj.all	central_nervous_system_depressants NNS B-noun.location	may MD 0	have VB B-verb.possession	an DT 0	additive JJ B-adj.all	effect NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d529.s12	Cimetidine NNP B-noun.person	, , 0	Ranitidine NNP B-noun.location	, , 0	In IN 0	normal JJ B-adj.all	volunteers NNS B-noun.person	( ( 0	n=9 NNP 0	) ) 0	, , 0	pretreatment NN B-noun.person	with IN 0	cimetidine NN B-noun.act	or CC 0	ranitidine NN B-noun.artifact	did VBD 0	not RB B-adv.all	affect VB B-verb.change	flurbiprofen JJ B-adj.all	pharmacokinetics NNS B-noun.person	except IN 0	that IN 0	a DT 0	small JJ B-noun.person	( ( 0	13 CD B-adj.all	% NN 0	) ) 0	but CC 0	statistically RB B-adv.all	significant JJ B-adj.all	increase NN B-noun.event	in IN 0	the DT 0	area NN B-noun.body	under IN 0	the DT 0	serum NN B-noun.body	concentration NN 0	curve NN B-noun.communication	of IN 0	flurbiprofen NN B-noun.person	resulted VBD B-verb.social	with IN 0	cimetidine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d541.s0	May MD 0	interact VB B-verb.change	with IN 0	the DT 0	following NN 0	, , 0	beta JJ 0	- : 0	adrenergic_blocking_agents NNS B-noun.person	( ( 0	these DT 0	medicines NNS B-noun.artifact	may MD 0	make VB B-verb.change	your PRP$ 0	condition NN B-noun.person	worse JJR B-verb.emotion	and CC 0	prevent VB B-verb.contact	the DT 0	adrenergic_bronchodilators NNS B-noun.person	from IN 0	working VBG B-verb.social	properly RB B-adv.all	) ) 0	and CC 0	disopyramide NN B-noun.person	, , 0	quinidine NN B-noun.location	, , 0	phenothiazines NNS B-noun.body	, , 0	and CC 0	procainamide NN B-noun.person	( ( 0	these DT 0	medicines NNS B-noun.artifact	may MD 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	heart NN B-noun.body	problems NNS I-noun.body	) ) 0	. . 0	. . 0
DDI-DrugBank.d75.s14	The DT 0	effects NNS B-noun.phenomenon	of IN 0	medicinal JJ B-adj.all	products NNS B-noun.person	with IN 0	similar JJ B-adj.all	properties NNS B-noun.attribute	such JJ 0	as IN 0	inotropes NNS 0	milrinone NN 0	, , 0	enoximone NN B-noun.person	, , 0	amrinone NN B-noun.person	, , 0	olprinone NN 0	and CC 0	cilostazol NN B-noun.act	may MD 0	be VB 0	exacerbated VBN B-verb.communication	by IN 0	anagrelide NN 0	. . 0	. . 0
DDI-DrugBank.d328.s31	Coadministration NN B-noun.person	of IN 0	valdecoxib NN B-noun.attribute	( ( 0	10 CD 0	mg IN 0	BID NNP 0	for IN 0	7 CD B-adj.all	days NNS B-noun.act	) ) 0	with IN 0	glyburide NN 0	( ( 0	5 CD 0	mg IN 0	QD NNP 0	or CC 0	10 CD B-adj.all	mg IN 0	BID NNP 0	) ) 0	did VBD 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	( ( 0	exposure NN B-noun.cognition	) ) 0	of IN 0	glyburide NN 0	. . 0	. . 0
DDI-DrugBank.d495.s4	Tricyclic_antidepressants NNS B-noun.act	may MD 0	antagonize VB B-verb.cognition	the DT 0	hypotensive JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	clonidine NN B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d99.s22	Clinically RB B-adv.all	significant JJ B-adj.all	effects NNS B-noun.phenomenon	have VBP 0	been VBN 0	reported VBN B-verb.communication	with IN 0	the DT 0	tricyclic_antidepressants NNS B-noun.group	when WRB 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	cimetidine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d247.s8	Diuretic_agents NNS B-noun.artifact	may MD 0	decrease VB B-verb.change	vascular JJ B-adj.all	response NN B-noun.communication	to TO 0	pressor VB B-verb.creation	drugs NNS B-noun.event	such JJ 0	as IN 0	epinephrine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d225.s3	In IN 0	vitro NN B-noun.animal	binding JJ B-verb.contact	studies NNS B-noun.plant	with IN 0	human JJ B-adj.all	serum NN B-noun.person	proteins NNS B-noun.person	indicate VBP B-verb.cognition	that IN 0	glipizide NN B-noun.animal	binds NNS I-noun.animal	differently RB B-adv.all	than IN 0	tolbutamide NN 0	and CC 0	does VBZ 0	not RB B-adv.all	interact VB B-verb.change	with IN 0	salicylate NN B-noun.substance	or CC 0	dicumarol NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d509.s15	Quinidine NNP B-noun.location	, , 0	Coadministration NNP B-noun.person	of IN 0	a DT 0	10-mg JJ B-adj.all	single JJ B-adj.all	dose NN B-noun.event	of IN 0	aripiprazole NN B-noun.shape	with IN 0	quinidine NN B-noun.attribute	( ( 0	166 CD 0	mg RB 0	/ JJ 0	day NN 0	for IN 0	13 CD B-adj.all	days NNS B-noun.act	) ) 0	, , 0	a DT 0	potent JJ B-adj.all	inhibitor NN B-noun.person	of IN 0	CYP2D6 NNP B-noun.person	, , 0	increased VBD B-verb.change	the DT 0	AUC NNP B-noun.group	of IN 0	aripiprazole NN B-noun.shape	by IN 0	112 CD 0	% NN 0	but CC 0	decreased VBD B-verb.change	the DT 0	AUC NNP B-noun.group	of IN 0	its PRP$ 0	active JJ B-adj.all	metabolite NN B-noun.food	, , 0	dehydroaripiprazole NN B-noun.person	, , 0	by IN 0	35 CD 0	% NN 0	. . 0	. . 0
DDI-DrugBank.d328.s29	Plasma NNP B-noun.person	exposure NN I-noun.person	( ( 0	AUC NNP 0	) ) 0	to TO 0	valdecoxib NN B-noun.person	was VBD 0	increased VBN B-verb.change	62 CD 0	% NN 0	when WRB 0	coadministered VBN B-verb.communication	with IN 0	fluconazole NN B-noun.attribute	and CC 0	38 CD 0	% NN 0	when WRB 0	coadministered VBN B-verb.communication	with IN 0	ketoconazole NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d514.s0	Opioids NNS B-noun.person	are VBP B-verb.stative	strong JJ B-adj.all	central_nervous_system_depressants NNS B-noun.location	, , 0	but CC 0	regular JJ B-adj.all	users NNS 0	develop VB B-verb.stative	physiological JJ B-adj.all	tolerance NN B-noun.act	allowing VBG B-verb.change	gradually RB B-adv.all	increased VBN B-verb.change	dosages NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d275.s2	In IN 0	a DT 0	study NN B-noun.artifact	in IN 0	which WDT 0	patients NNS B-noun.person	with IN 0	active JJ B-adj.all	RA NNP B-noun.group	were VBD 0	treated VBN B-verb.social	for IN 0	up RB 0	to TO 0	24 CD B-adj.all	weeks NNS B-noun.time	with IN 0	concurrent JJ B-noun.person	Kineret NNP I-noun.person	and CC 0	etanercept JJ 0	therapy NN 0	, , 0	a DT 0	7 CD B-adj.all	% NN 0	rate NN B-noun.time	of IN 0	serious JJ B-adj.all	infections NNS B-noun.person	was VBD 0	observed VBN B-verb.perception	, , 0	which WDT 0	was VBD B-verb.stative	higher JJR B-adj.all	than IN 0	that DT 0	observed VBN B-verb.perception	with IN 0	etanercept FW 0	alone RB 0	( ( 0	0 CD B-noun.quantity	% NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d11.s1	CYP2D6 JJ B-adj.all	inhibitors NNS B-noun.attribute	; : 0	Atomoxetine NNP B-noun.person	is VBZ B-verb.stative	primarily RB B-adv.all	metabolized VBN B-verb.social	by IN 0	the DT 0	CYP2D6 JJ B-adj.all	pathway NN B-noun.location	to TO 0	4-hydroxyatomoxetine JJ 0	. . 0	. . 0
DDI-DrugBank.d299.s1	Because IN 0	there EX 0	is VBZ B-verb.stative	a DT 0	theoretical JJ B-adj.all	basis NN B-noun.cognition	that IN 0	these DT 0	effects NNS B-noun.phenomenon	may MD 0	be VB B-verb.stative	additive JJ B-adj.all	, , 0	use NN 0	of IN 0	ergotamine NN B-noun.person	- : 0	containing VBG B-verb.communication	or CC 0	ergot NN B-noun.person	- : 0	type_medications NNS B-noun.person	( ( 0	like IN 0	dihydroergotamine NN B-noun.person	or CC 0	methysergide NN B-noun.attribute	) ) 0	and CC 0	AXERT NNP B-noun.act	within IN 0	24 CD B-adj.all	hours NNS B-noun.time	of IN 0	each DT 0	other JJ 0	should MD 0	be VB 0	avoided VBN B-verb.social	. . 0	. . 0
DDI-MedLine.d140.s15	For IN 0	a DT 0	4-fold JJ B-noun.person	range NN I-noun.person	of IN 0	everolimus NN 0	doses VBZ B-verb.stative	there EX 0	were VBD B-verb.stative	no DT 0	differential JJ B-adj.all	effects NNS B-noun.phenomenon	on IN 0	cyclosporine NN B-noun.act	dosing NN I-noun.act	or CC 0	pharmacokinetics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d488.s7	Heparin_Sodium NNP B-noun.person	Injection NNP I-noun.person	should MD 0	not RB 0	be VB 0	mixed VBN B-verb.change	with IN 0	doxorubicin NN B-noun.food	, , 0	droperidol NN B-noun.person	, , 0	ciprofloxacin NN B-noun.person	, , 0	or CC 0	mitoxantrone NN B-noun.substance	, , 0	since IN 0	it PRP 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	that IN 0	these DT 0	drugs NNS B-noun.artifact	are VBP B-verb.stative	incompatible JJ B-adj.all	with IN 0	heparin NN B-noun.person	and CC 0	a DT 0	precipitate NN B-noun.person	may MD 0	form VB B-verb.stative	. . 0	. . 0
DDI-DrugBank.d485.s16	Atorvastatin NNP B-noun.person	, , 0	Atorvastatin NNP B-noun.person	increases VBZ B-verb.change	the DT 0	AUC NNP B-noun.group	for IN 0	norethindrone NN B-noun.person	and CC 0	ethinyl_estradiol NN 0	. . 0	. . 0
DDI-DrugBank.d3.s20	Morphine NN B-noun.person	, , 0	TORADOLIV NNP 0	/ ( 0	IM NNP 0	has VBZ 0	been VBN 0	administered VBN B-verb.possession	concurrently RB B-adv.all	with IN 0	morphine NN B-noun.person	in IN 0	several JJ B-adj.all	clinical JJ B-adj.all	trials NNS B-noun.cognition	of IN 0	postoperative JJ B-adj.all	pain NN B-noun.person	without IN 0	evidence NN B-noun.time	of IN 0	adverse JJ B-adj.all	interactions NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d546.s2	Drug NN B-noun.person	Interactions NNS I-noun.person	, , 0	General NNP B-noun.person	, , 0	Although IN 0	there EX 0	have VBP 0	been VBN B-verb.stative	no RB 0	formal JJ 0	interaction NN B-noun.act	studies NNS B-noun.artifact	, , 0	intravenous JJ B-adj.all	fenoldopam NN B-noun.person	has VBZ 0	been VBN 0	administered VBN B-verb.possession	safely RB B-adv.all	with IN 0	drugs NNS B-noun.artifact	such JJ 0	as IN 0	digitalis NNS B-noun.person	and CC 0	sublingual JJ B-adj.all	nitroglycerin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d347.s3	FACTIVE NNP B-noun.group	had VBD B-verb.possession	no DT 0	significant JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	anticoagulant JJ B-adj.all	effect NN B-noun.cognition	of IN 0	warfarin NN B-noun.act	in IN 0	healthy JJ B-adj.all	subjects NNS B-noun.person	on IN 0	stable JJ B-adj.all	warfarin NN B-noun.act	therapy NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d82.s21	INDOCIN RB 0	given VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	digoxin NN B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	increase VB B-verb.change	the DT 0	serum NN B-noun.body	concentration NN B-noun.event	and CC 0	prolong VB B-verb.perception	the DT 0	half NN B-noun.person	- : 0	life NN B-noun.time	of IN 0	digoxin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d516.s1	In IN 0	clinical JJ B-adj.all	studies NNS B-noun.artifact	where WRB 0	patients NNS B-noun.person	were VBD B-verb.stative	on IN 0	chronic JJ B-adj.all	theophylline NN 0	therapy NN 0	, , 0	lomefloxacin NN B-noun.person	had VBD 0	no DT 0	measurable JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	mean JJ B-adj.all	distribution NN B-noun.act	of IN 0	theophylline JJ 0	concentrations NNS B-noun.attribute	or CC 0	the DT 0	mean JJ B-adj.all	estimates NNS B-noun.artifact	of IN 0	theophylline JJ 0	clearance NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d310.s3	A DT 0	study NN B-noun.artifact	in IN 0	eight CD 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	has VBZ 0	shown VBN B-verb.perception	a DT 0	50 CD B-adj.all	% NN 0	increase NN B-noun.event	in IN 0	mean JJ B-adj.all	peak JJ B-adj.all	nimodipine NN B-noun.artifact	plasma NN B-noun.substance	concentrations NNS B-noun.artifact	and CC 0	a DT 0	90 CD B-adj.all	% NN 0	increase NN B-noun.event	in IN 0	mean JJ B-adj.all	area NN B-noun.cognition	under IN 0	the DT 0	curve NN B-noun.communication	, , 0	after IN 0	a DT 0	one CD 0	week NN B-noun.event	course NN 0	of IN 0	cimetidine NN B-noun.person	at IN 0	1,000 CD 0	mg IN 0	/ JJ 0	day NN 0	and CC 0	nimodipine NN B-noun.person	at IN 0	90 CD 0	mg RB 0	/ JJ 0	day NN 0	. . 0	. . 0
DDI-DrugBank.d45.s5	Concomitant NNP B-noun.person	Crohn NNP I-noun.person	s PRP$ 0	disease NN B-noun.act	medications NNS B-noun.artifact	were VBD B-verb.stative	antibiotics NNS B-noun.person	, , 0	antivirals NNS B-noun.person	, , 0	corticosteroids NNS B-noun.person	, , 0	6-MP JJ 0	/ IN 0	AZA NNP B-noun.group	and CC 0	aminosalicylates NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d38.s9	CONCLUSIONS NNS B-noun.artifact	, , 0	In IN 0	contrast NN 0	to TO 0	the DT 0	effects NNS B-noun.phenomenon	of IN 0	glucocorticoids NNS B-noun.food	in IN 0	rodent NN B-noun.animal	studies NNS B-noun.group	, , 0	these DT 0	results NNS B-noun.communication	indicate VBP B-verb.communication	that IN 0	an DT 0	acute JJ B-adj.all	increase NN B-noun.event	in IN 0	cortisol NN 0	does VBZ 0	not RB B-adv.all	enhance VB B-verb.change	the DT 0	psychostimulant JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	d SYM 0	- : 0	amphetamine NN B-noun.person	in IN 0	humans NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d27.s4	In IN 0	separate JJ B-adj.all	studies NNS B-noun.communication	of IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	maintenance NN B-noun.phenomenon	doses NNS B-noun.event	of IN 0	warfarin NN B-noun.location	, , 0	hydrochlorothiazide NN 0	, , 0	or CC 0	digoxin NN B-noun.substance	, , 0	irbesartan JJ B-adj.all	administration NN B-noun.person	for IN 0	7 CD B-adj.all	days NNS B-noun.person	had VBD 0	no DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	pharmacodynamics NNS B-noun.person	of IN 0	warfarin NN B-noun.substance	( ( 0	prothrombin NN B-noun.person	time NN 0	) ) 0	or CC 0	pharmacokinetics NNS B-noun.person	of IN 0	digoxin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d146.s2	Colchicine NN B-noun.person	may MD 0	increase VB B-verb.change	sensitivity NN B-noun.feeling	to TO 0	the DT 0	CNS_depressants NNS B-noun.artifact	. . 0	. . 0
DDI-MedLine.d57.s1	The DT 0	literature NN B-noun.communication	provides VBZ B-verb.cognition	considerable JJ B-adj.all	evidence NN B-noun.person	indicating VBG B-verb.communication	that IN 0	several JJ B-adj.all	, , 0	but CC 0	not RB 0	all DT 0	antihistaminics NNS B-noun.object	, , 0	are VBP 0	indeed RB B-verb.communication	analgesic_agents NNS B-noun.person	and CC 0	some DT 0	are VBP B-verb.stative	analgesic_adjuvants NNS 0	as RB 0	well RB 0	. . 0	. . 0
DDI-DrugBank.d536.s10	However RB 0	, , 0	the DT 0	peak JJ B-adj.all	plasma NN B-noun.attribute	level NN I-noun.attribute	of IN 0	metformin NN B-noun.food	was VBD 0	reduced VBN B-verb.change	by IN 0	approximately RB B-noun.time	20 CD B-adj.all	% NN 0	when WRB 0	taking VBG 0	Acarbose NNP 0	due JJ 0	to TO 0	a DT 0	slight JJ B-adj.all	delay NN B-noun.food	in IN 0	the DT 0	absorption NN B-noun.artifact	of IN 0	metformin NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d216.s1	Paroxetine NNP B-noun.person	, , 0	Coadministration NNP B-noun.person	of IN 0	single JJ B-adj.all	doses NNS B-noun.event	of IN 0	eszopiclone NN B-noun.communication	3 CD B-adj.all	mg NN B-noun.quantity	and CC 0	paroxetine NN B-noun.communication	20 CD B-adj.all	mg NN B-noun.quantity	daily RB B-adv.all	for IN 0	7 CD B-adj.all	days NNS B-noun.person	produced VBD B-verb.perception	no DT 0	pharmacokinetic JJ B-adj.all	or CC 0	pharmacodynamic JJ B-adj.all	interaction NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d269.s7	Cyclosporine NNP B-noun.person	, , 0	Modest JJ B-adj.all	increases NNS B-noun.event	in IN 0	mean JJ B-adj.all	trough JJ B-adj.all	cyclosporine NN B-noun.person	concentrations NNS B-noun.person	were VBD 0	observed VBN B-verb.perception	following VBG B-verb.stative	initiation NN B-noun.act	of IN 0	carvedilol NN B-noun.food	treatment NN I-noun.food	in IN 0	21 CD B-adj.all	renal JJ B-adj.all	transplant NN B-noun.person	patients NNS B-noun.person	suffering VBG B-verb.body	from IN 0	chronic JJ B-adj.all	vascular JJ B-adj.all	rejection NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d108.s1	In IN 0	a DT 0	single JJ B-adj.all	study NN B-noun.artifact	, , 0	rats NNS 0	given VBN B-verb.possession	high JJ B-adj.all	intraperitoneal JJ B-adj.all	doses NNS B-noun.event	of IN 0	an DT 0	MAO_inhibitor NN B-noun.person	plus CC 0	disulfiram NN B-noun.person	experienced VBD B-verb.perception	severe JJ B-adj.all	toxicity NN B-noun.state	, , 0	including VBG B-verb.stative	convulsions NNS B-noun.possession	and CC 0	death NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d538.s1	Diphenoxylate_HCl NN B-noun.artifact	and CC 0	atropine_sulfate JJ B-noun.location	may MD 0	interact VB B-verb.change	with IN 0	MAO_inhibitors NNS B-noun.person	In IN 0	studies NNS B-noun.artifact	with IN 0	male NN B-noun.person	rats NNS B-noun.person	, , 0	diphenoxylate_hydrochloride NN B-noun.other	was VBD 0	found VBN B-verb.cognition	to TO 0	inhibit VB B-verb.change	the DT 0	hepatic JJ B-adj.all	microsomal JJ B-adj.all	enzyme NN B-noun.cognition	system NN I-noun.cognition	at IN 0	a DT 0	dose NN B-noun.quantity	of IN 0	2 CD 0	mg FW 0	/ FW 0	kg FW 0	/ FW 0	day NN 0	. . 0	. . 0
DDI-DrugBank.d536.s8	Acarbose NNP B-noun.person	may MD 0	affect VB B-verb.change	digoxin JJ B-adj.all	bioavailabillty NN B-noun.cognition	and CC 0	may MD 0	require VB B-verb.stative	dose JJ B-adj.all	adjustment NN B-noun.communication	of IN 0	digoxin NN B-noun.person	by IN 0	16 CD B-adj.all	% NN 0	( ( 0	90 CD B-adj.all	% NN 0	confidence NN B-noun.substance	interval NN I-noun.substance	, , 0	8 CD B-adj.all	- : 0	23 CD B-adj.all	% NN 0	) ) 0	, , 0	decrease VB B-verb.change	mean JJ B-adj.all	C NNP 0	max NN 0	digoxin NN 0	by IN 0	26 CD B-adj.all	% NN 0	( ( 0	90 CD B-adj.all	% NN 0	confidence NN B-noun.substance	interval NN I-noun.substance	, , 0	16 CD B-adj.all	- : 0	34 CD 0	% NN 0	) ) 0	and CC 0	decrease VB 0	mean VB B-verb.stative	trough JJ B-adj.all	concentrations NNS B-noun.attribute	of IN 0	digoxin NN B-noun.person	by IN 0	9 CD B-adj.all	% NN 0	( ( 0	90 CD B-adj.all	% NN 0	confidence NN B-adv.all	limit NN I-adv.all	, , 0	19 CD B-adj.all	% NN 0	decrease NN B-noun.act	to TO 0	2 CD B-adj.all	% NN 0	increase NN B-noun.event	) ) 0	. . 0	. . 0
DDI-DrugBank.d247.s2	Epinephrine NN B-noun.person	should MD 0	not RB 0	be VB 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	other JJ B-adj.all	sympathomimetic_drugs NNS B-noun.substance	( ( 0	such JJ 0	as IN 0	isoproterenol NN 0	) ) 0	because IN 0	of IN 0	possible JJ B-adj.all	additive JJ B-adj.all	effects NNS B-noun.phenomenon	and CC 0	increased VBD B-verb.change	toxicity NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d503.s2	If IN 0	chlorprothixene NN 0	is VBZ 0	given VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	opioids NNS B-noun.person	, , 0	the DT 0	opioid JJ B-adj.all	dose NN B-noun.substance	should MD 0	be VB 0	reduced VBN B-verb.change	( ( 0	by IN 0	approx NN B-noun.person	. . 0	50 CD B-adj.all	% NN 0	) ) 0	, , 0	because IN 0	chlorprothixene NN B-noun.person	amplifies VBZ B-verb.change	the DT 0	therapeutic JJ B-adj.all	actions NNS B-noun.act	and CC 0	side NN B-noun.body	- : 0	effects NNS B-noun.phenomenon	of IN 0	opioids NNS B-noun.person	massively RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d469.s0	Drugs NNS B-noun.artifact	which WDT 0	may MD 0	enhance VB B-verb.change	the DT 0	neuromuscular JJ B-adj.all	blocking VBG B-verb.change	action NN B-noun.process	of IN 0	TRACRIUM NNP B-noun.group	include VBP B-verb.stative	, , 0	enflurane NN B-noun.person	, , 0	. . 0
DDI-DrugBank.d200.s0	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	probenecid NN B-noun.person	with IN 0	acyclovir NN B-noun.person	has VBZ 0	been VBN 0	shown VBN B-verb.perception	to TO 0	increase VB B-verb.change	the DT 0	mean JJ B-adj.all	half NN B-noun.person	- : 0	life NN B-noun.person	and CC 0	the DT 0	area NN B-noun.body	under IN 0	the DT 0	concentration NN B-noun.group	- : 0	time NN B-noun.time	curve NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d409.s1	Since IN 0	bacteriostatic JJ B-adj.all	drugs NNS B-noun.artifact	, , 0	such JJ 0	as IN 0	the DT 0	tetracycline_class NN B-noun.group	of IN 0	antibiotics NNS B-noun.person	, , 0	may MD 0	interfere VB B-verb.stative	with IN 0	the DT 0	bactericidal JJ B-adj.all	action NN B-noun.process	of IN 0	penicillins NNS B-noun.person	, , 0	it PRP 0	is VBZ B-verb.stative	not RB B-adv.all	advisable JJ B-adj.all	to TO 0	administer VB B-verb.social	these DT 0	drugs NNS B-noun.artifact	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d460.s7	Warfarin NNP B-noun.person	, , 0	When WRB 0	healthy JJ B-adj.all	subjects NNS B-noun.person	were VBD 0	administered VBN B-verb.possession	Starlix NNP B-noun.communication	120 CD 0	mg IN 0	three CD 0	times NNS 0	daily RB 0	before IN 0	meals NNS B-noun.food	for IN 0	four CD B-adj.all	days NNS B-noun.artifact	in IN 0	combination NN 0	with IN 0	a DT 0	single JJ B-adj.all	dose NN B-noun.event	of IN 0	warfarin NN B-noun.communication	30 CD B-adj.all	mg NN B-noun.quantity	on IN 0	day NN 0	2 CD 0	, , 0	there EX 0	were VBD B-verb.stative	no DT 0	alterations NNS B-noun.act	in IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	either DT 0	agent NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d175.s9	For IN 0	example NN B-noun.person	, , 0	diuretics NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	thiazides NNS 0	) ) 0	may MD 0	activate VB B-verb.stative	the DT 0	renin NN B-noun.person	- : 0	angiotensin NN B-noun.person	- : 0	aldosterone NN 0	system NN 0	. . 0	. . 0
DDI-MedLine.d110.s16	The DT 0	data NNS B-noun.cognition	suggest VBP B-verb.communication	that IN 0	18-MC NNP B-noun.person	has VBZ B-verb.possession	a DT 0	narrower JJR B-adj.all	spectrum NN B-noun.attribute	of IN 0	actions NNS B-noun.act	and CC 0	will MD 0	have VB B-verb.stative	a DT 0	substantially RB B-adv.all	greater JJR B-adj.all	therapeutic JJ B-adj.all	index NN B-noun.communication	than IN 0	ibogaine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d84.s0	The DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	Exjade NNP B-noun.person	and CC 0	aluminum NN B-noun.person	- : 0	containing VBG B-verb.stative	antacid_preparations NNS B-noun.attribute	has VBZ 0	not RB 0	been VBN 0	formally RB B-adv.all	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d46.s16	Diuretic_agents NNS B-noun.person	reduce VB B-verb.change	the DT 0	renal JJ B-adj.all	clearance NN B-noun.act	of IN 0	lithium NN B-noun.substance	and CC 0	add VB B-verb.communication	a DT 0	high JJ B-adj.all	risk NN 0	of IN 0	lithium NN B-noun.phenomenon	toxicity NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d165.s27	Blood NNP B-noun.person	glucose NN I-noun.person	concentrations NNS B-noun.person	should MD 0	be VB 0	carefully RB B-adv.all	monitored VBN B-verb.perception	when WRB 0	Itraconazole NNP B-noun.person	and CC 0	oral JJ B-adj.all	hypoglycemic_agents NNS B-noun.person	are VBP 0	coadministered VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d328.s18	Coadministration NN B-noun.person	with IN 0	valdecoxib NN B-noun.attribute	( ( 0	40 CD 0	mg IN 0	BID NNP 0	for IN 0	7 CD B-adj.all	days NNS B-noun.act	) ) 0	resulted VBD B-verb.stative	in IN 0	a DT 0	significant JJ B-adj.all	increase NN B-noun.event	in IN 0	dextromethorphan JJ B-adj.all	plasma NN B-noun.plant	levels NNS B-noun.state	suggesting VBG B-verb.communication	that IN 0	, , 0	at IN 0	these DT 0	doses NNS B-noun.act	, , 0	valdecoxib NN B-noun.attribute	is VBZ B-verb.stative	a DT 0	weak JJ B-adj.all	inhibitor NN B-noun.person	of IN 0	2D6 NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d558.s22	In IN 0	addition NN 0	, , 0	drugs NNS B-noun.artifact	that WDT 0	are VBP 0	actively RB B-adv.all	secreted VBN B-verb.contact	via IN 0	this DT 0	route NN B-noun.communication	( ( 0	e.g. UH 0	, , 0	triamterene NN B-noun.person	, , 0	metformin NN B-noun.person	and CC 0	amiloride VB B-verb.social	) ) 0	should MD 0	be VB B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	care NN B-noun.group	as IN 0	they PRP 0	might MD 0	increase VB B-verb.change	dofetilide NN 0	levels NNS B-noun.state	. . 0	. . 0
DDI-MedLine.d132.s8	The DT 0	superiority NN B-noun.attribute	of IN 0	efavirenz NN B-noun.phenomenon	over IN 0	indinavir NN B-noun.person	- : 0	based VBN B-verb.cognition	regimens NNS 0	has VBZ 0	been VBN 0	observed VBN B-verb.perception	in IN 0	comparative JJ B-adj.all	data NNS B-noun.cognition	in IN 0	a DT 0	subset NN B-noun.event	of IN 0	patients NNS B-noun.person	with IN 0	high JJ B-adj.all	viral JJ B-noun.body	loads NNS I-noun.body	. . 0	. . 0
DDI-DrugBank.d545.s0	Geocillin NNP B-noun.person	( ( 0	carbenicillin_indanyl_sodium NN 0	) ) 0	blood NN B-noun.location	levels NNS B-noun.state	may MD 0	be VB 0	increased VBN B-verb.change	and CC 0	prolonged VBN B-verb.creation	by IN 0	concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	probenecid NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d270.s45	The DT 0	appropriate JJ B-adj.all	dose NN B-noun.quantity	for IN 0	nelfinavir JJ B-adj.all	incombination NN B-noun.act	with IN 0	nevirapine NN B-noun.person	, , 0	with IN 0	respectto NN B-noun.person	safety NN B-noun.person	and CC 0	efficacy NN B-noun.person	, , 0	has VBZ 0	not RB 0	been VBN 0	established VBN B-verb.creation	. . 0	. . 0
DDI-DrugBank.d485.s14	Ascorbic_acid JJ B-adj.all	, , 0	Doses NNP B-noun.person	of IN I-noun.person	ascorbic_acid JJ I-noun.person	( ( I-noun.person	vitamin_C NNP I-noun.person	) ) 0	1 CD B-noun.quantity	g RB 0	/ JJ 0	day NN 0	have VBP 0	been VBN 0	reported VBN B-verb.communication	to TO 0	increase VB B-verb.change	plasma NN 0	concentration NN 0	of IN 0	synthetic_estrogens NNS B-noun.artifact	by IN 0	~47 CD 0	% NN 0	, , 0	possibly RB B-adv.all	by IN 0	inhibiting VBG B-verb.possession	conjugation NN B-noun.act	, , 0	. . 0
DDI-DrugBank.d226.s4	The DT 0	effects NNS B-noun.phenomenon	of IN 0	adenosine NN B-noun.person	are VBP 0	antagonized VBN B-verb.cognition	by IN 0	methylxanthines NNS B-noun.object	such JJ 0	as IN 0	caffeine NN B-noun.person	and CC 0	theophylline PRP 0	. . 0	. . 0
DDI-MedLine.d81.s1	Decreased VBN B-verb.change	core NN B-noun.quantity	temperature NN B-noun.food	in IN 0	female JJ B-adj.all	rats NNS B-noun.person	was VBD 0	investigated VBN B-verb.communication	as IN 0	one CD 0	possible JJ B-adj.all	index NN B-noun.act	of IN 0	the DT 0	disulfiram NN B-noun.person	- : 0	ethanol NN 0	reaction NN B-noun.process	( ( 0	DER NNP 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d113.s4	Meclofenamate_sodium NN 0	does VBZ 0	not RB B-adv.all	affect VB B-verb.change	serum JJ B-adj.all	salicylate NN B-noun.substance	levels NNS B-noun.state	. . 0	. . 0
DDI-DrugBank.d139.s3	Cholestyramine SYM 0	- : 0	Concomitant JJ B-noun.person	intake NN I-noun.person	of IN 0	cholestyramine NN B-noun.act	and CC 0	vitamin_K NNP B-noun.group	may MD 0	reduce VB B-verb.change	the DT 0	absorption NN B-noun.artifact	of IN 0	vitamin_K. NNP B-noun.person	. . 0
DDI-MedLine.d56.s2	In IN 0	the DT 0	presence NN B-noun.person	of IN 0	ouabain NN B-noun.substance	( ( 0	10(-5 JJ 0	) ) 0	M NNP 0	) ) 0	, , 0	PTX NNP 0	( ( 0	10(-8 JJ 0	) ) 0	M NNP 0	) ) 0	failed VBD B-verb.social	to TO 0	cause VB B-verb.communication	the DT 0	first JJ B-adj.all	contraction NN B-noun.communication	, , 0	. . 0
DDI-DrugBank.d507.s4	TCAs NNP B-noun.person	decrease VB B-verb.cognition	the DT 0	hypotensive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	guanfacine NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d17.s31	( ( 0	Thiazide_drugs NNS 0	may MD 0	increase VB B-verb.change	the DT 0	responsiveness NN B-noun.cognition	to TO 0	tubocurarine VB B-verb.change	. . 0	) ) 0	. . 0
DDI-DrugBank.d561.s9	If IN 0	a DT 0	diuretic JJ B-noun.person	is VBZ B-verb.stative	also RB B-adv.all	used VBN B-verb.consumption	, , 0	the DT 0	risk NN 0	of IN 0	lithium NN B-noun.substance	toxicity NN B-noun.phenomenon	may MD 0	be VB 0	increased VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d115.s0	Drugs NNS B-noun.artifact	that WDT 0	may MD 0	alter VB B-verb.change	imatinib JJ B-adj.all	plasma NN B-noun.substance	concentrations NNS B-noun.artifact	Drugs NNS I-noun.artifact	that WDT 0	may MD 0	increase VB B-verb.change	imatinib JJ B-adj.all	plasma NN B-noun.substance	concentrations NNS I-noun.substance	, , 0	Caution NN B-noun.person	is VBZ 0	recommended VBN B-verb.communication	when WRB 0	administering VBG B-verb.communication	Gleevec NNP B-noun.person	with IN 0	inhibitors NNS B-noun.person	of IN 0	the DT 0	CYP3A4 NNP B-noun.person	family NN B-noun.group	( ( 0	e.g. UH 0	, , 0	ketoconazole NN B-noun.person	, , 0	itraconazole NN B-noun.person	, , 0	erythromycin NN B-noun.person	, , 0	clarithromycin NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d212.s6	Drug NN B-noun.person	- : 0	Drug NN B-noun.other	Interactions NNS I-noun.other	Between IN I-noun.other	Keppra NNP I-noun.other	_ : I-noun.other	And CC I-noun.other	Other JJ I-noun.other	Antiepileptic_Drugs NNS I-noun.other	( ( 0	AEDs NNP B-noun.group	) ) 0	Phenytoin NNP B-noun.person	Keppra NNP I-noun.person	_ . 0	( ( 0	3000 CD 0	mg PRP$ 0	daily JJ B-noun.event	) ) 0	had VBD 0	no DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	pharmacokinetic JJ B-adj.all	disposition NN B-noun.act	of IN 0	phenytoin NN B-noun.food	in IN 0	patients NNS B-noun.person	with IN 0	refractory JJ B-adj.all	epilepsy NN B-noun.person	. . 0	. . 0
DDI-MedLine.d15.s2	It PRP 0	is VBZ 0	assumed VBN B-verb.cognition	that IN 0	increased VBN B-verb.change	interaction NN B-noun.act	between IN 0	3H SYM 0	- : 0	spiroperidol NN B-noun.person	and CC 0	high JJ B-adj.all	affinity NN B-noun.phenomenon	binding NN B-noun.process	sites NNS B-noun.location	for IN 0	apomorphine NN B-noun.person	on IN 0	dopamine2- NNP B-noun.person	and CC 0	serotonin2-receptors NNS B-noun.person	underlies VBZ B-verb.cognition	the DT 0	antipsychotic JJ B-adj.all	action NN B-noun.state	of IN 0	neuroleptics NNS B-noun.person	after IN 0	their PRP$ 0	prolonged VBN B-verb.consumption	administration NN I-verb.consumption	. . 0	. . 0
DDI-MedLine.d83.s8	However RB 0	, , 0	preliminary JJ B-adj.all	results NNS B-noun.event	from IN 0	an DT 0	8-week JJ B-adj.all	trial NN B-noun.person	showed VBD B-verb.communication	comparable JJ B-adj.all	cognitive NN B-noun.person	enhancing VBG B-verb.change	effects NNS B-noun.phenomenon	of IN 0	olanzapine JJ B-adj.all	and CC 0	risperidone NN 0	treatment NN B-noun.artifact	in IN 0	patients NNS B-noun.person	with IN 0	schizophrenia NN B-noun.person	or CC 0	schizoaffective JJ B-adj.all	disorder NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d340.s16	Ritonavir NNP B-noun.person	, , 0	Coadministration NNP B-noun.person	of IN 0	ritonavir NN B-noun.person	with IN 0	VIRACEPT NNP B-noun.group	resulted VBD B-verb.competition	in IN 0	a DT 0	152 CD 0	% NN 0	increase NN B-noun.event	in IN 0	nelfinavir JJ B-adj.all	plasma NN B-noun.person	AUC NNP I-noun.person	and CC 0	very RB B-adv.all	little JJ B-adj.all	change NN B-noun.act	in IN 0	ritonavir NN 0	plasma NN 0	A.C. NNP 0	. . 0
DDI-MedLine.d54.s2	Since IN 0	photic JJ B-adj.all	evoked JJ B-adj.all	potential JJ B-adj.all	components NNS B-noun.person	are VBP B-verb.stative	representations NNS B-noun.person	of IN 0	neural JJ B-adj.all	pathways NNS B-noun.artifact	which WDT 0	are VBP 0	activated VBN B-verb.creation	during IN 0	photic JJ B-adj.all	stimulation NN B-noun.artifact	, , 0	study NN B-noun.artifact	of IN 0	the DT 0	effects NNS B-noun.phenomenon	of IN 0	alcohol NN B-noun.animal	on IN 0	these DT 0	components NNS B-noun.person	may MD 0	help VB 0	to TO 0	trace VB B-verb.contact	pathways NNS B-noun.location	which WDT 0	are VBP 0	affected VBN B-verb.change	by IN 0	alcohol NN B-noun.person	. . 0	. . 0
DDI-MedLine.d95.s6	However RB 0	, , 0	L NNP 0	- : 0	NAME NN B-noun.group	( ( 0	100 CD 0	and CC 0	300 CD 0	micromol NN B-noun.quantity	/ : 0	l LS 0	) ) 0	did VBD 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	effects NNS B-noun.phenomenon	of IN 0	reseveratrol NN B-noun.act	on IN 0	arteries NNS B-noun.artifact	from IN 0	dietary JJ B-noun.person	- : 0	obese NN B-noun.animal	rats NNS B-noun.animal	, , 0	giving VBG B-verb.possession	superimposed JJ B-adj.all	concentration NN B-noun.person	- : 0	responses VBZ B-verb.communication	curves NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d132.s19	NSAIDs NNS B-noun.person	should MD 0	be VB 0	used VBN B-verb.consumption	with IN 0	caution NN B-noun.cognition	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	cyclosporine NN I-verb.social	, , 0	and CC 0	renal JJ B-adj.all	function NN B-noun.act	should MD 0	be VB 0	carefully RB B-adv.all	monitored VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d195.s5	At IN 0	a DT 0	median JJ B-adj.all	follow NN B-noun.person	- : 0	up IN 0	of IN 0	33 CD 0	months NNS B-noun.person	, , 0	the DT 0	combination NN B-noun.event	of IN 0	ARIMIDEX NNP B-noun.group	and CC 0	tamoxifen NNS B-noun.person	did VBD 0	not RB B-adv.all	demonstrate VB B-verb.cognition	any DT 0	efficacy NN 0	benefit NN 0	when WRB 0	compared VBN B-verb.cognition	with IN 0	tamoxifen NNS B-noun.person	in IN 0	all DT 0	patients NNS B-noun.person	as RB 0	well RB 0	as IN 0	in IN 0	the DT 0	hormone NN B-noun.artifact	receptor NN B-noun.person	- : 0	positive JJ B-adj.all	subpopulation NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d123.s0	Some DT 0	quinolones NNS B-noun.communication	, , 0	including VBG B-verb.change	ciprofloxacin NN B-noun.food	, , 0	have VBP 0	also RB B-adv.all	been VBN 0	shown VBN B-verb.perception	to TO 0	interfere VB B-verb.stative	with IN 0	the DT 0	metabolism NN B-noun.attribute	of IN 0	caffeine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d81.s1	Hydrochlorothiazide NNP B-noun.person	, , 0	A DT 0	study NN B-noun.artifact	in IN 0	normal JJ B-adj.all	healthy JJ B-adj.all	volunteers NNS B-noun.person	has VBZ 0	shown VBN B-verb.cognition	that DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	DynaCirc NNP B-noun.person	_ . 0	( ( 0	isradipine NN 0	) ) 0	and CC 0	hydrochlorothiazide NN 0	does VBZ 0	not RB B-adv.all	result VB B-verb.stative	in IN 0	altered JJ B-adj.all	pharmacoktnetics NNS B-noun.person	of IN 0	either DT 0	drug NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d21.s0	Tissue NN B-adj.all	culture NN B-noun.cognition	and CC 0	animal NN B-noun.animal	studies NNS I-noun.animal	indicate VBP B-verb.cognition	that IN 0	ELSPAR NNP B-noun.group	can MD 0	diminish VB B-verb.change	or CC 0	abolish VB B-verb.cognition	the DT 0	effect NN B-noun.cognition	of IN 0	methotrexate NN B-noun.attribute	on IN 0	malignant JJ B-adj.all	cells.14 NN 0	This DT 0	effect NN B-noun.cognition	on IN 0	methotrexate NN B-noun.location	activity NN B-noun.state	persists VBZ B-verb.stative	as RB 0	long RB 0	as IN 0	plasma NN 0	asparagine NN 0	levels NNS B-noun.attribute	are VBP 0	suppressed VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d106.s3	Coadministration NN B-noun.person	of IN 0	phenytoin NN B-noun.person	with IN 0	40 CD 0	mg IN 0	SULAR NNP B-noun.group	tablets NNS B-noun.artifact	in IN 0	epileptic JJ B-adj.all	patients NNS B-noun.person	lowered VBD B-verb.motion	the DT 0	nisoldipine NN B-noun.artifact	plasma NN B-noun.substance	concentrations NNS B-noun.artifact	to TO 0	undetectable JJ B-adj.all	levels NNS B-noun.state	. . 0	. . 0
DDI-DrugBank.d288.s5	Reports NNS B-noun.person	in IN 0	the DT 0	literature NN B-noun.act	suggest VBP B-verb.communication	that IN 0	plasma NN B-noun.state	levels NNS B-noun.state	of IN 0	doxorubicin NN B-noun.substance	( ( 0	and CC 0	its PRP$ 0	active JJ B-adj.all	metabolite NN 0	doxorubicinol NN 0	) ) 0	may MD 0	be VB 0	increased VBN B-verb.change	when WRB 0	paclitaxel NN B-noun.person	and CC 0	doxorubicin NN B-noun.person	are VBP 0	used VBN B-verb.consumption	in IN 0	combination NN 0	. . 0	. . 0
DDI-DrugBank.d489.s0	The DT 0	following VBG 0	drugs NNS B-noun.communication	have VBP 0	been VBN 0	coadministered VBN B-verb.contact	with IN 0	Kerlone NNP B-noun.person	and CC 0	have VBP 0	not RB B-adv.all	altered VBN B-verb.change	its PRP$ 0	pharmacokinetics NNS B-noun.time	, , 0	cimetidine NN B-noun.person	, , 0	nifedipine NN B-noun.person	, , 0	chlorthalidone NN 0	, , 0	and CC 0	hydrochlorothiazide NN 0	. . 0	. . 0
DDI-DrugBank.d143.s13	Monitoring VBG B-verb.perception	for IN 0	amiodarone JJ B-adj.all	toxicity NN B-noun.attribute	and CC 0	serial JJ B-adj.all	measurement NN B-noun.attribute	of IN 0	amiodarone NN 0	serum NN 0	concentration NN 0	during IN 0	concomitant JJ B-adj.all	protease_inhibitor NN B-noun.person	therapy NN B-noun.group	should MD 0	be VB 0	considered VBN B-verb.cognition	. . 0	. . 0
DDI-MedLine.d54.s3	In IN 0	the DT 0	present JJ B-adj.all	study NN B-noun.artifact	, , 0	evoked JJ B-adj.all	potentials NNS B-noun.person	were VBD 0	recorded VBN B-verb.communication	at IN 0	5 CD B-adj.all	, , 0	20 CD B-adj.all	, , 0	and CC 0	40 CD B-adj.all	min NN 0	following VBG 0	IP NNP 0	injections NNS 0	of IN 0	saline NN B-noun.act	, , 0	ethanol NN 0	( ( 0	2.0 CD B-noun.quantity	g PRP 0	/ : 0	kg LS 0	) ) 0	, , 0	physostigmine NN B-noun.person	( ( 0	0.6 CD 0	mg PRP 0	/ : 0	kg LS 0	) ) 0	or CC 0	atropine NN B-noun.substance	( ( 0	15.0 CD 0	mg PRP 0	/ : 0	kg LS 0	) ) 0	on IN 0	separate JJ B-adj.all	days NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d53.s3	In IN 0	the DT 0	experiments NNS B-noun.person	reported VBN B-verb.communication	here RB 0	, , 0	we PRP 0	examined VBD B-verb.perception	the DT 0	interactions NNS B-noun.artifact	between IN 0	1,25(OH)2D3 JJ B-noun.location	and CC 0	the DT 0	antiestrogen NN 0	4-hydroxytamoxifen JJ 0	( ( 0	TAM NNP 0	) ) 0	, , 0	which WDT 0	also RB B-adv.all	induces VBZ B-verb.communication	apoptosis NN B-noun.person	in IN 0	MCF-7 NNP B-noun.other	cells NNS B-noun.body	. . 0	. . 0
DDI-DrugBank.d314.s16	Ephedrine NNP B-noun.person	, , 0	Ephedrine NNP B-noun.location	may MD 0	enhance VB B-verb.change	the DT 0	metabolic JJ B-adj.all	clearance NN B-noun.attribute	of IN 0	corticosteroids NNS B-noun.shape	, , 0	resulting VBG B-verb.stative	in IN 0	decreased VBN B-verb.change	blood NN B-noun.body	levels NNS B-noun.attribute	and CC 0	lessened VBD B-verb.change	physiologic JJ B-adj.pert	activity NN B-noun.state	, , 0	thus RB 0	requiring VBG B-verb.stative	an DT 0	increase NN B-noun.act	in IN 0	corticosteroid JJ B-adj.all	dosage NN B-noun.quantity	. . 0	. . 0
DDI-DrugBank.d263.s25	Doxorubicin NNP B-noun.person	, , 0	Doxorubicin NNP B-noun.person	caused VBD B-verb.communication	a DT 0	decrease NN B-noun.event	in IN 0	zalcitabine JJ B-adj.all	phosphorylation NN B-noun.artifact	( ( 0	50 CD B-adj.all	% NN 0	inhibition NN B-noun.attribute	of IN 0	total JJ B-adj.all	phosphate JJ B-adj.all	formation NN B-noun.act	) ) 0	in IN 0	U937/Molt JJ 0	4 CD B-adj.all	cells NNS B-noun.body	. . 0	. . 0
DDI-DrugBank.d238.s4	Several JJ B-adj.all	tricyclic_antidepressants NNS B-noun.communication	have VBP 0	been VBN 0	reported VBN B-verb.communication	to TO 0	block VB B-verb.change	the DT 0	pharmacologic JJ B-adj.pert	effects NNS B-noun.phenomenon	of IN 0	guanethidine NN B-noun.location	, , 0	clonidine NN B-noun.person	, , 0	or CC 0	similar JJ B-adj.all	agents NNS B-noun.person	, , 0	and CC 0	such PDT 0	an DT 0	effect NN B-noun.cognition	may MD 0	be VB 0	anticipated VBN B-verb.cognition	with IN 0	CMI NNP B-noun.group	because IN 0	of IN 0	its PRP$ 0	structural JJ B-adj.all	similarity NN B-noun.attribute	to TO 0	other JJ 0	tricyclic_antidepressants NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d427.s2	Therefore RB 0	, , 0	monitoring NN B-verb.perception	of IN 0	theophylline JJ 0	plasma NN B-noun.substance	levels NNS B-noun.attribute	should MD 0	be VB 0	considered VBN B-verb.cognition	and CC 0	dosage NN B-noun.act	of IN 0	theophylline NN 0	adjusted VBN B-verb.change	, , 0	as IN 0	required VBN B-verb.stative	. . 0	. . 0
DDI-MedLine.d46.s16	CONCLUSION NN B-noun.group	, , 0	Cisapride NNP B-noun.person	can MD 0	be VB 0	administered VBN B-verb.possession	safely RB B-adv.all	to TO 0	patients NNS B-noun.person	receiving VBG B-verb.communication	low JJ B-adj.all	therapeutic JJ B-adj.all	dosages NNS B-noun.event	of IN 0	fluoxetine NN B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d237.s10	H2_Receptor_Antagonists NNS B-noun.person	, , 0	Cimetidine NNP B-noun.person	coadministration NN B-noun.person	leads VBZ B-verb.cognition	to TO 0	an DT 0	increased VBN B-verb.change	peak JJ B-adj.all	plasma NN B-noun.substance	concentration NN B-noun.event	and CC 0	AUC NNP B-noun.group	of IN 0	cisapride NN B-noun.location	, , 0	there EX 0	is VBZ B-verb.stative	no DT 0	effect NN B-noun.cognition	on IN 0	cisapride JJ B-adj.all	absorption NN B-noun.artifact	when WRB 0	it PRP 0	is VBZ 0	coadministered VBN B-verb.contact	with IN 0	ranitidine NN B-noun.state	. . 0	. . 0
DDI-MedLine.d106.s5	there EX 0	was VBD B-verb.stative	no DT 0	significant JJ B-adj.all	change NN B-noun.relation	in IN 0	prothrombin NN 0	test NN B-adj.all	results NNS B-noun.artifact	during IN 0	the DT 0	trials NNS B-noun.cognition	of IN 0	chloral_hydrate NNP B-noun.person	and CC 0	methaqualone NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d410.s8	fluoxetine NN B-noun.state	, , 0	fluvoxamine NN B-noun.person	, , 0	paroxetine NN B-noun.person	, , 0	sertraline NN B-noun.body	) ) 0	. . 0	. . 0
DDI-MedLine.d99.s0	Fluvoxamine NN B-noun.person	inhibits VBZ B-verb.change	the DT 0	CYP2C9 NNP B-noun.person	catalyzed VBD B-verb.communication	biotransformation NN B-noun.cognition	of IN 0	tolbutamide NN 0	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d162.s8	Skeletal_muscle_relaxants NNS B-noun.person	, , 0	nondepolarizing VBG B-verb.communication	( ( 0	e.g. UH 0	, , 0	tubocurarine NN 0	) ) 0	, , 0	possible JJ B-adj.all	increased VBN B-verb.change	responsiveness NN 0	to TO 0	the DT 0	muscle_relaxant NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d178.s13	Coadministration NN B-noun.person	of IN 0	gly RB B-adv.all	- : 0	buride NN B-noun.person	and CC 0	metformin NN B-noun.attribute	did VBD 0	not RB B-adv.all	result VB B-verb.stative	in IN 0	any DT 0	changes NNS B-noun.possession	in IN 0	either DT 0	metformin NN B-noun.object	pharmacokinetics NNS I-noun.object	or CC 0	pharmaco NN B-noun.substance	- : 0	dynamics NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d139.s0	[ : 0	Quantitative JJ B-adj.all	approach NN B-noun.person	to TO 0	treatment NN B-noun.person	with IN 0	incisive JJ B-adj.all	neuroleptics NNS B-noun.person	by IN 0	therapeutic JJ 0	monitoring NN B-verb.perception	] : 0	, , 0	The DT 0	problems NNS B-noun.communication	encountered VBN B-verb.communication	during IN 0	the DT 0	longterm JJ B-adj.all	treatment NN B-noun.communication	of IN 0	psychotic JJ B-adj.all	patients NNS B-noun.person	with IN 0	neuroleptics NNS B-noun.person	are VBP 0	illustrated VBN B-verb.creation	by IN 0	six CD 0	typical JJ B-adj.all	case NN B-noun.state	reports NNS B-noun.communication	. . 0	. . 0
DDI-DrugBank.d220.s17	In IN 0	clinical JJ B-adj.all	trials NNS B-noun.communication	, , 0	the DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	sulfadoxine NN B-noun.person	and CC 0	pyrimethamine NN B-noun.person	did VBD 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	adverse JJ B-adj.all	reaction NN B-noun.process	profile NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d277.s19	Digoxin NNP B-noun.person	, , 0	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	tiagabine NN B-noun.artifact	did VBD 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	steady JJ B-noun.artifact	- : 0	state NN B-adj.all	pharmacokinetics NNS B-noun.person	of IN 0	digoxin NN B-noun.substance	or CC 0	the DT 0	mean JJ B-adj.all	daily JJ B-adj.pert	trough NN B-noun.body	serum NN B-noun.body	level NN B-noun.attribute	of IN 0	digoxin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d277.s22	Tiagabine NNP B-noun.person	has VBZ 0	shown VBN B-verb.perception	no DT 0	clinically RB B-adv.all	important JJ B-adj.all	potentiation NN B-noun.cognition	of IN 0	the DT 0	pharmacodynamic JJ B-adj.pert	effects NNS B-noun.phenomenon	of IN 0	triazo NN B-noun.act	lam NN B-noun.act	or CC 0	alcohol NN B-noun.possession	. . 0	. . 0
DDI-DrugBank.d169.s0	Results NNS B-noun.person	from IN 0	human JJ B-adj.all	in IN 0	vitro NN B-noun.artifact	metabolism NN B-noun.artifact	studies NNS B-noun.artifact	and CC 0	nonclinical JJ B-adj.all	studies NNS B-noun.group	show VBP B-verb.communication	that IN 0	REVLIMID NNP B-noun.group	_ : 0	( ( 0	lenalidomide NN 0	) ) 0	is VBZ B-verb.stative	neither DT 0	metabolized VBN B-verb.cognition	by IN 0	nor CC 0	inhibits NNS B-noun.attribute	or CC 0	induces VBZ B-verb.communication	the DT 0	cytochrome NN 0	P450 NN 0	pathway NN B-noun.artifact	suggesting VBG B-verb.communication	that IN 0	lenalidomide NN B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	likely JJ B-adj.all	to TO 0	cause VB B-verb.communication	or CC 0	be VB B-verb.stative	subject JJ B-adj.all	to TO I-adj.all	P450-based JJ B-verb.emotion	metabolic JJ B-adj.all	drug NN B-noun.object	interactions NNS I-noun.object	in IN 0	man NN 0	. . 0	. . 0
DDI-DrugBank.d353.s13	Other JJ 0	, , 0	There EX 0	appears VBZ B-verb.perception	to TO 0	be VB B-verb.stative	no DT 0	pharmacokinetic JJ B-adj.all	interaction NN B-noun.act	between IN 0	acitretin NN B-noun.person	and CC 0	cimetidine NN B-noun.person	, , 0	digoxin NN B-noun.person	, , 0	or CC 0	glyburide NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d53.s7	When WRB 0	used VBN B-verb.consumption	in IN 0	therapeutic JJ B-adj.all	doses NNS B-noun.event	, , 0	azithromycin NN B-noun.person	had VBD 0	a DT 0	modest JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	atorvastatin NN B-noun.food	, , 0	carbamazepine NN 0	, , 0	cetirizine NN B-noun.location	, , 0	didanosine NN B-noun.person	, , 0	efavirenz NN B-noun.person	, , 0	fluconazole NN B-noun.person	, , 0	indinavir NN B-noun.person	, , 0	midazolam NN B-noun.person	, , 0	rifabutin NN B-noun.person	, , 0	sildenafil NN B-noun.attribute	, , 0	theophylline PRP 0	( ( 0	intravenous JJ B-adj.all	and CC 0	oral JJ B-noun.body	) ) 0	, , 0	triazolam NN B-noun.person	, , 0	trimethoprim VBP B-verb.change	/ : 0	sulfamethoxazole NN B-noun.attribute	or CC 0	zidovudine NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d3.s21	Do VB 0	not RB 0	mix VB 0	TORADOL NNP B-noun.person	and CC 0	morphine NN B-noun.person	in IN 0	the DT 0	same JJ B-adj.all	syringe NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d27.s0	No DT 0	significant JJ B-adj.all	drug NN B-noun.person	- : 0	drug NN B-noun.person	pharmacokinetic NN B-noun.person	( ( 0	or CC 0	pharmacodynamic JJ B-noun.body	) ) 0	interactions NNS B-noun.quantity	have VBP 0	been VBN 0	found VBN B-verb.possession	in IN 0	interaction NN B-noun.act	studies NNS B-noun.artifact	with IN 0	hydrochlorothiazide NN 0	, , 0	digoxin NN B-noun.person	, , 0	warfarin NN B-noun.location	, , 0	and CC 0	nifedipine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d196.s6	Stavudine NNP B-noun.person	and CC 0	Zidovudine NNP B-noun.person	Ribavirin NNP I-noun.person	can MD 0	antagonize VB B-verb.cognition	the DT 0	in FW 0	vitro FW 0	antiviral JJ 0	activity NN B-noun.process	of IN 0	stavudine NN B-noun.state	and CC 0	zidovudine NN B-noun.act	against IN 0	HIV NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d178.s11	Metformin NNP B-noun.person	, , 0	In IN 0	a DT 0	single JJ B-noun.act	- : 0	dose NN 0	interaction NN 0	study NN B-noun.artifact	in IN 0	NIDDM NNP B-noun.other	subjects NNS B-noun.artifact	, , 0	decreases VBZ B-verb.change	in IN 0	glyburide NN 0	AUC NNP B-noun.group	and CC 0	Cmax NNP B-noun.person	were VBD 0	observed VBN B-verb.perception	, , 0	but CC 0	were VBD B-verb.stative	highly RB B-adv.all	variable JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d437.s5	Indinavir NNP B-noun.person	steady JJ B-noun.artifact	- : 0	state NN B-adj.all	Cmax NNP B-noun.person	, , 0	A.C. NNP B-noun.person	and CC 0	Cmin NNP B-noun.person	were VBD 0	decreased VBN B-verb.change	by IN 0	22 CD B-adj.all	% NN 0	, , 0	38 CD 0	% NN 0	, , 0	and CC 0	27 CD B-adj.all	% NN 0	, , 0	respectively RB B-adv.all	, , 0	by IN 0	concomitant JJ B-adj.all	amprenavir NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d179.s40	- : 0	Phenytoin NN B-noun.person	( ( 0	e.g. UH 0	, , 0	Dilantin NNP B-noun.location	) ) 0	Use NNP 0	of IN 0	phenytoin NN B-noun.person	with IN 0	sulfapyridine NN 0	may MD 0	increase VB B-verb.change	the DT 0	chance NN B-noun.act	of IN 0	side JJ B-adj.all	effects NNS B-noun.phenomenon	affecting VBG B-verb.change	the DT 0	liver NN B-noun.possession	and/or CC 0	the DT 0	side NN B-noun.location	effects NNS B-noun.phenomenon	of IN 0	phenytoin NN B-noun.food	. . 0
DDI-DrugBank.d20.s10	Nonsteroidal_Anti SYM 0	- : 0	Inflammatory_Drugs NNS B-noun.cognition	( ( 0	NSAIDs)-A JJ B-noun.artifact	drug NN I-noun.artifact	interaction NN B-noun.act	study NN B-noun.artifact	of IN 0	eplerenone NN 0	with IN 0	an DT 0	NSAID NNP B-noun.group	has VBZ 0	not RB 0	been VBN 0	conducted VBN B-verb.creation	. . 0	. . 0
DDI-DrugBank.d106.s6	Propranolol NNP B-noun.person	attenuated VBD B-verb.contact	the DT 0	heart NN B-noun.body	rate NN B-noun.time	increase NN B-noun.event	following VBG 0	administration NN B-noun.person	of IN 0	immediate JJ B-adj.all	release NN B-noun.communication	nisoldipine NN I-noun.communication	. . 0	. . 0
DDI-DrugBank.d27.s2	However RB 0	, , 0	in IN 0	clinical JJ B-adj.all	studies NNS B-noun.communication	the DT 0	consequences NNS B-noun.group	of IN 0	concomitant JJ B-adj.all	irbesartan NN B-noun.person	on IN 0	the DT 0	pharmacodynamics NNS B-noun.person	of IN 0	warfarin NN B-noun.act	were VBD B-verb.stative	negligible JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d272.s2	Compounds NNS B-noun.person	in IN 0	these DT 0	categories NNS B-noun.location	result VBP B-verb.stative	in IN 0	a DT 0	decreased JJ B-adj.all	efficacy NN B-noun.person	of IN 0	bromocriptine_mesylate NNP B-noun.person	, , 0	phenothiazines NNS B-noun.body	, , 0	haloperidol NN B-noun.person	, , 0	metoclopramide NN B-noun.attribute	, , 0	pimozide NN 0	. . 0	. . 0
DDI-DrugBank.d384.s15	Magnesium NN B-noun.person	, , 0	Magnesium NNP B-noun.person	- : 0	containing VBG B-verb.stative	preparations NNS B-noun.substance	( ( 0	eg UH 0	, , 0	antacids NNS B-noun.location	) ) 0	may MD 0	cause VB B-verb.communication	hypermagnesemia NN B-noun.person	and CC 0	should MD 0	therefore RB 0	not RB B-adv.all	be VB 0	taken VBN B-verb.social	during IN 0	therapy NN 0	with IN 0	vitamin_D JJ 0	by IN 0	patients NNS B-noun.person	on IN 0	chronic JJ B-adj.all	renal JJ B-adj.all	dialysis NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d98.s8	Ketoconazole NNP B-noun.person	, , 0	Ketoconazole NNP B-noun.person	may MD 0	inhibit VB B-verb.possession	both DT 0	synthetic JJ B-adj.all	and CC 0	catabolic JJ B-adj.all	enzymes NNS B-noun.event	of IN 0	vitamin_D. NNP B-noun.person	. . 0
DDI-DrugBank.d328.s43	Oral NNP B-noun.group	Contraceptives NNPS I-noun.group	, , 0	Valdecoxib NNP B-noun.person	( ( 0	40 CD 0	mg IN 0	BID NNP 0	) ) 0	did VBD 0	not RB B-adv.all	induce VB B-verb.cognition	the DT 0	metabolism NN B-noun.attribute	of IN 0	the DT 0	combination NN B-noun.event	oral JJ B-adj.all	contraceptive JJ 0	norethindrone NN 0	/ : 0	ethinyl_estradiol NN 0	( ( 0	1 CD 0	mg RB 0	/35 JJ 0	mcg NN 0	combination NN 0	, , 0	Ortho NNP B-noun.person	- : 0	Novum NN 0	1/35 CD 0	) ) 0	. . 0	. . 0
DDI-MedLine.d1.s5	Sildenafil NNP B-noun.person	is VBZ 0	contraindicated VBN B-verb.communication	in IN 0	patients NNS B-noun.person	using VBG B-verb.consumption	long RB 0	- : 0	acting_nitrates NNS B-noun.time	or CC 0	who WP 0	may MD 0	need VB 0	to TO 0	use VB B-verb.consumption	short JJ I-verb.consumption	- : 0	acting_nitrates NNS B-noun.time	, , 0	because IN 0	the DT 0	combination NN B-noun.group	may MD 0	cause VB B-verb.communication	a DT 0	sharp JJ B-adj.all	fall NN B-noun.event	of IN 0	the DT 0	blood NN B-noun.group	pressure NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d427.s1	There EX 0	have VBP 0	been VBN 0	reports NNS B-noun.communication	of IN 0	theophylline PRP 0	- : 0	related JJ B-adj.all	side NN B-noun.location	effects NNS B-noun.phenomenon	in IN 0	patients NNS B-noun.person	on IN 0	concomitant JJ B-adj.all	therapy NN B-noun.person	with IN 0	quinolones NNS B-noun.communication	and CC 0	theophylline PRP 0	. . 0	. . 0
DDI-MedLine.d135.s4	PCP NNP 0	produced VBD B-verb.creation	distinctive JJ B-adj.all	effects NNS B-noun.phenomenon	in IN 0	each DT 0	task NN 0	, , 0	it PRP 0	substituted VBD B-verb.cognition	for IN 0	the DT 0	training NN B-noun.artifact	dose NN I-noun.artifact	in IN 0	PCP NNP 0	discrimination NN 0	and CC 0	it PRP 0	increased VBD B-verb.change	the DT 0	number NN B-noun.quantity	of IN 0	responses NNS B-noun.act	with IN 0	short JJ B-noun.body	( ( 0	<3 : 0	s LS 0	) ) 0	interresponse NN B-noun.phenomenon	times NNS B-noun.event	as RB 0	well RB 0	as IN 0	increasing VBG B-verb.change	overall JJ B-adj.all	response NN B-noun.communication	rates NNS B-noun.time	in IN 0	the DT 0	DRL NNP B-noun.group	schedule NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d414.s2	EDECRIN NNP B-noun.group	may MD 0	increase VB B-verb.change	the DT 0	ototoxic JJ B-adj.all	potential NN B-noun.state	of IN 0	other JJ 0	drugs NNS B-noun.object	such JJ 0	as IN 0	aminoglycoside JJ 0	and CC 0	some DT 0	cephalosporin_antibiotics NNS B-noun.location	. . 0	. . 0
DDI-DrugBank.d22.s0	Aminosalicylic_acid JJ B-noun.possession	may MD 0	decrease VB B-verb.cognition	the DT 0	amount NN B-noun.possession	of IN 0	digoxin NN B-noun.substance	( ( 0	Lanoxin NNP B-noun.person	, , 0	Lanoxicaps NNP B-noun.location	) ) 0	that WDT 0	gets VBZ 0	absorbed VBN B-verb.contact	into IN 0	your PRP$ 0	body NN B-noun.object	. . 0	. . 0
DDI-DrugBank.d368.s13	Acetazolamide NNP B-noun.person	and CC 0	sodium_bicarbonate NNP B-noun.person	used VBD B-verb.consumption	concurrently RB B-adv.all	increases VBZ B-verb.change	the DT 0	risk NN 0	of IN 0	renal JJ B-adj.all	calculus NN 0	formation NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d485.s19	Cyclosporine NNP B-noun.person	, , 0	Combination NNP B-noun.group	hormonal_contraceptives NNPS I-noun.group	may MD 0	inhibit VB B-verb.change	the DT 0	metabolism NN B-noun.attribute	of IN 0	cyclosporine NN B-noun.person	, , 0	leading VBG B-verb.motion	to TO 0	increased VBN B-verb.change	plasma NN B-noun.substance	concentrations NNS I-noun.substance	, , 0	. . 0
DDI-DrugBank.d328.s47	Diazepam NNP B-noun.person	, , 0	Diazepam NNP B-noun.person	( ( 0	Valium NNP B-noun.location	) ) 0	is VBZ B-verb.stative	a DT 0	CYP NNP B-noun.person	3A4 NNP I-noun.person	and CC 0	CYP NNP B-noun.group	2C19 JJ I-noun.group	substrate NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d364.s5	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	alosetron RB 0	and CC 0	moderate JJ B-noun.person	CYP1A2 NNP I-noun.person	inhibitors NNS I-noun.person	, , 0	including VBG B-verb.social	quinolone_antibiotics NNS B-noun.act	and CC 0	cimetidine NN B-noun.person	, , 0	has VBZ 0	not RB 0	been VBN 0	evaluated VBN B-verb.communication	, , 0	but CC 0	should MD 0	be VB 0	avoided VBN B-verb.social	unless IN 0	clinically RB B-adv.all	necessary JJ B-adj.all	because IN 0	of IN 0	similar JJ B-adj.all	potential JJ B-adj.all	drug NN B-noun.person	interactions NNS I-noun.person	. . 0	. . 0
DDI-DrugBank.d434.s26	Corresponding JJ B-adj.all	values NNS B-noun.attribute	for IN 0	free JJ B-noun.person	valproate NN I-noun.person	Cmin NNP I-noun.person	concentrations NNS I-noun.person	were VBD B-verb.stative	7 CD B-adj.all	3 CD B-adj.all	, , 0	9 CD 0	4 CD B-noun.quantity	, , 0	and CC 0	11 CD 0	6 CD B-adj.all	micrograms NNS B-noun.quantity	/ : 0	mL CC 0	for IN 0	0 CD B-noun.quantity	, , 0	1200 CD 0	, , 0	and CC 0	2400 CD 0	mg RB 0	/ JJ 0	day NN 0	Felbatol NNP B-noun.person	, , 0	respectively RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d325.s13	Administration NN B-noun.person	of IN 0	phenytoin NN B-noun.person	to TO 0	patients NNS B-noun.person	receiving VBG B-verb.communication	dopamine_HCl NNP B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	lead VB B-verb.cognition	to TO 0	hypotension NN B-noun.act	and CC 0	bradycardia NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d328.s14	Valdecoxib NNP B-noun.person	did VBD 0	not RB B-adv.all	have VB B-verb.stative	a DT 0	statistically RB B-adv.all	significant JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	phenytoin NN B-noun.substance	( ( 0	a DT 0	CYP NNP B-noun.person	2C9 NNP I-noun.person	and CC 0	CYP NNP B-noun.group	2C19 JJ B-adj.all	substrate NN I-adj.all	) ) 0	. . 0	. . 0
DDI-DrugBank.d124.s23	Sedatives NNS B-noun.time	/ POS 0	Hypnotics NNS B-noun.person	, , 0	triazolam NN B-noun.person	, , 0	midazolam NN 0	CONTRAINDICATED VBN 0	due JJ 0	to TO 0	potential JJ B-adj.all	for IN 0	serious JJ B-adj.all	and/or NN B-noun.attribute	life NN I-noun.attribute	- : 0	threatening JJ B-verb.communication	reactions NNS B-noun.state	such JJ 0	as IN 0	prolonged VBN B-verb.communication	or CC 0	increased VBN B-verb.change	sedation NN B-noun.act	or CC 0	respiratory JJ B-adj.pert	depression NN B-noun.process	. . 0	. . 0
DDI-DrugBank.d82.s30	INDOCIN NNP B-noun.group	and CC 0	potassium NN B-noun.person	- : 0	sparing_diuretics NNS B-noun.person	each DT 0	may MD 0	be VB 0	associated VBN B-verb.cognition	with IN 0	increased VBN B-adj.all	serum NN B-noun.body	potassium NN I-noun.body	levels NNS B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d141.s2	CIMETlDINE JJ 0	, , 0	Cerivastatin NNP B-noun.person	plasma NN I-noun.person	concentrations NNS I-noun.person	were VBD B-verb.stative	not RB B-adv.all	affected VBN B-verb.change	by IN 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	cimetidine NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d503.s5	Consider VB B-verb.communication	additive JJ B-adj.all	sedative JJ B-adj.all	effects NNS B-noun.phenomenon	and CC 0	confusional JJ B-adj.all	states NNS B-noun.location	to TO 0	emerge VB B-verb.change	, , 0	if IN 0	chlorprothixene NN B-noun.person	is VBZ 0	given VBN B-verb.possession	with IN 0	benzodiazepines NNS B-noun.artifact	or CC 0	barbituates NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d212.s22	Probenecid NNP B-noun.person	, , 0	Probenecid NNP B-noun.person	, , 0	a DT 0	renal JJ B-adj.all	tubular JJ B-adj.all	secretion NN B-noun.act	blocking VBG B-verb.change	agent NN B-noun.person	, , 0	administered VBN B-verb.possession	at IN 0	a DT 0	dose NN B-noun.quantity	of IN 0	500 CD 0	mg IN 0	four CD 0	times NNS B-noun.event	a DT 0	day NN B-noun.person	, , 0	did VBD 0	not RB B-adv.all	change VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	levetiracetam NN B-noun.communication	1000 CD 0	mg NN B-noun.quantity	twice RB 0	daily RB 0	. . 0	. . 0
DDI-DrugBank.d195.s8	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	anastrozole NN B-noun.animal	and CC 0	tamoxifen NNS B-noun.person	resulted VBD B-verb.social	in IN 0	a DT 0	reduction NN B-noun.act	of IN 0	anastrozole NN B-noun.animal	plasma NN B-noun.plant	levels NNS B-noun.state	by IN 0	27 CD B-adj.all	% NN 0	compared VBN B-verb.communication	with IN 0	those DT 0	achieved VBN B-verb.social	with IN 0	anastrozole NN B-noun.group	alone RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d487.s2	Drugs NNS B-noun.person	such JJ 0	as IN 0	troleandomycin NN B-noun.person	and CC 0	ketoconazole NN B-noun.group	may MD 0	inhibit VB B-verb.change	the DT 0	metabolism NN B-noun.attribute	of IN 0	corticosteroids NNS B-noun.food	and CC 0	thus RB B-adv.all	decrease VB B-verb.change	their PRP$ 0	clearance NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d525.s3	Ranitidine NNP B-noun.person	also RB B-adv.all	has VBZ B-verb.possession	no DT 0	effect NN B-noun.cognition	on IN 0	eprosartan JJ B-adj.all	pharmacokinetics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d351.s0	Probenecid NNP B-noun.person	, , 0	As IN 0	with IN 0	other JJ 0	b SYM 0	- : 0	lactam_antibiotics NNS B-noun.person	, , 0	renal JJ B-adj.all	excretion NN B-noun.act	of IN 0	loracarbef NN B-noun.food	is VBZ 0	inhibited VBN B-verb.change	by IN 0	probenecid NN B-noun.person	and CC 0	resulted VBD B-verb.communication	in IN 0	an DT 0	approximate JJ B-adj.all	80 CD B-adj.all	% NN 0	increase NN B-noun.event	in IN 0	the DT 0	AUC NNP B-noun.group	for IN 0	loracarbef NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d94.s5	Thus RB 0	, , 0	if IN 0	a DT 0	patient NN B-noun.person	has VBZ 0	been VBN 0	titrated VBN B-verb.communication	to TO 0	a DT 0	stable JJ B-adj.all	dosage NN B-noun.attribute	of IN 0	EQUETROTM NNP B-noun.group	, , 0	and CC 0	then RB B-adv.all	begins VBZ B-verb.stative	a DT 0	course NN B-noun.object	of IN 0	treatment NN B-noun.plant	with IN 0	one CD 0	of IN 0	these DT 0	CYP3A4 NNP B-noun.other	or CC 0	epoxide JJ B-adj.all	hydrolase NN B-noun.event	inhibitors NNS B-noun.person	, , 0	it PRP 0	is VBZ B-verb.stative	reasonable JJ B-adj.all	to TO 0	expect VB B-verb.cognition	that IN 0	a DT 0	dose NN B-noun.event	reduction NN B-noun.process	for IN 0	EQUETROTM NNP B-noun.group	may MD 0	be VB B-verb.stative	necessary JJ B-adj.all	. . 0	. . 0
DDI-MedLine.d86.s8	CONCLUSIONS NNS B-noun.artifact	, , 0	Single NNP B-noun.person	- : 0	dose NN 0	diltiazem NN 0	coadministration NN B-noun.person	leads VBZ B-verb.cognition	to TO 0	higher JJR B-adj.all	sirolimus NN B-noun.communication	exposure NN B-noun.communication	, , 0	presumably RB B-adv.all	by IN 0	inhibition NN B-noun.time	of IN 0	the DT 0	first JJ B-noun.person	- : 0	pass NN B-noun.time	metabolism NN B-noun.attribute	of IN 0	sirolimus NN 0	. . 0	. . 0
DDI-DrugBank.d236.s8	d SYM 0	- : 0	amphetamine NN B-noun.person	with IN 0	desipramine NN B-noun.state	or CC 0	protriptyline NN B-noun.person	and CC 0	possibly RB B-adj.all	other JJ 0	tricyclics NNS B-noun.person	cause VBP B-verb.communication	striking JJ B-verb.contact	and CC 0	sustained VBD B-verb.contact	increases NNS B-noun.person	in IN 0	the DT 0	concentration NN B-noun.event	of IN 0	d SYM 0	- : 0	amphetamine NN B-noun.person	in IN 0	the DT 0	brain NN B-noun.person	, , 0	. . 0
DDI-DrugBank.d143.s7	In IN 0	view NN 0	of IN 0	the DT 0	long JJ B-noun.body	and CC 0	variable JJ B-adj.all	half NN B-noun.person	- : 0	life NN B-noun.time	of IN 0	amiodarone NN 0	, , 0	potential JJ B-adj.all	for IN 0	drug NN B-noun.act	interactions NNS I-noun.act	exists VBZ B-verb.stative	not RB I-verb.stative	only RB B-adv.all	with IN 0	concomitant JJ B-adj.all	medication NN B-noun.person	but CC 0	also RB B-adv.all	with IN 0	drugs NNS B-noun.artifact	administered VBN B-verb.possession	after IN 0	discontinuation NN B-noun.act	of IN 0	amiodarone NN 0	. . 0	. . 0
DDI-DrugBank.d219.s22	Warfarin NNP B-noun.person	, , 0	The DT 0	effects NNS B-noun.phenomenon	of IN 0	warfarin NN B-noun.act	and CC 0	NSAIDs NNP B-noun.person	on IN 0	GI NNP 0	bleeding NN B-verb.body	are VBP B-verb.stative	synergistic JJ B-adj.all	, , 0	such JJ 0	that IN 0	users NNS B-noun.person	of IN 0	both DT 0	drugs NNS B-noun.artifact	together RB B-adv.all	have VBP 0	a DT 0	risk NN 0	of IN 0	serious JJ B-adj.all	GI NNP 0	bleeding VBG B-verb.body	higher JJR B-adj.all	than IN 0	that DT 0	of IN 0	users NNS B-noun.person	of IN 0	either DT 0	drug NN B-noun.state	alone RB 0	. . 0	. . 0
DDI-DrugBank.d254.s0	Other JJ 0	CNS_depressant_drugs NNS 0	( ( 0	e.g. JJ B-adj.all	barbiturates NNS B-noun.artifact	, , 0	tranquilizers NNS B-noun.person	, , 0	opioids NNS B-noun.person	and CC 0	general JJ B-adj.all	anesthetics NNS B-noun.group	) ) 0	have VBP 0	additive JJ B-verb.communication	or CC 0	potentiating JJ B-adj.all	effects NNS B-noun.phenomenon	with IN 0	INAPSINE NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d267.s5	Other JJ 0	drugs NNS B-noun.artifact	which WDT 0	may MD 0	enhance VB B-verb.change	the DT 0	neuromuscular JJ B-adj.all	blocking VBG B-verb.change	action NN B-noun.process	of IN 0	nondepolarizing VBG B-verb.communication	agents NNS B-noun.person	such JJ 0	as IN 0	NUROMAX NNP B-noun.group	include VBP B-verb.change	certain JJ B-adj.all	antibiotics NNS B-noun.attribute	( ( 0	e. FW 0	g. FW 0	, , 0	aminoglycosides NNS B-noun.person	, , 0	tetracyclines NNS B-noun.artifact	, , 0	bacitracin NN B-noun.person	, , 0	polymyxins NNS B-noun.person	, , 0	lincomycin NN B-noun.communication	, , 0	clindamycin NN B-noun.person	, , 0	colistin NN B-noun.person	, , 0	and CC 0	sodium_colistimethate NNP B-noun.location	) ) 0	, , 0	magnesium NN B-noun.person	salts NNS B-noun.substance	, , 0	lithium NN B-noun.person	, , 0	local JJ B-adj.all	anesthetics NNS B-noun.person	, , 0	procainamide NN B-noun.person	, , 0	and CC 0	quinidine NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d438.s8	Carbamazepine NNP B-noun.person	, , 0	Steady NNP B-noun.person	- : 0	state NN B-adj.all	trough NN 0	plasma NN 0	carbamazepine NN 0	and CC 0	carbamazepine_10,_11_epoxide JJ 0	concentrations NNS B-noun.attribute	were VBD B-verb.stative	not RB B-adv.all	affected VBN B-verb.change	by IN 0	concomitant JJ B-adj.all	gabapentin NN B-noun.communication	( ( 0	400 CD 0	mg IN 0	TID NNP 0	, , 0	. . 0
DDI-DrugBank.d284.s12	Beta SYM 0	- : 0	adrenergic_receptor_antagonists NNS B-noun.person	( ( 0	beta JJ 0	- : 0	blockers NNS B-noun.time	) ) 0	and CC 0	BROVANA NNP B-noun.group	may MD 0	interfere VB B-verb.stative	with IN 0	the DT 0	effect NN B-noun.cognition	of IN 0	each DT 0	other JJ 0	when WRB 0	administered VBN B-verb.communication	concurrently RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d45.s0	Concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	etanercept NN 0	( ( 0	another DT 0	TNF NNP B-noun.group	-blocking VBG B-verb.cognition	agent NN B-noun.attribute	) ) 0	and CC 0	anakinra NN B-noun.body	( ( 0	an DT 0	interleukin-1_antagonist JJ 0	) ) 0	has VBZ 0	been VBN 0	associated VBN B-verb.cognition	with IN 0	an DT 0	increased VBN B-verb.change	risk NN 0	of IN 0	serious JJ B-adj.all	infections NNS B-noun.communication	, , 0	and CC 0	increased VBN B-verb.change	risk NN 0	of IN 0	neutropenia NN B-noun.person	and CC 0	no DT 0	additional JJ B-adj.all	benefit NN B-noun.communication	compared VBN B-verb.change	to TO 0	these DT 0	medicinal JJ B-adj.all	products NNS B-noun.artifact	alone RB 0	. . 0	. . 0
DDI-DrugBank.d107.s1	The DT 0	possibility NN B-noun.state	of IN 0	hypotensive JJ B-adj.all	effects NNS B-noun.phenomenon	with IN 0	enalapril NN B-noun.time	or CC 0	enalaprilat NN B-noun.person	can MD 0	be VB 0	minimized VBN B-verb.change	by IN 0	either DT 0	discontinuing VBG B-verb.communication	the DT 0	diuretic JJ B-adj.all	or CC 0	increasing VBG B-verb.change	the DT 0	salt NN 0	intake NN 0	prior RB 0	to TO 0	initiation NN B-noun.act	of IN 0	treatment NN B-noun.plant	with IN 0	enalapril NN B-noun.time	or CC 0	enalaprilat NN B-noun.person	. . 0	. . 0
DDI-MedLine.d81.s6	Maximal JJ B-adj.all	hypotension NN B-noun.person	was VBD 0	found VBN B-verb.possession	120 CD 0	minutes NNS B-noun.time	post VBP B-verb.possession	ethanol NN B-noun.person	, , 0	and CC 0	returned VBD B-verb.motion	to TO 0	normal JJ B-adj.all	300 CD 0	minutes NNS B-noun.time	after IN 0	ethanol NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d78.s20	Antidiabetic_Agents NNS B-noun.artifact	, , 0	Disturbances NNPS B-noun.person	of IN 0	blood NN B-noun.location	glucose NN B-noun.person	, , 0	including VBG B-verb.change	hyperglycemia NN B-noun.food	and CC 0	hypoglycemia NN B-noun.person	, , 0	have VBP 0	been VBN 0	reported VBN B-verb.communication	in IN 0	patients NNS B-noun.person	treated VBD B-verb.communication	concomitantly RB B-adv.all	with IN 0	quinolones NNS B-noun.communication	and CC 0	an DT 0	antidiabetic_agent JJ B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d192.s0	Dexbrompheniramine NN B-noun.person	can MD 0	interact VB B-verb.change	with IN 0	alcohol NN B-noun.feeling	or CC 0	other JJ B-adj.all	CNS_depressants NNS B-noun.person	( ( 0	may MD 0	potentiate VB B-verb.communication	the DT 0	CNS NNP B-noun.group	depressant JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	either CC 0	these DT 0	medications NNS B-noun.artifact	or CC 0	antihistamines NNS B-noun.attribute	) ) 0	, , 0	anticholinergics NNS B-noun.person	or CC 0	other JJ B-adj.all	medications NNS B-noun.person	with IN 0	anticholinergic JJ B-adj.all	activity NN B-noun.state	( ( 0	anticholinergic JJ B-adj.pert	effects NNS B-noun.phenomenon	may MD 0	be VB 0	potentiated VBN B-verb.cognition	when WRB 0	these DT 0	medications NNS B-noun.artifact	are VBP 0	used VBN B-verb.consumption	concurrently RB B-adv.all	with IN 0	antihistamines NNS B-noun.attribute	) ) 0	, , 0	and CC 0	monoamine_oxidase_(MAO)_inhibitors NNS B-noun.person	( ( 0	concurrent JJ B-adj.all	use NN 0	with IN 0	antihistamines NNS B-noun.object	may MD 0	prolong VB B-verb.perception	and CC 0	intensify VB B-verb.change	the DT 0	anticholinergic JJ B-adj.all	and CC 0	CNS NNP B-noun.group	depressant JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	antihistamines NNS B-noun.attribute	) ) 0	. . 0	. . 0
DDI-DrugBank.d499.s19	Probenecid NNP B-noun.person	, , 0	Probenecid NNP B-noun.person	increases VBZ B-verb.change	both DT 0	free JJ B-noun.person	and CC 0	bound VBD 0	ketoprofen VBN B-verb.stative	by IN 0	reducing VBG B-verb.change	the DT 0	plasma NN B-noun.plant	clearance NN B-noun.attribute	of IN 0	ketoprofen NN B-noun.person	to TO 0	about IN 0	one CD 0	- : 0	third JJ B-noun.act	, , 0	as RB 0	well RB 0	as IN 0	decreasing VBG B-verb.communication	its PRP$ 0	protein NN B-noun.substance	binding NN B-verb.contact	. . 0	. . 0
DDI-DrugBank.d395.s23	Warfarin NNP B-noun.person	, , 0	Quinolones NNPS B-noun.person	, , 0	including VBG B-verb.change	enoxacin NN B-noun.food	, , 0	decrease VB B-verb.communication	the DT 0	clearance NN B-noun.act	of IN 0	R SYM 0	- : 0	warfarin NN B-noun.act	, , 0	the DT 0	less RBR B-adv.all	active JJ B-adj.all	isomer NN B-noun.person	of IN 0	racemic JJ B-adj.all	warfarin NN B-noun.act	. . 0	. . 0
DDI-MedLine.d140.s6	Potential JJ B-noun.phenomenon	differences NNS I-noun.phenomenon	in IN 0	cyclosporine JJ B-adj.all	dosing NN B-noun.act	and CC 0	pharmacokinetics NNS B-noun.person	at IN 0	different JJ B-adj.all	levels NNS B-noun.state	of IN 0	everolimus NN 0	exposure NN B-noun.state	were VBD 0	assessed VBN B-verb.communication	in IN 0	the DT 0	context NN B-noun.state	of IN 0	ANOVA NNP 0	. . 0	. . 0
DDI-DrugBank.d466.s19	Drug NN B-noun.person	Interactions NNS I-noun.person	with IN 0	Antacids NNPS B-noun.group	Administration NNP I-noun.group	of IN 0	120 CD 0	mg NN B-noun.quantity	of IN 0	fexofenadine_hydrochloride JJ 0	( ( 0	2 CD B-adj.all	x NN B-noun.communication	60 CD B-adj.all	mg NN B-noun.quantity	capsule NN B-noun.location	) ) 0	within IN 0	15 CD B-adj.all	minutes NNS B-noun.time	of IN 0	an DT 0	aluminum NN B-noun.person	and CC 0	magnesium NN B-noun.artifact	containing VBG B-verb.stative	antacid NN B-noun.substance	( ( 0	Maalox NNP B-noun.person	) ) 0	decreased VBD B-verb.change	fexofenadine JJ B-adj.all	AUC NNP B-noun.group	by IN 0	41 CD 0	% NN 0	and CC 0	cmax NN B-noun.person	by IN 0	43 CD 0	% NN 0	. . 0	. . 0
DDI-DrugBank.d263.s5	Zalcitabine NNP B-noun.person	inhibited VBD B-verb.change	lamivudine JJ B-adj.all	phosphorylation NN B-noun.artifact	at IN 0	high JJ B-adj.all	concentration NN B-noun.artifact	ratios NNS I-noun.artifact	( ( 0	10 CD B-adj.all	and CC 0	100 CD 0	) ) 0	, , 0	. . 0
DDI-DrugBank.d438.s27	Morphine RBR B-adv.all	pharmacokinetic JJ B-adj.all	parameter NN B-noun.object	values NNS B-noun.attribute	were VBD B-verb.stative	not RB B-adv.all	affected VBN B-verb.change	by IN 0	administration NN B-noun.time	of IN 0	Neurontin NNP B-noun.person	_ # 0	2 CD B-adj.all	hours NNS B-noun.person	after IN 0	morphine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d105.s0	Anticoagulants NNS B-noun.person	including VBG B-verb.social	coumarin NN B-noun.act	derivatives NNS B-noun.event	, , 0	indandione NN 0	derivatives NNS B-noun.person	, , 0	and CC 0	platelet_aggregation_inhibitors NNS 0	such JJ 0	as IN 0	nonsteroidal_anti NNS B-noun.person	- : 0	inflammatory_drugs NNS B-noun.cognition	( ( 0	NSAIDs NNP B-noun.person	) ) 0	, , 0	and CC 0	aspirin NN B-noun.person	may MD 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	bleeding VBG B-verb.body	when WRB 0	administered VBN B-verb.communication	concomitantly RB B-adv.all	with IN 0	ardeparin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d567.s21	Digoxin NNP B-noun.person	, , 0	In IN 0	patients NNS B-noun.person	with IN 0	hypercholesterolemia NN B-noun.person	, , 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	lovastatin NN B-noun.feeling	and CC 0	digoxin NN B-noun.person	resulted VBD B-verb.contact	in IN 0	no DT 0	effect NN B-noun.cognition	on IN 0	digoxin NN B-noun.substance	plasma NN B-noun.substance	concentrations NNS B-noun.artifact	. . 0	. . 0
DDI-MedLine.d2.s3	Neomycin NNP B-noun.person	has VBZ B-verb.possession	no DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	blood NN B-noun.group	pressure NN B-noun.state	or CC 0	metabolic JJ B-adj.all	responses NNS B-noun.act	to TO 0	ACTH NNP B-noun.person	in IN 0	sheep NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d548.s22	It PRP 0	is VBZ B-verb.stative	unknown JJ B-adj.all	whether IN 0	the DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	proton_pump_inhibitors NNS B-noun.person	affects VBZ B-verb.change	duloxetine JJ B-adj.all	absorption NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d522.s23	Ergotamine NNP B-noun.person	, , 0	Concurrent JJ 0	use NN 0	of IN 0	erythromycin NN B-noun.food	and CC 0	ergotamine NN B-noun.act	or CC 0	dihydroergotamine NN B-noun.person	has VBZ 0	been VBN 0	associated VBN B-verb.cognition	in IN 0	some DT 0	patients NNS B-noun.person	with IN 0	acute JJ B-adj.all	ergot NN B-noun.person	toxicity NN B-noun.person	characterized VBN B-verb.communication	by IN 0	severe JJ B-adj.all	peripheral JJ B-adj.pert	vasospasm NN B-noun.cognition	and CC 0	dysesthesia NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d400.s12	Thus RB 0	, , 0	when WRB 0	NSAIDs NNP B-noun.person	and CC 0	lithium NN B-noun.person	are VBP 0	administered VBN B-verb.possession	concurrently RB B-adv.all	, , 0	subjects NNS B-noun.person	should MD 0	be VB 0	observed VBN B-verb.perception	carefully RB B-adv.all	for IN 0	signs NNS B-noun.communication	of IN 0	lithium NN B-noun.phenomenon	toxicity NN B-noun.attribute	. . 0	. . 0
DDI-MedLine.d29.s2	( ( 0	1968 CD 0	, , 0	1970 CD 0	) ) 0	, , 0	the DT 0	higher JJR B-adj.all	serum NN B-noun.body	concentrations NNS B-noun.attribute	of IN 0	penicillins NNS B-noun.person	and CC 0	cephaloridine NN 0	reached VBN B-verb.creation	after IN 0	administration NN B-noun.time	of IN 0	probenecid NN B-noun.person	are VBP B-verb.stative	due JJ 0	not RB 0	only RB B-adv.all	to TO 0	slower VB B-verb.change	renal JJ B-adj.all	elimination NN B-noun.act	but CC 0	also RB B-adv.all	to TO 0	an DT 0	altered JJ B-adj.all	distribution NN B-noun.act	in IN 0	the DT 0	body NN B-noun.object	. . 0	. . 0
DDI-DrugBank.d410.s4	Nicotine NNP B-noun.person	, , 0	Nicotine NNP B-noun.person	may MD 0	provoke VB B-verb.communication	vasoconstriction NN B-noun.act	in IN 0	some DT 0	patients NNS B-noun.person	, , 0	predisposing VBG B-verb.communication	to TO 0	a DT 0	greater JJR B-adj.all	ischemic JJ B-adj.all	response NN B-noun.communication	to TO 0	ergot VB B-verb.change	therapy NN 0	. . 0	. . 0
DDI-DrugBank.d484.s0	Etonogestrel NNP B-noun.person	may MD 0	interact VB B-verb.change	with IN 0	the DT 0	following JJ B-adj.all	medications NNS B-noun.person	, , 0	acetaminophen RB B-adv.all	( ( 0	Tylenol NNP B-noun.location	) ) 0	, , 0	antibiotics NNS B-noun.person	such JJ 0	as IN 0	ampicillin NN B-noun.person	and CC 0	tetracycline NN B-noun.person	, , 0	anticonvulsants NNS B-noun.person	( ( 0	Dilantin NNP B-noun.person	, , 0	Phenobarbital NNP B-noun.person	, , 0	Tegretol NNP B-noun.person	, , 0	Trileptal NNP B-noun.person	, , 0	Topamax NNP B-noun.person	, , 0	Felbatol NNP B-noun.location	) ) 0	, , 0	antifungals NNS B-noun.person	( ( 0	Gris NNP B-noun.person	- : 0	PEG NNP B-noun.group	, , 0	Nizoral NNP B-noun.person	, , 0	Sporanox NNP B-noun.location	) ) 0	, , 0	atorvastatin NN 0	( ( 0	Lipitor NNP B-noun.person	) ) 0	, , 0	clofibrate NN B-noun.person	( ( 0	Atromid NNP B-noun.person	- : 0	S NNP 0	) ) 0	, , 0	cyclosporine NN B-noun.person	( ( 0	Neoral JJ 0	, , 0	Sandimmune NNP 0	) ) 0	, , 0	HIV NNP 0	drugs NNS B-noun.artifact	classified VBN B-verb.cognition	as IN 0	protease NN B-noun.person	inhibitors NNS B-noun.person	( ( 0	Agenerase NNP B-noun.person	, , 0	Crixivan NNP B-noun.person	, , 0	Fortovase NNP B-noun.person	, , 0	Invirase NNP B-noun.person	, , 0	Kaletra NNP B-noun.person	, , 0	Norvir NNP B-noun.person	, , 0	Viracept NNP B-noun.location	) ) 0	, , 0	morphine NN B-noun.person	( ( 0	Astramorph NNP B-noun.person	, , 0	Kadian NNP B-noun.person	, , 0	MS NNP 0	Contin NNP 0	) ) 0	, , 0	phenylbutazone NN B-noun.person	, , 0	prednisolone NN B-noun.person	( ( 0	Prelone NNP B-noun.person	) ) 0	, , 0	rifadin NN 0	( ( 0	rifampin VB 0	) ) 0	, , 0	St. NNP 0	Johns NNP 0	wort NN 0	, , 0	temazepam NN B-noun.person	, , 0	theophylline PRP 0	( ( 0	Theo RB B-adv.all	- : 0	Dur NNP B-noun.location	) ) 0	, , 0	and CC 0	vitamin NN B-noun.person	C. NNP I-noun.person	. . 0
DDI-MedLine.d3.s13	Rifampin NNP B-noun.person	markedly RB I-noun.person	increases VBZ B-verb.change	the DT 0	metabolic JJ B-adj.all	clearance NN B-noun.attribute	of IN 0	amprenavir NN B-noun.person	, , 0	and CC 0	coadministration NN B-noun.person	is VBZ 0	contraindicated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d357.s3	Dopamine_Antagonists NNS B-noun.person	, , 0	Since IN 0	apomorphine NN B-noun.person	is VBZ B-verb.stative	a DT 0	dopamine_agonist NN B-noun.person	, , 0	it PRP 0	is VBZ B-verb.stative	possible JJ B-adj.all	that IN 0	dopamine_antagonists NNS B-noun.person	, , 0	such JJ 0	as IN 0	the DT 0	neuroleptics NNS B-noun.person	( ( 0	phenothiazines NNS B-noun.animal	, , 0	butyrophenones NNS 0	, , 0	thioxanthenes NNS 0	) ) 0	or CC 0	metoclopramide NN B-noun.attribute	, , 0	may MD 0	diminish VB B-verb.change	the DT 0	effectiveness NN B-noun.cognition	of IN 0	APOKYN NNP B-noun.other	. . 0	. . 0
DDI-DrugBank.d175.s1	The DT 0	possibility NN B-noun.state	of IN 0	hypotensive JJ B-adj.all	effects NNS B-noun.phenomenon	with IN 0	captopril NN B-noun.person	can MD 0	be VB 0	minimized VBN B-verb.change	by IN 0	either DT 0	discontinuing VBG B-verb.communication	the DT 0	diuretic JJ B-adj.all	or CC 0	increasing VBG B-verb.change	the DT 0	salt NN 0	intake NN 0	approximately RB B-adj.all	one CD 0	week NN 0	prior RB 0	to TO 0	initiation NN B-noun.act	of IN 0	treatment NN B-noun.plant	with IN 0	captopril NN B-noun.artifact	( ( 0	captopril NN B-noun.substance	tablets NNS B-noun.artifact	, , 0	USP NNP B-noun.group	) ) 0	or CC 0	initiating VBG B-verb.social	therapy NN I-verb.social	with IN 0	small JJ B-adj.all	doses NNS B-noun.quantity	( ( 0	6.25 CD 0	or CC 0	12.5 CD 0	mg NN B-noun.quantity	) ) 0	. . 0	. . 0
DDI-DrugBank.d518.s0	Prolonged VBN B-verb.creation	recovery NN B-noun.process	time NN B-noun.time	may MD 0	occur VB B-verb.cognition	if IN 0	barbiturates NNS B-noun.artifact	and/or CC 0	narcotics NNS B-noun.person	are VBP 0	used VBN B-verb.consumption	concurrently RB B-adv.all	with IN 0	ketamine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d567.s5	Itraconazole NNP B-noun.person	Ketoconazole NNP I-noun.person	Erythromycin NNP I-noun.person	Clarithromycin NNP I-noun.person	Telithromycin NNP I-noun.person	HIV_protease_inhibitors NNPS I-noun.person	Nefazodone NNP B-noun.person	Cyclosporine NNP I-noun.person	Large JJ I-noun.person	quantities NNS I-noun.person	of IN 0	grapefruit NN B-noun.phenomenon	juice NN B-noun.person	( ( 0	1 CD 0	quart NN 0	daily RB 0	) ) 0	. . 0
DDI-DrugBank.d103.s0	Short JJ B-noun.body	- : 0	Acting_beta2-agonists NNS B-noun.person	, , 0	Aerosol NNP B-noun.person	bronchodilators NNS I-noun.person	of IN 0	the DT 0	short JJ B-noun.body	- : 0	acting VBG B-verb.body	adrenergic JJ B-adj.all	stimulant JJ B-adj.all	type NN B-noun.person	may MD 0	be VB 0	used VBN B-verb.consumption	for IN 0	relief NN B-noun.time	of IN 0	breakthrough NN B-noun.plant	symptoms NNS B-noun.body	while IN 0	using VBG B-verb.consumption	formoterol NN I-verb.consumption	. . 0	. . 0
DDI-DrugBank.d172.s20	Patients NNS B-noun.person	on IN 0	lithium NN B-noun.substance	treatment NN B-noun.plant	should MD 0	be VB B-verb.stative	closely RB B-adj.all	monitored VBN I-adj.all	when WRB 0	CELEBREX NNP B-noun.group	is VBZ 0	introduced VBN B-verb.contact	or CC 0	withdrawn VBN B-verb.contact	. . 0	. . 0
DDI-DrugBank.d456.s1	Caution NN B-noun.person	should MD 0	be VB 0	used VBN B-verb.consumption	when WRB 0	administering VBG B-verb.perception	or CC 0	taking VBG B-verb.social	TARCEVA NNP I-verb.social	with IN 0	ketoconazole NN B-noun.person	and CC 0	other JJ 0	strong JJ B-noun.person	CYP3A4 CD I-noun.person	inhibitors NNS I-noun.person	such JJ 0	as IN 0	, , 0	but CC 0	not RB B-adv.all	limited VBN B-verb.change	to TO 0	, , 0	atazanavir NN B-noun.person	, , 0	clarithromycin NN B-noun.person	, , 0	indinavir NN B-noun.person	, , 0	itraconazole NN B-noun.person	, , 0	nefazodone NN 0	, , 0	nelfinavir NN B-noun.person	, , 0	ritonavir NN B-noun.person	, , 0	saquinavir NN B-noun.person	, , 0	telithromycin NN B-noun.person	, , 0	troleandomycin NN B-noun.person	( ( 0	TAO NNP 0	) ) 0	, , 0	and CC 0	voriconazole NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d561.s3	Potassium NNP B-noun.person	Supplements NNPS I-noun.person	and CC 0	Potassium NNP B-noun.person	- : 0	Sparing_Diuretics NNS B-noun.person	Lotensin NNP I-noun.person	can MD 0	attenuate VB B-verb.social	potassium NN 0	loss NN 0	caused VBN B-verb.communication	by IN 0	thiazide_diuretics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d246.s8	The DT 0	safety NN B-noun.artifact	of IN 0	using VBG B-verb.consumption	STADOL_NS NNS B-noun.artifact	and CC 0	IMITREX NNP B-noun.group	( ( 0	sumatriptan NN 0	) ) 0	Nasal NNP B-noun.location	Spray NNP I-noun.location	during IN 0	the DT 0	same JJ B-adj.all	episode NN B-noun.person	of IN 0	migraine NN 0	has VBZ 0	not RB 0	been VBN 0	established VBN B-verb.creation	. . 0	. . 0
DDI-DrugBank.d438.s10	Likewise RB 0	, , 0	gabapentin NN B-adj.all	pharmacokinetics NNS B-noun.person	were VBD B-verb.stative	unaltered JJ B-adj.all	by IN 0	carbamazepine JJ B-adj.all	administration NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d175.s10	Agents NNPS B-noun.person	Affecting NNP I-noun.person	Sympathetic NNP I-noun.person	Activity NNP I-noun.person	The DT 0	sympathetic JJ B-adj.all	nervous JJ B-adj.all	system NN B-noun.cognition	may MD 0	be VB B-verb.stative	especially RB B-adv.all	important JJ B-adj.all	in IN 0	supporting VBG B-verb.social	blood NN B-noun.act	pressure NN B-noun.act	in IN 0	patients NNS B-noun.artifact	receiving VBG B-verb.change	captopril NN B-noun.artifact	alone RB 0	or CC 0	with IN 0	diuretics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d364.s0	Because IN 0	alosetron NN B-noun.person	is VBZ 0	metabolized VBN B-verb.change	by IN 0	a DT 0	variety NN B-noun.cognition	of IN 0	hepatic JJ B-adj.all	CYP NNP B-noun.group	drug NN B-noun.group	- : 0	metabolizing NN B-verb.cognition	enzymes NNS B-noun.person	, , 0	inducers NNS B-noun.person	or CC 0	inhibitors NNS B-noun.attribute	of IN 0	these DT 0	enzymes NNS B-noun.act	may MD 0	change VB B-verb.change	the DT 0	clearance NN B-noun.act	of IN 0	alosetron RB 0	. . 0	. . 0
DDI-DrugBank.d99.s9	The DT 0	extent NN B-noun.attribute	to TO 0	which WDT 0	SSRI NNP B-noun.group	- : 0	TCA NNP B-noun.group	interactions NNS B-noun.possession	may MD 0	pose VB B-verb.possession	clinical JJ B-adj.all	problems NNS B-noun.communication	will MD 0	depend VB B-verb.cognition	on IN 0	the DT 0	degree NN B-noun.communication	of IN 0	inhibition NN B-noun.attribute	and CC 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	the DT 0	SSRI NNP B-noun.group	involved VBD B-verb.stative	. . 0	. . 0
DDI-DrugBank.d88.s6	Deaths NNP B-noun.person	from IN 0	severe JJ B-adj.all	enterocolitis NN B-noun.person	, , 0	diarrhea NN B-noun.person	, , 0	and CC 0	dehydration NN B-noun.act	have VBP 0	been VBN 0	reported VBN B-verb.communication	in IN 0	elderly JJ B-adj.all	patients NNS B-noun.person	receiving VBG B-verb.communication	weekly JJ B-adj.all	leucovorin NN B-noun.communication	and CC 0	fluorouracil NN B-noun.plant	. . 0	. . 0
DDI-DrugBank.d475.s3	In IN 0	patients NNS B-noun.person	given VBN B-verb.possession	very RB B-adv.all	high JJ B-adj.all	doses NNS B-noun.artifact	( ( 0	3900 CD 0	mg NN B-noun.quantity	) ) 0	of IN 0	aspirin NN 0	daily RB 0	, , 0	increases NNS B-noun.quantity	in IN 0	serum NN 0	salicylate NN 0	levels NNS B-noun.state	were VBD 0	seen VBN B-verb.perception	when WRB 0	nizatidine NN B-noun.person	, , 0	150 CD 0	mg IN 0	b.i.d NNP B-noun.person	. . 0	, , 0	was VBD 0	administered VBN B-verb.possession	concurrently RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d72.s2	Phenytoin NN B-noun.person	increases VBZ B-verb.change	the DT 0	clearance NN B-noun.act	of IN 0	busulfan NN B-noun.animal	by IN 0	15 CD B-adj.all	% NN 0	or CC 0	more JJR B-noun.quantity	, , 0	possibly RB 0	due JJ 0	to TO 0	the DT 0	induction NN B-noun.act	of IN 0	glutathione NN B-noun.person	- : 0	S SYM 0	- : 0	transferase NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d94.s9	Agents NNS B-noun.person	with IN 0	Decreased NNP B-noun.group	Levels NNP I-noun.group	in IN 0	the DT 0	Presence NNP B-noun.person	of IN 0	Carbamazepine NNP 0	due JJ 0	to TO 0	Induction NNP B-noun.person	of IN 0	Cytochrome NNP B-noun.person	P450 NNP I-noun.person	Enzymes NNP I-noun.person	Carbamazepine NNP I-noun.person	is VBZ 0	known VBN B-verb.cognition	to TO 0	induce VB B-verb.cognition	CYP1A2 NNP B-noun.person	and CC 0	CYP3A4 NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d458.s8	Data NNS B-noun.cognition	suggest VBP B-verb.communication	that IN 0	coadministration NN B-noun.person	of IN 0	oral JJ B-adj.all	ketoconazole NN B-noun.attribute	and CC 0	cisapride NN B-noun.person	can MD 0	result VB B-verb.stative	in IN 0	prolongation NN 0	of IN 0	the DT 0	QT NNP 0	interval NN 0	on IN 0	the DT 0	ECG NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d175.s8	Agents NNS B-noun.person	Causing VBG I-noun.person	Renin NNP I-noun.person	Release NNP I-noun.person	Captopril NNP I-noun.person	's POS 0	effect NN B-noun.cognition	will MD 0	be VB 0	augmented VBN B-verb.change	by IN 0	antihypertensive_agents NNS B-noun.person	that WDT 0	cause VBP B-verb.emotion	renin NN I-verb.emotion	release NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d373.s8	Quinidine NNP B-noun.location	, , 0	Immediate NNP B-noun.other	Release NNP I-noun.other	Capsules NNP I-noun.other	, , 0	There EX 0	have VBP 0	been VBN B-verb.stative	rare JJ B-adj.all	reports NNS B-noun.artifact	of IN 0	an DT 0	interaction NN B-noun.act	between IN 0	quinidine JJ B-adj.all	and CC 0	nifedipine NN B-noun.person	( ( 0	with IN 0	a DT 0	decreased VBN B-adj.all	plasma NN B-noun.substance	level NN B-noun.state	of IN 0	quinidine NN B-noun.location	) ) 0	. . 0	. . 0
DDI-DrugBank.d165.s10	therefore RB B-adv.all	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	Itraconazole NNP B-noun.person	with IN 0	cisapride NN 0	is VBZ 0	contraindicated VBN B-verb.communication	. . 0	. . 0
DDI-MedLine.d12.s5	Dexamethasone NNP B-noun.person	had VBD B-verb.creation	a DT 0	similar JJ B-adj.all	effect NN B-noun.phenomenon	in IN 0	the DT 0	presence NN B-noun.person	of IN 0	insulin NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d186.s4	In IN 0	a DT 0	study NN B-noun.artifact	of IN 0	12 CD B-adj.all	schizophrenic NN B-noun.person	patients NNS B-noun.person	coadministered VBD B-verb.communication	oral JJ B-adj.all	haloperidol NN B-noun.person	and CC 0	rifampin NN B-noun.person	, , 0	plasma NN B-noun.plant	haloperidol NN B-noun.body	levels NNS B-noun.state	were VBD 0	decreased VBN B-verb.change	by IN 0	a DT 0	mean NN B-noun.attribute	of IN 0	70 CD B-adj.all	% NN 0	and CC 0	mean JJ B-adj.all	scores NNS B-noun.cognition	on IN 0	the DT 0	Brief NNP B-noun.other	Psychiatric NNP I-noun.other	Rating NNP I-noun.other	Scale NNP I-noun.other	were VBD 0	increased VBN B-verb.change	from IN 0	baseline NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d35.s0	Interactions NNS B-noun.possession	may MD 0	occur VB B-verb.stative	between IN 0	EPA NNP B-noun.group	supplements NNS B-noun.artifact	and CC 0	aspirin NN B-noun.person	and CC 0	other JJ 0	non NN B-noun.person	- : 0	steroidal_anti SYM 0	- : 0	inflammatory_drugs NNS B-noun.person	and CC 0	herbs NNS 0	such JJ 0	as IN 0	garlic NN B-noun.animal	( ( 0	Allium NNP B-noun.person	sativum NN 0	) ) 0	and CC 0	ginkgo NN B-noun.person	( ( 0	Ginkgo_biloba NNP 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d276.s3	The DT 0	resulting VBG B-adj.all	increase NN B-noun.event	in IN 0	nitrofurantoin NN B-adj.all	serum NN B-noun.body	levels NNS B-noun.state	may MD 0	increase VB B-verb.change	toxicity NN B-noun.attribute	, , 0	and CC 0	the DT 0	decreased VBN B-verb.change	urinary JJ B-adj.all	levels NNS B-noun.state	could MD 0	lessen VB B-verb.social	its PRP$ 0	efficacy NN B-noun.phenomenon	as IN 0	a DT 0	urinary JJ B-adj.all	tract NN B-noun.body	antibacterial JJ I-noun.body	. . 0	. . 0
